Cover Page
Cover Page | 6 Months Ended |
Jun. 30, 2022 | |
Cover [Abstract] | |
Entity Registrant Name | GreenLight Biosciences Holdings, PBC |
Document Type | S-1 |
Amendment Flag | false |
Entity Central Index Key | 0001822691 |
Entity Filer Category | Non-accelerated Filer |
Entity Small Business | true |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Current assets | |||
Cash and cash equivalents | $ 44,132 | $ 31,446 | $ 95,068 |
Accounts receivable | 10,000 | ||
Prepaid expenses | 9,870 | 2,331 | 2,031 |
Total Current Assets | 64,002 | 33,777 | 97,099 |
Restricted cash | 1,321 | 362 | 80 |
Property and equipment, net | 32,085 | 23,399 | 16,279 |
Deferred offering costs | 4,099 | ||
Other assets | 1,402 | 1,420 | 370 |
TOTAL ASSETS | 98,810 | 63,058 | 113,828 |
CURRENT LIABILITIES | |||
Accounts payable | 4,155 | 7,551 | 4,537 |
Accrued expenses | 30,427 | 14,624 | 6,826 |
Convertible debt | 31,691 | ||
Long-term debt, current portion | 11,402 | 7,234 | 633 |
Deferred revenue, current portion | 8,939 | 963 | 1,663 |
Other current liabilities | 294 | 278 | 252 |
Total Current Liabilities | 55,217 | 62,341 | 13,911 |
Warrant liabilities | 470 | 2,105 | 125 |
Long-term debt, net of current portion | 20,156 | 27,152 | 992 |
Convertible debt | 17,273 | ||
Other liabilities | 9,242 | 1,435 | 1,562 |
TOTAL LIABILITIES | 85,085 | 93,033 | 33,863 |
Commitments and Contingencies | |||
LEGACY REDEEMABLE CONVERTIBLE PREFERRED STOCK | 218,790 | 218,787 | |
STOCKHOLDERS' EQUITY (DEFICIT) | |||
Common stock, $0.0001 par value; 500,000,000 shares authorized, 123,663,315 and 96,575,107 shares issued and outstanding at June 30, 2022, and December 31, 2021, respectively | 13 | 10 | 10 |
Preferred stock | |||
Additional paid-in capital | 357,428 | 223,584 | 221,214 |
Accumulated deficit | (343,716) | (253,569) | (141,259) |
TOTAL STOCKHOLDERS' EQUITY (DEFICIT) | 13,725 | (29,975) | 79,965 |
TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) | $ 98,810 | $ 63,058 | $ 113,828 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - $ / shares | Jun. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 |
Preferred stock, par value (in Dollars per share) | $ 0.0001 | $ 0.0001 | ||||
Preferred stock, shares authorized | 10,000,000 | 10,000,000 | ||||
Preferred stock, shares issued | 0 | 0 | ||||
Preferred stock, shares outstanding | 0 | 0 | ||||
Common stock, par value (in Dollars per share) | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 500,000,000 | 500,000,000 | 500,000,000 | |||
Common stock, shares issued | 123,663,315 | 96,575,107 | 96,284,283 | |||
Common stock, shares outstanding | 123,663,315 | 96,575,107 | 96,284,283 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
REVENUE: | ||||||
Collaboration revenue | $ 962 | |||||
License and collaboration revenue | $ 1,748 | $ 1,748 | ||||
Grant revenue | 20 | $ 493 | 277 | $ 818 | $ 1,595 | 785 |
Total revenue | 1,768 | 493 | 2,025 | 818 | 1,595 | 1,747 |
OPERATING EXPENSES: | ||||||
Research and development | 44,151 | 22,009 | 71,432 | 39,420 | 89,832 | 42,866 |
General and administrative | 9,577 | 4,933 | 19,332 | 8,831 | 20,321 | 11,165 |
Total operating expenses | 53,728 | 26,942 | 90,764 | 48,251 | 110,153 | 54,031 |
LOSS FROM OPERATIONS | (51,960) | (26,449) | (88,739) | (47,433) | (108,558) | (52,284) |
OTHER INCOME (EXPENSE) | ||||||
Interest income | 57 | 5 | 61 | 16 | 37 | 83 |
Interest expense | (2,419) | (1,028) | ||||
Interest and other expense | (1,338) | (529) | (2,411) | (840) | ||
Change in fair value of warrant liabilities | 1,315 | (201) | 956 | (200) | (1,370) | (22) |
Total other income (expense), net | 34 | (725) | (1,394) | (1,024) | (3,752) | (967) |
Net loss | $ (51,926) | $ (27,174) | $ (90,133) | $ (48,457) | $ (112,310) | $ (53,251) |
Net loss per share available to common stockholders — basic | $ (0.42) | $ (0.28) | $ (0.76) | $ (0.5) | $ (1.17) | $ (0.69) |
Net loss per share available to common stockholders — diluted | $ (0.42) | $ (0.28) | $ (0.76) | $ (0.5) | $ (1.17) | $ (0.69) |
Weighted-average common stock outstanding — basic | 123,249,757 | 96,327,956 | 118,430,851 | 96,314,179 | 96,371,189 | 77,673,953 |
Weighted-average common stock outstanding — diluted | 123,249,757 | 96,327,956 | 118,430,851 | 96,314,179 | 96,371,189 | 77,673,953 |
Consolidated Statements of Chan
Consolidated Statements of Changes in Stockholders' (Deficit) Equity - USD ($) $ in Thousands | Total | Convertible Note PIPE Investors [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | As Previously Reported [Member] | Retroactive Application of Business Combination | Common Stock | Common Stock Convertible Note PIPE Investors [Member] | Common Stock As Previously Reported [Member] | Common Stock Retroactive Application of Business Combination | Additional Paid-in Capital | Additional Paid-in Capital Convertible Note PIPE Investors [Member] | Additional Paid-in Capital GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Additional Paid-in Capital As Previously Reported [Member] | Additional Paid-in Capital Retroactive Application of Business Combination | Accumulated Deficit | Accumulated Deficit As Previously Reported [Member] | Preferred Stock [Member] As Previously Reported [Member] Redeemable Convertible Preferred Stock [Member] | Preferred Stock [Member] Retroactive Application of Business Combination Redeemable Convertible Preferred Stock [Member] |
Balance at Dec. 31, 2019 | $ 23,664 | $ (86,624) | $ 110,288 | $ 6 | $ 3 | $ 3 | $ 111,666 | $ 1,381 | $ 110,285 | $ (88,008) | $ (88,008) | $ 110,288 | $ (110,288) | |||||
Balance (in Shares) at Dec. 31, 2019 | 56,138,316 | 3,121,514 | 53,016,802 | 74,768,305 | (74,768,305) | |||||||||||||
Issuance of Legacy Series D convertible preferred stock at $1.8118 per share, net of issuance costs of $543 | 108,856 | $ 4 | 108,852 | |||||||||||||||
Issuance of Legacy Series D convertible preferred stock at $1.8118 per share, net of issuance costs of $543 (in Shares) | 40,058,691 | |||||||||||||||||
Vesting of restricted stock awards (in Shares) | 20,691 | |||||||||||||||||
Exercise of common stock options | 37 | 37 | ||||||||||||||||
Exercise of common stock options (in Shares) | 66,585 | |||||||||||||||||
Stock-based compensation expense | 659 | 659 | ||||||||||||||||
Net loss | (53,251) | (53,251) | ||||||||||||||||
Balance at Dec. 31, 2020 | 79,965 | (138,822) | 218,787 | $ 10 | $ 3 | $ 7 | 221,214 | 2,434 | 218,780 | (141,259) | (141,259) | |||||||
Balance (in Shares) at Dec. 31, 2020 | 96,284,283 | 3,252,636 | 93,031,647 | |||||||||||||||
Balance at Dec. 31, 2020 | $ 218,787 | $ (218,787) | ||||||||||||||||
Balance (in Shares) at Dec. 31, 2020 | 134,952,637 | (134,952,637) | ||||||||||||||||
Vesting of restricted stock awards (in Shares) | 7,271 | |||||||||||||||||
Exercise of common stock options | 6 | 6 | ||||||||||||||||
Exercise of common stock options (in Shares) | 24,582 | |||||||||||||||||
Stock-based compensation expense | 348 | 348 | ||||||||||||||||
Net loss | (21,283) | (21,283) | ||||||||||||||||
Balance at Mar. 31, 2021 | 59,036 | $ 10 | 221,568 | (162,542) | ||||||||||||||
Balance (in Shares) at Mar. 31, 2021 | 96,316,136 | |||||||||||||||||
Balance at Dec. 31, 2020 | 79,965 | (138,822) | 218,787 | $ 10 | $ 3 | $ 7 | 221,214 | 2,434 | 218,780 | (141,259) | (141,259) | |||||||
Balance (in Shares) at Dec. 31, 2020 | 96,284,283 | 3,252,636 | 93,031,647 | |||||||||||||||
Balance at Dec. 31, 2020 | $ 218,787 | $ (218,787) | ||||||||||||||||
Balance (in Shares) at Dec. 31, 2020 | 134,952,637 | (134,952,637) | ||||||||||||||||
Exercise of series A convertible preferred stock warrant | 4 | 4 | ||||||||||||||||
Exercise of series A convertible preferred stock warrant (in Shares) | 17,090 | |||||||||||||||||
Vesting of restricted stock awards (in Shares) | 20,706 | |||||||||||||||||
Exercise of common stock options | $ 143 | 143 | ||||||||||||||||
Exercise of common stock options (in Shares) | 253,027 | 253,028 | ||||||||||||||||
Warrants issued in connection with debt | $ 232 | 232 | ||||||||||||||||
Stock-based compensation expense | 1,991 | 1,991 | ||||||||||||||||
Net loss | (112,310) | (112,310) | ||||||||||||||||
Balance at Dec. 31, 2021 | (29,975) | (248,765) | 218,790 | $ 10 | $ 4 | $ 6 | 223,584 | 4,800 | 218,784 | (253,569) | (253,569) | |||||||
Balance (in Shares) at Dec. 31, 2021 | 96,575,107 | 3,663,894 | 92,911,213 | |||||||||||||||
Balance at Mar. 31, 2021 | 59,036 | $ 10 | 221,568 | (162,542) | ||||||||||||||
Balance (in Shares) at Mar. 31, 2021 | 96,316,136 | |||||||||||||||||
Vesting of restricted stock awards (in Shares) | 6,171 | |||||||||||||||||
Exercise of common stock options | 24 | 24 | ||||||||||||||||
Exercise of common stock options (in Shares) | 53,398 | |||||||||||||||||
Stock-based compensation expense | 407 | 407 | ||||||||||||||||
Net loss | (27,174) | (27,174) | ||||||||||||||||
Balance at Jun. 30, 2021 | 32,293 | $ 10 | 221,999 | (189,716) | ||||||||||||||
Balance (in Shares) at Jun. 30, 2021 | 96,375,705 | |||||||||||||||||
Balance at Dec. 31, 2021 | (29,975) | (248,765) | 218,790 | $ 10 | $ 4 | $ 6 | 223,584 | 4,800 | 218,784 | (253,569) | (253,569) | |||||||
Balance (in Shares) at Dec. 31, 2021 | 96,575,107 | 3,663,894 | 92,911,213 | |||||||||||||||
Balance at Dec. 31, 2021 | $ 218,790 | $ (218,790) | ||||||||||||||||
Balance (in Shares) at Dec. 31, 2021 | 134,972,944 | (134,972,944) | ||||||||||||||||
Exercise of series A convertible preferred stock warrant | 460 | 460 | ||||||||||||||||
Exercise of series A convertible preferred stock warrant (in Shares) | 490,031 | |||||||||||||||||
Cashless exercise of Legacy GreenLight common stock warrants | 1,183 | 1,183 | ||||||||||||||||
Cashless exercise of Legacy GreenLight common stock warrants (in Shares) | 170,981 | |||||||||||||||||
Reclassification of common stock warrants to equity | $ 352 | $ 352 | ||||||||||||||||
Conversion of convertible notes | 18,291 | $ 35,250 | $ 1 | 18,290 | $ 35,250 | |||||||||||||
Conversion of convertible notes (in Shares) | 6,719,116 | 3,525,000 | ||||||||||||||||
Business Combination transaction, net of transaction costs of $26.7 million | 72,989 | $ 2 | 72,987 | |||||||||||||||
Business Combination transaction, net of transaction costs of $26.7 million (in Shares) | 15,285,374 | |||||||||||||||||
Vesting of restricted stock awards (in Shares) | 1,567 | |||||||||||||||||
Exercise of common stock options | 22 | 22 | ||||||||||||||||
Exercise of common stock options (in Shares) | 79,055 | |||||||||||||||||
Stock-based compensation expense | 2,187 | 2,187 | ||||||||||||||||
Exercise of public warrants | 1,209 | 1,209 | ||||||||||||||||
Exercise of public warrants (in Shares) | 105,120 | |||||||||||||||||
Other | 65 | 79 | (14) | |||||||||||||||
Other (in Shares) | 29,154 | |||||||||||||||||
Net loss | (38,207) | (38,207) | ||||||||||||||||
Balance at Mar. 31, 2022 | 63,826 | $ 13 | 355,603 | (291,790) | ||||||||||||||
Balance (in Shares) at Mar. 31, 2022 | 122,980,505 | |||||||||||||||||
Balance at Dec. 31, 2021 | (29,975) | $ (248,765) | $ 218,790 | $ 10 | $ 4 | $ 6 | 223,584 | $ 4,800 | $ 218,784 | (253,569) | $ (253,569) | |||||||
Balance (in Shares) at Dec. 31, 2021 | 96,575,107 | 3,663,894 | 92,911,213 | |||||||||||||||
Balance at Dec. 31, 2021 | $ 218,790 | $ (218,790) | ||||||||||||||||
Balance (in Shares) at Dec. 31, 2021 | 134,972,944 | (134,972,944) | ||||||||||||||||
Exercise of common stock options (in Shares) | 760,534 | |||||||||||||||||
Balance at Jun. 30, 2022 | 13,725 | $ 13 | 357,428 | (343,716) | ||||||||||||||
Balance (in Shares) at Jun. 30, 2022 | 123,663,315 | |||||||||||||||||
Balance at Mar. 31, 2022 | 63,826 | $ 13 | 355,603 | (291,790) | ||||||||||||||
Balance (in Shares) at Mar. 31, 2022 | 122,980,505 | |||||||||||||||||
Reclassification of common stock warrants to equity | 35 | 35 | ||||||||||||||||
Vesting of restricted stock awards (in Shares) | 1,331 | |||||||||||||||||
Exercise of common stock options | 314 | 314 | ||||||||||||||||
Exercise of common stock options (in Shares) | 681,479 | |||||||||||||||||
Stock-based compensation expense | 1,634 | 1,634 | ||||||||||||||||
Other | (158) | (158) | ||||||||||||||||
Net loss | (51,926) | (51,926) | ||||||||||||||||
Balance at Jun. 30, 2022 | $ 13,725 | $ 13 | $ 357,428 | $ (343,716) | ||||||||||||||
Balance (in Shares) at Jun. 30, 2022 | 123,663,315 |
Consolidated Statements of Ch_2
Consolidated Statements of Changes in Stockholders' (Deficit) Equity (Parentheticals) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
Temporary equity, par or stated value per share | $ 0.001 | |
Common stock, par value (in Dollars per share) | $ 0.0001 | 0.0001 |
Business Combination, Acquisition Related Costs | $ 26,700 | |
Legacy Redeemable Convertible Preferred Stock [Member] | ||
Temporary equity, par or stated value per share | $ 0.001 | 0.001 |
Temporary Equity Issue Price Per Share | $ 1.8118 | |
Temporary Equity Stock Issuance Costs | $ 543 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||
Net loss | $ (90,133) | $ (48,457) | $ (112,310) | $ (53,251) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||
Depreciation and amortization expense | 4,120 | 2,302 | 5,772 | 1,754 |
Gain (loss) on disposal of property and equipment | 28 | (5) | (5) | (15) |
Stock-based compensation expense | 3,821 | 755 | 1,991 | 659 |
Non-cash interest expense | 422 | 828 | 588 | |
Change in fair value of warrant liability | (956) | 200 | 1,370 | 22 |
Amortization of deferred finance costs | 423 | 166 | 588 | |
Changes in operating assets and liabilities | ||||
Accounts receivable | (10,000) | |||
Prepaid expenses and other assets | (7,521) | (1,909) | (920) | (1,489) |
Accounts payable | (2,979) | 3,967 | 3,697 | 1,172 |
Accrued expenses and other liabilities | 21,680 | 1,289 | 8,181 | 1,904 |
Accrued interest | 344 | (83) | ||
Deferred rent | 1,376 | (46) | (80) | 477 |
Deferred revenue | 7,976 | (818) | (700) | 1,663 |
Net cash used in operating activities | (72,165) | (42,300) | (91,832) | (46,599) |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||
Proceeds from sale of property and equipment | 37 | 109 | ||
Purchases of property and equipment | (12,870) | (6,786) | (15,148) | (10,047) |
Net cash used in investing activities | (12,833) | (6,786) | (15,039) | (10,047) |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||
Proceeds from business combination, net of transaction costs | 78,543 | |||
Proceeds from issuance of convertible debt - PIPE Investors | 21,750 | 13,500 | 16,775 | |
Payment of Legacy Series D issuance costs | (186) | |||
Proceeds from issuance of Legacy Series D Preferred Stock | 109,042 | |||
Payment of Convertible Debt issuance costs | (134) | |||
Proceeds from stock option exercises | 336 | 30 | 143 | 37 |
Proceeds from secured debt, net of issuance costs and security deposits | 7,084 | 10,360 | ||
Proceeds from secured term loan, net of issuance costs | 24,973 | |||
Proceeds from tenant improvement allowance | 1,250 | |||
Principal payments on secured debt and term loan payable | (1,795) | |||
Principal payments on tenant improvement allowance payable | (161) | (304) | ||
Payment of deferred offering costs | (2,857) | |||
Principal payments on debt | (2,732) | (265) | ||
Exercise of public warrants | 1,209 | |||
Repayments of tenant improvement allowance | (136) | (79) | ||
Principal Payments on Capital Lease Obligations | (327) | (325) | (632) | (632) |
Net cash provided by financing activities | 98,643 | 6,445 | 43,531 | 125,848 |
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | 13,645 | (42,641) | (63,340) | 69,202 |
Cash, cash equivalents and restricted cash at beginning of year | 31,808 | 95,148 | 95,148 | 25,946 |
Cash, cash equivalents and restricted cash at end of year | 45,453 | 52,507 | 31,808 | 95,148 |
SUPPLEMENTAL DISCLOSURE OF CASH-FLOW INFORMATION | ||||
Cash paid for interest | 1,303 | 203 | 867 | 376 |
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES | ||||
Property and equipment included in accrued expenses and accounts payable | 1,218 | 2,930 | 1,216 | 3,562 |
Conversion of convertible debt to equity | 53,541 | |||
Legacy GreenLight cashless warrant exercises | 1,643 | |||
Warrant liabilities assumed in the Business Combination | 1,341 | |||
Deferred financing costs in accrued expenses and accounts payable | 559 | 1,242 | ||
Property and equipment acquired under capital lease | 0 | 934 | ||
Non-cash Legacy Series D issuance costs | 357 | |||
Non-cash debt issuance costs | 610 | |||
Non-cash equipment financing issuance costs | 138 | |||
Reconciliation of cash, cash equivalents and restricted cash | ||||
Cash and cash equivalents | 44,132 | 52,340 | 31,446 | 95,068 |
Restricted cash | 1,321 | 167 | 362 | 80 |
Total cash, cash equivalents and restricted cash | $ 45,453 | $ 52,507 | $ 31,808 | $ 95,148 |
Nature of Business and Basis of
Nature of Business and Basis of Presentation | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
NATURE OF BUSINESS AND BASIS OF PRESENTATION | 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION Organization GreenLight Biosciences, Inc. (“GreenLight” or the “Company”) was incorporated in Delaware in 2008. GreenLight, together with its wholly owned subsidiaries, GreenLight Pandemic Response, Inc. (“GLPRI”), and GreenLight Security Corporation (“GLSC”), is referred to on a consolidated basis as the “Company”. The Company has developed technology to create high-performing, natural ribonucleic acid (“RNA”) products to address global sustainability challenges and promote healthier plants, foods, and people. The Company is located and headquartered in Medford, Massachusetts. The Company has additional lab and office space in Research Triangle Park, North Carolina, a manufacturing facility in Burlington, Massachusetts, additional lab and office space in Woburn, Massachusetts, and a manufacturing facility in Rochester, New York. The Company’s revenues and expenses are derived from operations in the United States. Since its inception, the Company has devoted substantially all of its efforts to research and development activities, including the development of the Company’s cell-free RNA production process. The Company does not currently generate revenue from sales of any products. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). Business Combination Transaction On August 9, 2021, the Company entered into the business combination agreement (“Business Combination Agreement”) with Environmental Impact Acquisition Corp. (“ENVI”) and Honey Bee Merger Sub, Inc. (“Merger Sub”). Pursuant to the Business Combination Agreement, on February 2, 2022, Merger Sub merged with and into GreenLight (the “Merger”), with GreenLight surviving the Merger as a wholly owned subsidiary of ENVI (the Merger, together with the other transactions contemplated by the Business Combination Agreement, the “Business Combination”). Immediately before the closing of the Business Combination, ENVI held approximately $207.0 million in a trust account for its public stockholders. In connection with the Business Combination, ENVI’s public stockholders redeemed shares of public common stock for approximately $194.9 million, and the funds remaining after such redemptions, totaling approximately $12.1 million, became available to finance transaction expenses and the future operations of New GreenLight. In connection with the Business Combination, ENVI entered into agreements with new investors and existing GreenLight investors to subscribe for and purchase an aggregate of approximately 12.4 million shares of ENVI Class A Common Stock (the “PIPE Financing”). The PIPE Financing was consummated on February 2, 2022 and resulted in gross proceeds of approximately $ The Merger is accounted for as a reverse recapitalization, whereby for accounting and financial reporting purposes, the Company was the acquirer. A reverse recapitalization does not result in a new basis of accounting, and the financial statements of the combined entity will represent the continuation of the consolidated financial statements of the Company in many respects. The shares of ENVI remaining after redemptions of shares of ENVI public common stock and the unrestricted net cash and cash equivalents on the date the Business Combination was consummated will be accounted for as a capital infusion to GreenLight. Retrospective Adjustment In accordance with guidance applicable to these circumstances, the Company retroactively applied the recapitalization to the Company’s equity structure including the consolidated statement of stockholders’ (deficit) equity from January 1, 2020 to December 31, 2021, the total stockholders’ (deficit) equity within the Company’s consolidated balance sheet as of December 31, 2021 and 2020, and the weighted average outstanding shares basic and diluted for the years ended December 31, 2021 and 2020. The retroactive application reflects the equivalent number of shares of the Company’s common Additionally, Legacy GreenLight’s convertible preferred stock previously classified as temporary equity was retroactively adjusted, converted into common stock and reclassified to permanent equity as a result of the reverse recapitalization. All periods prior to the Business Combination have been restated to reflect the convertible preferred stock as converted to common stock, with no convertible preferred stock outstanding. Liquidity and going concern Since its inception, the Company has devoted substantially all of its resources to building its platform and advancing development of its portfolio of programs, establishing and protecting its intellectual property, conducting research and development activities, organizing and staffing the Company, business planning, raising capital and providing general and administrative support for these operations. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive field trials, preclinical and clinical trials and regulatory approvals prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. As presented in the financial statements, the Company has incurred substantial losses since inception and incurred net losses of approximately $53.3 million and $112.3 million for the years ended December 31, 2020 and 2021, respectively. As of December 31, 2021, the Company had an accumulated deficit of approximately $253.6 million and cash and cash equivalents of approximately $31.4 million. Cash used in operating activities totaled approximately $46.6 million and $91.8 million for the years ended December 31, 2020 and 2021, respectively. The Company expects to generate operating losses and negative operating cash flows for the foreseeable future. As of March 31, 2022, the issuance The Company will not generate any revenue from product sales unless and until it successfully completes development and obtains regulatory approval for one or more of its product candidates. If the Company obtains regulatory approval for any of its product candidates, it expects to incur significant expenses related to developing its internal commercialization capability to support product sales, marketing and distribution. As a result, the Company will need substantial additional funding to support its operating activities as it advances its product candidates through development, seeks regulatory approval and prepares for and, if any of its product candidates are approved, proceeds to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings, debt financings, and license and development agreements in connection with any future collaborations. Adequate funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to obtain funding, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. Based on its recurring losses from operations incurred since inception, expectation of continuing operating losses for the foreseeable future, and need to raise additional capital to finance its future operations, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments that might result from the outcome of this uncertainty. | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
NATURE OF BUSINESS AND BASIS OF PRESENTATION | 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION Organization GreenLight Biosciences Holdings, PBC (formerly known as Environmental Impact Acquisition Corp.) (“New GreenLight,” “ENVI” or the “Company”) was incorporated in Delaware on July 2, 2020. The Company has developed technology to create high-performing, natural ribonucleic acid (“RNA”) products to address global sustainability challenges and promote healthier plants, foods, and people. The Company is located and headquartered in Medford, Massachusetts. The Company has additional lab and office space in Durham, North Carolina, additional lab and office space in Woburn, Massachusetts, additional lab and office space in Lexington, Massachusetts, and a manufacturing facility in Rochester, New York. The Company’s revenues and expenses are derived from operations in the United States. Since its inception, the Company has devoted substantially all of its efforts to research and development activities, including the development of the Company’s cell-free RNA production process. The Company does not currently generate revenue from sales of any products. On August 9, 2021, ENVI entered into the business combination agreement (“Business Combination Agreement”) with its wholly owned subsidiary, Honey Bee Merger Sub, Inc. (“Merger Sub”) and GreenLight Biosciences, Inc. (“Greenlight”), which was incorporated in Delaware in 2008. Pursuant to the Business Combination Agreement, on February 2, 2022 (the “ Closing Date”), Merger Sub merged with and into GreenLight (the “Merger”), with GreenLight surviving the Merger as a wholly owned subsidiary of ENVI (the Merger, together with the other transactions contemplated by the Business Combination Agreement, the “Business Combination”). In connection with the consummation of the Merger on the Closing Date, ENVI changed its name to GreenLight Biosciences Holdings, PBC (“New GreenLight”) and became a public benefit corporation. References to “Legacy GreenLight” refer to GreenLight Biosciences, Inc. prior to the consummation of the Business Combination. Although New GreenLight was the legal acquirer of GreenLight in the Business Combination, GreenLight is deemed to be the accounting acquirer, and the historical financial statements of GreenLight became the basis for the historical financial statements of New GreenLight upon the closing of the Business Combination. New GreenLight, together with its wholly owned subsidiaries, GreenLight Biosciences, Inc., GreenLight Pandemic Response, Inc. (“GLPRI”), and GreenLight Security Corporation (“GLSC”), is referred to on a consolidated basis as the “Company”. Upon the closing of the Business Combination, each share of Legacy GreenLight stock was exchanged for shares of Class A common stock in an amount determined by application of the exchange ratio of approximately 0.6656 (the “Exchange Ratio”). In connection with the Business Combination, the Company entered into the February 2022 Subscription Agreements with subscribers who agreed to purchase an aggregate of 12,425,000 shares of Class A common stock for a purchase price of $124.3 million (the “PIPE”), all of which were issued on the effective date. Of the total $124.3 million of PIPE proceeds, $13.5 million was received in December 2021 and $21.8 million was received January 2022 in the form of convertible notes. Upon the closing of the Business Combination, these convertible notes converted into Class A common stock. In total, the Company received proceeds of $136.4 million inclusive of the February 2022 PIPE Financing and after redemptions which provided the Company with cash of $109.7 million, which is net of transaction costs of $26.7 million consisting of equity underwriting, legal, and other professional fees, all of which were recorded to additional paid-in per share. The Public and Private Placement Warrants expire five years after the completion of the Business Combination. Both the Private Placement Warrants and Public Warrants are further described in the Business Combination Agreement. Legacy GreenLight was deemed to be the accounting acquirer in the Business Combination. The determination was primarily based on Legacy GreenLight’s stockholders having a majority of the voting power in the combined Company, Legacy GreenLight having the ability to appoint a majority of the Board of Directors of the Company, Legacy GreenLight’s existing management team comprising the senior management of the combined Company, Legacy GreenLight comprising the ongoing operations of the combined Company and the combined Company assuming GreenLight’s name. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Legacy GreenLight issuing stock for the net assets of ENVI, accompanied by a recapitalization. The net assets of ENVI are stated at historical cost, with no goodwill or other intangible assets recorded. While ENVI was the legal acquirer in the Business Combination because Legacy GreenLight was deemed the accounting acquirer, the historical financial statements of Legacy GreenLight became the historical financial statements of the combined Company upon the consummation of the Business Combination. As a result, the financial statements included in this report reflect (i) the historical operating results of Legacy GreenLight prior to the Business Combination; (ii) the combined results of ENVI and Legacy GreenLight following the close of the Business Combination; (iii) the assets and liabilities of Legacy GreenLight at their historical cost; and (iv) the Legacy GreenLight’s equity structure for all periods presented, as affected by the recapitalization presentation after completion of the Business Combination. In accordance with guidance applicable to these circumstances, the equity structure has been restated in all comparable periods up to February 2, 2022, to reflect the number of shares of the Company’s common stock, $0.0001 par value per share, issued to Legacy GreenLight’s stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to Legacy GreenLight’s outstanding convertible preferred stock and Legacy GreenLight’s common stock prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio of 0.6656 established in the Business Combination. Legacy GreenLight’s convertible preferred stock previously classified as temporary equity was retroactively adjusted, converted into common stock and reclassified to permanent equity as a result of the reverse recapitalization. See Note 3 for further details of the Business Combination. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany transactions and balances have been eliminated in consolidation. The condensed consolidated balance sheet as of December 31, 2021 included herein, was derived from the audited annual consolidated financial statements as of that date, but does not include all disclosures including certain notes required by GAAP on an annual reporting basis and also give effect to the reverse recapitalization described above. Certain information and note disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed consolidated or omitted pursuant to such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements as of December 31, 2021 and 2020 and the years then ended, and the related notes thereto, which are included as Exhibit 99.1 to the Company’s Current Report on Form 8-K, In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary for the fair statement of the Company’s financial position, results of operations, and cash flows for the interim periods presented. The results for the three and six months ended June 30, 2022 are not necessarily indicative of the results to be expected for any subsequent quarter, the fiscal year ending December 31, 2022, or any other period. Liquidity and Going Concern Since its inception, the Company has devoted substantially all of its resources to building its platform and advancing development of its portfolio of programs, establishing, and protecting its intellectual property, conducting research and development activities, organizing, and staffing the Company, business planning, raising capital and providing general and administrative support for these operations. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive field trials, preclinical and clinical trials, and regulatory approvals prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. As presented in the financial statements, the Company has incurred substantial losses since inception and incurred net losses of approximately $90.1 million and $48.5 million for the six months ended June 30, 2022 and 2021, respectively. As of June 30, 2022, the Company had an accumulated deficit of approximately $343.7 million and cash and cash equivalents of approximately $44.1 million. Cash used in operating activities totaled approximately $72.2 million and $42.3 million for six months ended June 30, 2022 and 2021, respectively. The Company expects to generate operating losses and negative operating cash flows for the foreseeable future. On August 11, 2022, the Company entered into Subscription Agreements (the “August 2022 Subscription Agreements”) with certain accredited investors (collectively, the “Purchasers”), providing for the sale by the Company of 27,640,301 shares (the “Shares”) of its common stock (the “Common Stock”) at a purchase price of $3.92 per share, in a private placement (the “Private Placement”). The Shares were issued (the “Closing”) simultaneously with the execution and delivery of the August 2022 Subscription Agreements. As of August 15, 2022, the issuance date of the Company’s unaudited interim consolidated financial statements as of June 30, 2022 The Company will not generate any revenue from product sales unless and until it successfully completes development and obtains regulatory approval for one or more of its product candidates. If the Company obtains regulatory approval for any of its product candidates, it expects to incur significant expenses related to developing its internal commercialization capability to support product sales, marketing, and distribution. As a result, the Company will need substantial additional funding to support its operating activities as it advances its product candidates through development, seeks regulatory approval and prepares for and, if any of its product candidates are approved, proceeds to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings, debt financings, and license and development agreements in connection with any future collaborations. Adequate funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to obtain funding or if the funding it does obtain is insufficient to support existing operational plans, the Company will be forced to delay, reduce, or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. Based on its recurring losses from operations incurred since inception, expectation of continuing operating losses for the foreseeable future, and need to raise additional capital to finance its future operations, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the issuance date of these consolidated financial statements. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments that might result from the outcome of this uncertainty. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Summary of Significant Accounting Policies [Line Items] | ||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The accompanying consolidated financial statements include the operations of the Company and its wholly owned subsidiaries, GLPRI and GLSC. All intercompany transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the accrual of research and development costs, acquisition of in-process Operating Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The CODM is the Company’s Chief Executive Officer. The Company manages its operations as a single Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Investments qualifying as cash equivalents primarily consist of money market funds. The Company’s cash equivalents in the consolidated balance sheets at December 31, 2020 and 2021, were approximately $95.1 million and $31.4 million, respectively. Restricted Cash The Company maintains letters of credit in conjunction with the Company’s lease agreements. As of December 31, 2020 and 2021, the underlying cash balance securing these letters of credit of approximately $0.1 million and $0.3 million, respectively, was classified as a noncurrent asset in the consolidated balance sheets based on the terms of the lease agreement. Concentrations of Credit Risk The Company has no significant off-balance Fair Value Measurements ASC 820, Fair Value Measurements and Disclosures (“ASC 820”), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier • Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. • Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for a similar asset or liability, either directly or indirectly. • Level 3 inputs are unobservable inputs that reflect the Company’s own assumptions about the inputs that market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hie Property and Equipment Property and equipment are recorded at cost and depreciated over the estimated useful lives of the related assets using the straight-line method. Maintenance and repairs to an asset that do not improve or extend its life are expensed in the period incurred. Expenditures made to improve or extend the life of property and equipment are capitalized. Leasehold improvements are depreciated over the shorter of the useful life of the improvements or the remaining term of the associated lease. The estimated useful lives of property and equipment are as follows: ESTIMATED USEFUL LIFE Laboratory equipment 5 years Computer equipment and software 3 years Leasehold improvements Shorter of useful life or Property and equipment subject to a capital lease are depreciated over the shorter of the useful life or the term of the lease. Construction in progress is stated at cost, which includes direct costs attributable to the setup or construction of the related asset. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the Company’s statement of operations. Acquired In-process The Company measures and recognizes acquisitions that are not deemed to be business combinations as acquisitions of assets based on the cost to acquire the assets, which includes transaction costs, and the consideration is allocated to the items acquired based on a relative fair value methodology. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process The Company applied asset acquisition treatment in accounting for the acquisition of the intangible assets of Bayer Crop Science, LLP acquired during the year ended December 31, 2020. Impairment of Long-lived Assets The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Such events and circumstances include, but are not limited to, significant decreases in the market value of an asset, adverse changes in the extent or manner in which the asset is being used, or significant changes in business climate. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. During the years ended December 31, 2020 and 2021, no impairment indicators were identified. Redeemable Convertible Preferred Stock The Company classifies redeemable convertible Preferred Stock (“Preferred Stock”) as temporary equity in the accompanying consolidated balance sheets due to certain redemption events that are not within the Company’s control such as a liquidation, winding up, certain mergers, and the occurrence of a deemed liquidation event as defined in the Company’s certificate of incorporation. In the event of a deemed liquidation event, the proceeds from the event are distributed in accordance with liquidation preferences (Note 12). Prior to the retroactive impact of the recapitalization, as of December 31, 2020 and 2021, none of the circumstances under which the Company’s Preferred Stock would become redeemable are probable, and, as a result, the Company does not accrete the carrying values of the Preferred Stock to the redemption values. Subsequent adjustments of the carrying values to the ultimate redemption values will be made only when it becomes probable that such a liquidation event will occur. Warrants The Company applies relevant accounting guidance for warrants to purchase the Company’s stock based on the nature of the relationship with the counterparty. For warrants issued to investors or lenders in exchange for cash or other financial assets, the Company follows guidance issued within ASC 480, Distinguishing Liabilities from Equity (“ASC 480”), and ASC 815, Derivatives and Hedging (“ASC 815”), to assist in the determination of whether the warrants should be classified as liabilities or equity. Warrants that are determined to require liability classification are measured at fair value upon issuance and are subsequently remeasured to their then fair value at each subsequent reporting period with changes in fair value recorded in current earnings. Warrants that are determined to require equity classification are measured at fair value upon issuance and are not subsequently remeasured unless they are required to be reclassified. For warrants issued to nonemployees for goods or services, or to customers as non-cash Contract Revenue The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), which provides a five-step model for recognizing revenue from contracts with customers as follows: • Identify the contract with a customer • Identify the performance obligations in the contract • Determine the transaction price • Allocate the transaction price to the performance obligations in the contract • Recognize revenue when or as performance obligations are satisfied For the year ended December 31, 2020, all contract revenue was generated from a collaboration agreement with Ingredion Incorporated (“Ingredion”) to develop a semicontinuous cell-free production process for the commercial production of certain molecules using biological synthesis tools and proprietary technology developed by the Company. The Ingredion Agreement is within the scope of ASC 606. There was no contract revenue generated during 2021 from the collaboration agreement with Ingredion. Under ASC 606, an entity recognizes revenue when or as its customer obtains control of distinct promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. Our customer arrangements primarily consist of a license, rights to our intellectual property, and research and developments services. Performance obligations are promises in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, we consider factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own, or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract. The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration, which is included in the transaction price, may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the variability is resolved. Under the collaboration agreement with Ingredion, the variability related to the variable consideration would be resolved when the Company has successfully achieved pilot scale production that satisfies specified volume, yield, and cost targets (“Milestone 2”). For revenue related to sales-based royalties received from licensees, including milestone payments based on the level of sales, where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any consideration related to sales-based royalty revenue resulting from the Ingredion collaboration agreement. The Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations and develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in a contract with a customer. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations, which may include other comparable transactions, pricing considered in negotiating the transaction, and the estimated costs. Any variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts we would expect to receive for the satisfaction of each performance obligation. The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations that consist of licenses and other promises, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company has determined that the license and research and development services under the Ingredion agreement are a single combined performance obligation satisfied over time. The Company must select a single measure of progress that best depicts the Company’s measurement of progress. ASC 606-10-26-33 appropriate method for measuring progress. Since activities performed to research and validate one phase may be useful in researching and validating subsequent phases, the Company believes that an input method, which tracks the Company’s efforts required to perform the contracted activities during the contract term, is more representationally faithful tha n a Grant Revenue In July 2020, we entered into a grant agreement with the Bill & Melinda Gates Foundation to advance research in in vivo gene therapy for sickle cell disease and to explore new, low-cost Deferred Revenue Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company’s consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve months, the related deferred revenue will be classified in current liabilities. Research and Development Costs Research and development expenses consist primarily of costs related to discovery and research and development of products, including personnel expenses, stock-based compensation expense, allocated facility-related General and Administrative Expenses The Company expenses general and administrative costs to operations as incurred. General and administrative expenses consist primarily of compensation, benefits and other employee-related expenses for personnel in the Company’s administrative, finance, legal, information technology, business development, communications, and human resources functions. Other costs include the legal costs incurred in connection with filing and prosecuting patent and trademark applications, general and administrative related facility costs, insurance costs and professional fees for accounting, tax, consulting, legal and other services. Stock-Based Compensation Expense The Company accounts for all stock-based payment awards granted to employees and non-employees non-employee stock-based The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing Share-Based non-employees, non-employees Income Taxes The Company is primarily subject to U.S. federal, Massachusetts, North Carolina and New York state income taxes. The Company accounts for income taxes using the asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities represent future tax consequences of temporary differences between the consolidated financial statement carrying amounts and the tax basis of assets and liabilities and for loss carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. The Company also recognizes a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. We evaluate uncertain tax positions on a regular basis. The evaluations are based on several factors, including changes in facts and circumstances, and changes in tax law. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax. To date, we have not been subject to any interest or penalties. Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net l os In connection with the Merger, GreenLight equity has been retroactively adjusted to the earliest period presented to reflect the legal capital of the legal acquirer, ENVI. As a result, net loss per share was also retrospectively adjusted for periods ended prior to the Merger. See Note 1 for details of the Merger and Note 16 for discussion of the retrospective adjustment of net loss per share. Comprehensive Loss Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner Deferred Offering Costs As of December 31, 2021, the Company capitalized deferred offering costs of approximately $4.1 million. Deferred offering costs include certain legal, accounting, consulting and other third-party fees incurred directly related to the anticipated business combination. At the closing of the business combination, these costs will be recorded in stockholders’ deficit as a reduction of additional paid-in Subsequent Events The Company considers events or transactions that have occurred after the balance sheet date of December 31, 2021, but prior to March 31, 2022, the date the consolidated financial statements were issued, to provide additional evidence relative to certain estimates or to identify matters that require additional recognition or disclosure. Subsequent events have been evaluated through the date these financial statements were issued. Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, 2020-05, COVID-19 one-year beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. As the Company qualifies as an emerging growth company, the Company will follow the annual reporting guidance as of January 1, 2022 in connection with the issuance of its annual financial statements for the year ended December 31, 2022, and apply the provisions of ASC 842 in interim periods commencing after December 15, 2022. The Company will use the optional transition method to the modified retrospective approach in which Topic 842 will not be applied to comparative periods presented and incremental disclosures are not required for periods before the Company’s adoption of Topic 842. The Company has elected this transition approach as well as the package of practical expedients permitted under the transition guidance within the new standard, which allowed the Company to carry forward the historical lease classification of contracts entered into prior to January 1, 2022. As a result of electing the package of practical expedients described above, existing leases and related initial direct costs have not been reassessed prior to the effective date, and therefore, adoption of the lease standard did not have an impact on the Company’s previously reported consolidated financial statements. The Company also elected the following p rac non-lease ter The Company expects the adoption of Topic 842 will result in the recognition of right-of-use In August 2020, the FASB issued ASU No. 2020-06, 470-20) 815-40): 2020-06”). 2020-06 2020-06, if-converted 2020-06 2020-06 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Summary of Significant Accounting Policies [Line Items] | ||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Emerging Growth Company and Smaller Reporting Company Status Following the Business Combination, the Company qualifies as an emerging growth company (‘‘EGC’’) as defined in the Jumpstart our Business Startups (‘‘JOBS’’) Act. The JOBS Act permits companies with EGC status to take advantage of an extended transition period to comply with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies. The Company intends to use this extended transition period to enable the Company to comply with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date the Company (i) is no longer an EGC or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, the Company’s condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting standards as of public company effective dates. In addition, the Company intend to rely on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an EGC, the Company is not required to, among other things: (i) provide an auditor’s attestation report on our system of internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act; (ii) provide all of the compensation disclosures that may be required of non-EGCs The Company will remain an emerging growth company until the earlier of: (i) the last day of the fiscal year (a) following the fifth anniversary of the closing of ENVI’s initial public offering, (b) in which the Company has total annual gross revenue of at least $1.1 billion, or (c) in which the Company is deemed to be a large accelerated filer, which means the market value of its common equity that is held by non-affiliates exceeds $700.0 million as of the last business day of its most recently completed second fiscal quarter; and (ii) the date on which the Company has issued more than $1.0 billion in non-convertible three-year The Company is also a “smaller reporting company” as defined in the Exchange Act. The Company may continue to be a smaller reporting company even after the Company is no longer an emerging growth company. The Company may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as the market value of the Company’s voting and non-voting non-affiliates non-voting non-affiliates Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the accrual of research and development costs, acquisition of in-process Operating Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The CODM is the Company’s Chief Executive Officer. The Company manages its operations as a single Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Investments qualifying as cash equivalents primarily consist of money market funds. The Company’s cash and cash equivalents in the condensed consolidated balance sheets at June 30, 2022 and December 31, 2021, were approximately $44.1 million and $31.4 million, respectively. Restricted Cash The Company maintains letters of credit in conjunction with the Company’s lease agreements. As of June 30, 2022 and December 31, 2021, the underlying cash balance securing these letters of credit of approximately $1.3 million and $0.4 million, respectively, was classified as a noncurrent asset in the condensed consolidated balance sheets based on the terms of the lease agreement. Accounts Receivable Our accounts receivable consists of amounts due from one customer. We extend credit to our customer based on our evaluation of the customer’s financial condition. Accounts receivable are stated at amounts due net of applicable prompt pay discounts and other adjustments. We assess the need for an allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due and the customer’s ability to pay its obligation. Based on a review of these factors, as of June 30, 2022, we determined that an allowance for doubtful accounts was not required. Concentrations of Credit Risk The Company has no significant off-balance Fair Value Measurements ASC 820, Fair Value Measurements and Disclosures ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier • Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. • Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for a similar asset or liability, either directly or indirectly. • Level 3 inputs are unobservable inputs that reflect the Company’s own assumptions about the inputs that market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Property and Equipment Property and equipment are recorded at cost and depreciated over the estimated useful lives of the related assets using the straight-line method. Maintenance and repairs to an asset that do not improve or extend its life are expensed in the period incurred. Expenditures made to improve or extend the life of property and equipment are capitalized. Leasehold improvements are depreciated over the shorter of the useful life of the improvements or the remaining term of the associated lease. The estimated useful lives of property and equipment are as follows: ESTIMATED USEFUL LIFE Manufacturing equipment 10 Furniture and fixtures 7 years Laboratory equipment 5 years Computer equipment and software 3 years Leasehold improvements Shorter of useful Property and equipment subject to a capital lease are depreciated over the shorter of the useful life or the term of the lease. Construction in progress is stated at cost, which includes direct costs attributable to the setup or construction of the related asset. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the Company’s statement of operations. Acquired In-process The Company measures and recognizes acquisitions that are not deemed to be business combinations as acquisitions of assets based on the cost to acquire the assets, which includes transaction costs, and the consideration is allocated to the items acquired based on a relative fair value methodology. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process Impairment of Long-lived Assets The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Such events and circumstances include, but are not limited to, significant decreases in the market value of an asset, adverse changes in the extent or manner in which the asset is being used, or significant changes in business climate. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. During the six months ended June 30, 2022 and 2021, no impairment indicators were identified and no impairments were recorded. Warrants The Company applies relevant accounting guidance for warrants to purchase the Company’s stock based on the nature of the relationship with the counterparty. For warrants issued to investors or lenders in exchange for cash or other financial assets, the Company follows guidance issued within ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging For warrants issued to nonemployees for goods or services, or to customers as non-cash Compensation — Stock Compensation Contract Revenue The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers • Identify the contract with a customer • Identify the performance obligations in the contract • Determine the transaction price • Allocate the transaction price to the performance obligations in the contract • Recognize revenue when or as performance obligations are satisfied Under ASC 606, an entity recognizes revenue when or as its customer obtains control of distinct promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. Our customer arrangements primarily consist of a license, rights to our intellectual property, and research and developments services. Performance obligations are promises in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, we consider factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own, or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract. The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration, which is included in the transaction price, may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the variability is resolved. For revenue related to sales-based royalties received from licensees, including milestone payments based on the level of sales, where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). The Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations and develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in a contract with a customer. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations, which may include other comparable transactions, pricing considered in negotiating the transaction, and the estimated costs. Any variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts we would expect to receive for the satisfaction of each performance obligation. The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services, which is either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receive and consumes the benefits provided by the entity’s performance, (ii) the entity’s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the entity’s performance does not create an asset with an alternative use to the Company and the Company has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to the customer. For contracts that include a license of intellectual property (“IP”), the Company applies judgment to determine if the license of IP is distinct from other promises in the contract. License of IP that are determined to be distinct from other promises in the contract are recognized as revenue at a point in time when the license of IP is transferred to the customer and the customer can use and benefit from the license. For licenses of IP that are combined with other promises in a contract, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Determining the revenue recognition of a license of IP requires significant judgment and is discussed further in for the Company’s license and collaboration agreements in Note 4, License Agreement At the inception of a contract that includes development or regulatory milestone payment, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable a significant reversal of revenue would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s control or the licensee’s control, such as milestone payments for regulatory approvals, are not considered probable of being achieve until those approvals are received. Therefore, related revenue associated with the milestone payment is constrained as management is unable to assert that a significant reversal or revenue would not be possible. At the end of each subsequent reporting period, the Company re-evaluates catch-up For contracts that include commercial milestone payments, which are based on the achievement of future sales, and sales-based royalties, if the license is determined to be the predominant item to which the commercial milestones and royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the milestone or royalty has been allocated has been satisfied (or partially satisfied). Grant Revenue In July 2020, we entered into a grant agreement with the Bill & Melinda Gates Foundation to advance research in in vivo gene therapy for sickle cell disease and to explore new, low-cost with the Bill & Melinda Gates foundation provides for payments for reimbursed costs, which include general and administrative costs. As we are performing services under the agreement that are consistent with the Company’s ongoing central activities and we have determined that we are the principal in the agreement, we recognize grant revenue as we perform services under this agreement when the funding is committed, which occurs as underlying costs are incurred. Revenues and related expenses are presented gross in the condensed consolidated statements of operations as we have determined that we are the primary obligor under the agreement relative to the research and development services we perform as the lead technical expert. Deferred Revenue Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company’s condensed consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve months, the related deferred revenue will be classified in current liabilities. Deferred Financing Costs The incremental cost, including the fair value of warrants, directly associated with obtaining debt financing is capitalized as deferred financing costs upon the issuance of the debt and amortized over the term of the related debt agreement using the effective-interest method with such amortized amounts included as a component of interest expense in the condensed consolidated statement of operations. Unamortized deferred financing costs are presented on the condensed consolidated balance sheets as a direct deduction from the carrying amount of the related debt obligation. Research and Development Costs Research and development expenses consist primarily of costs related to discovery and research and development of products, including personnel expenses, stock-based compensation expense, allocated facility-related General and Administrative Expenses The Company expenses general and administrative costs to operations as incurred. General and administrative expenses consist primarily of compensation, benefits, and other employee-related expenses for personnel in the Company’s administrative, finance, legal, information technology, business development, communications, and human resources functions. Other costs include the legal costs incurred in connection with filing and prosecuting patent and trademark applications, general and administrative related facility costs, insurance costs and professional fees for accounting, tax, consulting, legal and other services. Stock-Based Compensation Expense The Company accounts for all stock-based payment awards granted to employees and non-employees options and grants of common stock, including common stock subject to vesting. The measurement date for employee and non-employee stock-based The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing Share-Based non-employees, non-employees Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Net loss per share attributable to common stockholders is calculated using the two-class The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, warrants and unvested restricted stock. Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the three and six months ended June 30, 2022 and 2021. As the Merger has been accounted for as a reverse recapitalization, the condensed consolidated financial statements of the merged entity reflect the continuation of the pre-merger Comprehensive Loss Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner Deferred Offering Costs As of December 31, 2021, the Company capitalized deferred offering costs of approximately $4.1 million. Deferred offering costs include certain legal, accounting, consulting and other third-party fees incurred directly related to the anticipated business combination. At the closing of the business combination during the first quarter of 2022, these previously deferred costs were recorded in stockholders’ equity as a reduction of additional paid-in Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) 2020-05, COVID-19 one-year non-lease The Company expects the adoption of Topic 842 will result in the recognition of material right-of-use In June 2016, the FASB issued ASU 2016-13, model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. This new standard is effective for the Company in the fiscal year beginning January 1, 2023 and must be adopted using a modified retrospective approach, with certain exceptions. The Company is currently evaluating the impact of this standard on its consolidated financial statements. |
Business Combination
Business Combination | 6 Months Ended |
Jun. 30, 2022 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |
Business Combination | 3. BUSINESS COMBINATION On February 2, 2022, Legacy GreenLight consummated a Business Combination with ENVI. The Business Combination, and the February 2022 PIPE Financing which was entered into as of the same date, are further described in Note 1. Upon the closing of the Business Combination, the Company’s certificate of incorporation was amended and restated to, among other things, increase the total number of authorized shares of all classes of capital stock to 510,000,000 shares, of which 500,000,000 were designated as common stock and 10,000,000 were designated as preferred stock, both having a par value of $0.0001 per share. Upon the closing of the Business Combination, holders of Legacy GreenLight common stock and preferred stock received shares of common stock in an amount determined by application of the Exchange Ratio. Legacy GreenLight additionally converted all of their convertible notes, including both the GLPRI convertible notes and the PIPE prepayment notes, to shares of common stock. For periods prior to the Business Combination, the reported share and per share amounts have been retroactively converted by applying the Exchange Ratio. The consolidated assets, liabilities, and results of operations prior to the Business Combination are those of Legacy GreenLight. The following table reconciles the elements of the Business Combination to the Condensed Consolidated Statements of Cash Flows and the Condensed Consolidated Statements of Stockholders’ Deficit: BUSINESS Cash — ENVI trust and cash (net of redemptions) $ 12,123 Cash — February 2022 PIPE Investors, including proceeds from conversion of Convertible notes — February 2022 PIPE Investors 124,250 Gross proceeds 136,373 Less: total transaction costs (26,660 ) Less: cash proceeds from Convertible notes — PIPE Investors (35,250 ) Add: transaction costs paid in 2021 4,080 Cash proceeds from Business Combination received in 2022 78,543 Less: transaction costs paid in 2021 (4,080 ) Less: warrant liabilities assumed (1,341 ) Less: net liabilities assumed in the Business Combination (133 ) Reverse merger, net of transactions costs $ 72,989 The number of shares of common stock outstanding immediately following the consummation of the Business Combination was as follows: Number of Common stock, outstanding prior to the Business Combination 20,700,000 Less: Redemption of ENVI shares (19,489,626 ) ENVI Public Shares 1,210,374 ENVI Sponsor Shares 5,175,000 Shares issued in February 2022 PIPE Financing 12,425,000 Business combination and February 2022 PIPE Financing shares 18,810,374 Legacy GreenLight shares (1) 104,011,760 Total shares of common stock immediately after Business Combination 122,822,134 (1) - The number of Legacy GreenLight shares was determined from the shares of Legacy GreenLight outstanding immediately prior to the closing of the Business Combination converted at the Exchange Ratio. All fractional shares were rounded down. Public Warrants The Company concluded that following the close of the transaction the Public Warrants met the criteria for equity classification. As of the February 2022 Closing Date, the 10,350,000 shares of Public Warrants were classified as equity in accordance with the accounting policy described within Note 2 and recognized in additional paid-in Private Placement Warrants As of the February 2022 Closing Date, the total value of the liability associated with the Private Placement Warrants was $1.3 million. The Company concluded that the Private Warrants met the definition of a liability in accordance with the accounting policy described within Note 2 and have been classified as such on the balance sheet. At June 30, 2022, the fair value of the warrant liability was $0.5 million. |
Bayer Asset Acquisition
Bayer Asset Acquisition | 12 Months Ended |
Dec. 31, 2021 | |
Bayer Asset Acquisition | 3. BAYER ASSET ACQUISITION On December 10, 2020, the Company entered into an Assignment and License Agreement (“ALA”) with Bayer CropScience LLP (“Bayer”) to acquire certain assets related to Bayer’s Bee Health, Insect Control, and Deliver intellectual property (the “Bayer Assets” or the “acquired IPR&D”). The Company acquired the Bayer Assets for cash consideration of $2.0 million. As of the acquisition date, the acquired set of assets does not meet the definition of a business and thus the IPR&D acquired was accounted for as an asset acquisition. As of the acquisition date, the assets acquired had no alternative future use and had not reached a stage of technological feasibility. As a result, the amounts were recorded as research and development expense in the accompanying consolidated statements of operations. Additionally, the Company has also agreed to make additional contingent cash payments up to an aggregate of $2.0 million based on the achievement of certain development, regulatory and commercialization events as set forth in the ALA. The ALA includes potential milestone payments that are dependent upon the development of products using the intellectual property licensed under the ALA and contingent upon the achievement of certain development or regulatory approval milestones, as well as commercial milestones. As of December 31, 2020 and 2021, no milestones have been achieved and it is not probable that the Company will reach any milestones and hence did not recognize these potential obligations in the consolidated financial statements. As the acquired IPR&D was determined to have no alternative future use and the contingent payments were not determined to be a derivative, these payments will be recorded when the contingency is resolved, and the related consideration is issued or becomes issuable. As of December 31, 2020 and 2021, no contingent payments have been accrued or paid. |
License Agreement
License Agreement | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
License Agreement | 4. LICENSE AGREEMENT In August 2020, the Company entered into a Development and Option Agreement (the “Development and Option Agreement”) with Acuitas Therapeutics, Inc. (“Acuitas”). Under the terms of the Development and Option Agreement, the parties agreed to a program for the joint development of certain products combining the Company’s mRNA constructs with Acuitas’s liquid nanoparticle technology (“Acuitas LNP Technology”). Upon entering the Development and Option Agreement, the Company incurred a $0.8 million technology access fee. Under the Development and Option Agreement, the Company may reserve up to three specified targets (“Reserved Targets”) for development of therapeutic products related to such targets, using the Acuitas LNP Technology. In order to reserve a Reserved Target, the Company must provide a target reservation notice to Acuitas and must pay a target reservation and maintenance fee of $0.1 million per target per contract year. For each Reserved Target, the Company may also reserve up to three additional vaccine or antibody targets meant to be included within the same product as the Reserved Target (“Additional Targets”), which incur additional target reservation fees per contract year. Under the Development and Option Agreement, the Company is required to maintain at least one Reserved Target. Under the Development and Option Agreement, the Company has the right to exercise a license option to develop and commercialize one or more therapeutic products relating to each Reserved Target. In the event that the Company exercises the options, the Company will pay $1.5 million for the first non-exclusive non-exclusive $2.8 million for the third non-exclusive license. Under the terms of the Development and Option Agreement, the Company is also responsible for the full-time employee funding obligations and reimbursements to Acuitas for certain development and material costs incurred by them, which totaled approximately $0.5 million in 2021. In January 2021, the Company exercised the first option under the Development and Option Agreement and entered into a non-exclusive non-exclusive, clinical The option exercise fee under the Development and Option Agreement was recorded as research and development expense upon the Company’s exercise of the first option. Additionally, the technology access fees, target reservation and maintenance fees, expenses associated with the full-time employee funding obligations and reimbursements for development and material costs incurred by Acuitas are recorded as research and development expense when incurred. The annual maintenance fee will be recorded as an expense on an annual basis based on the stated amount for the applicable year. Upon determination that a milestone payment is probable to occur, the amount of the milestone payment will be recorded as research and development expense. As the triggering of these milestone payments was not considered probable as of December 31, 2020 and 2021, no expense has been recorded during these periods. The royalty payment is contingent upon sales of licensed products under the Acuitas License Agreement. As such, when such expenses are considered probable and estimable at the commencement of sales, the Company will accrue royalty expense for the amount the Company is obligated to pay. The Company recorded an aggregate of $0.8 million and $2.0 million of research and development expenses, consisting of the technology access fees, option exercise fee and technology maintenance fees, for the years ended December 31, 2020 and 2021, respectively. | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
License Agreement | 4. LICENSE AGREEMENT Acuitas License Agreement In August 2020, the Company entered into a Development and Option Agreement (the “Development and Option Agreement”) with Acuitas Therapeutics, Inc. (“Acuitas”). Under the terms of the Development and Option Agreement, the parties agreed to a program for the joint development of certain products combining the Company’s mRNA constructs with Acuitas’ liquid nanoparticle technology (“Acuitas LNP Technology”). Upon entering the Development and Option Agreement, the Company incurred a $0.8 million technology access fee. Under the Development and Option Agreement, the Company may reserve up to three specified targets (“Reserved Targets”) for development of therapeutic products related to such targets, using the Acuitas LNP Technology. In order to reserve a Reserved Target, the Company must provide a target reservation notice to Acuitas and must pay a target reservation and maintenance fee of $0.1 million per target per contract year. For each Reserved Target, the Company may also reserve up to three additional vaccine or antibody targets meant to be included within the same product as the Reserved Target (“Additional Targets”), which incur additional target reservation fees per contract year. Under the Development and Option Agreement, the Company is required to maintain at least one Reserved Target. Under the Development and Option Agreement, the Company has the right to exercise a license option to develop and commercialize one or more therapeutic products relating to each Reserved Target. In the event that the Company exercises the options, the Company will pay $1.5 million for the first non-exclusive non-exclusive third non-exclusive In January 2021, the Company exercised the first option under the Development and Option Agreement and entered into a non-exclusive non-exclusive, The option exercise fee under the Development and Option Agreement was recorded as research and development expense upon the Company’s exercise of the first option. Additionally, the technology access fees, target reservation and maintenance fees, expenses associated with the full-time employee funding obligations and reimbursements for development and material costs incurred by Acuitas are recorded as research and development expense when incurred. The annual maintenance fee will be recorded as an expense on an annual basis based on the stated amount for the applicable year. Upon determination that a milestone payment is probable to occur, the amount of the milestone payment will be recorded as research and development expense. As the triggering of these milestone payments was not considered probable as of June 30, 2022 and December 31, 2021, no expense has been recorded during these periods. The royalty payment is contingent upon sales of licensed products under the Acuitas License Agreement. As such, when such expenses are considered probable and estimable at the commencement of sales, the Company will accrue royalty expense for the amount the Company is obligated to pay. The Company recorded research and development expenses, consisting of the technology access fees, option exercise fee and technology maintenance fees of approximately $0.2 million and $0.5 million for the three and six months ended June 30, 2022, respectively, and $0.3 million and $2.0 million for the three and six months ended June 30, 2021, respectively. |
License And Collaboration Agree
License And Collaboration Agreement | 6 Months Ended |
Jun. 30, 2022 | |
License And Collaboration Agreement [Abstract] | |
License And Collaboration Agreement | 5. LICENSE AND COLLABORATION AGREEMENT Serum License Agreement In March 2022, the Company entered into a License Agreement (the “Agreement”) with Serum Institute of India Private Limited (“SIIPL”), pursuant to which the Company granted SIIPL an exclusive, sub-licensable, product target, and SIIPL has an option to select the additional two licensed product targets through the end of 2024. Under the terms of the Agreement with SIIPL, the Company will provide research services related to the shingles product target to develop a “proof of concept” and will provide manufacturing technology transfer services. In addition, GreenLight retains the option purchase research plan and clinical trial data, developed by SIIPL, for 50% of the cost of the research plan and clinical trials for use in the Company’s own development. SIIPL is responsible for the development, formulation, filling and finishing, registration and commercialization of the products in the SIIPL Territory, subject to oversight from a joint steering committee composed of representatives of the Company and SIIPL. SIIPL will use commercially reasonable efforts to develop and obtain regulatory approval for the products in the countries in the SIIPL Territory. The License Agreement includes terms customary in the industry for provisions related to sublicensing, intellectual property, and termination, and customary representations and warranties of GreenLight and SIIPL, along with certain customary covenants, including confidentiality, limitation of liability and indemnity provisions. Pursuant to the License Agreement, SIIPL will pay the Company an upfront license fee of $5.0 million, as well as payments upon additional target selection and reservation of exclusivity. The Company may receive up to a total of an additional $17.0 million in development, regulatory and commercial (net sales) based milestone payments across all three product targets, as well as manufacturing technology transfer payments up to $10.0 million. SIIPL shall pay royalty payments in the mid-double product-by-product country-by-country The Company has determined that the Agreement falls within the scope of ASC 606, Revenue Recognition, (“ASC 606”) |
Fair Value Measurements
Fair Value Measurements | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
FAIR VALUE MEASUREMENTS | 5. FAIR VALUE MEASUREMENTS The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands): DESCRIPTION DECEMBER 31, QUOTED IN ACTIVE MARKETS IDENTICAL ASSETS (LEVEL 1) SIGNIFICANT INPUTS SIGNIFICANT (LEVEL 3) Asset Money market funds $ 55,747 $ 55,747 $ — $ — Total assets measured at fair value $ 55,747 $ 55,747 $ — $ — Liability Warrant liability $ 125 $ — $ — $ 125 Convertible debt $ 17,273 $ — $ — $ 17,273 Total liabilities measured at fair value $ 17,398 $ — $ — $ 17,398 DESCRIPTION DECEMBER 31, QUOTED PRICES SIGNIFICANT SIGNIFICANT Asset Money market funds $ 31,446 $ 31,446 $ — $ — Total assets measured at fair value $ 31,446 $ 31,446 $ — $ — Liability Warrant liabilities $ 2,105 $ — $ — $ 2,105 Convertible debt $ 31,691 $ — $ — $ 31,691 Total liabilities measured at fair value $ 33,796 $ — $ — $ 33,796 Money market funds were valued by the Company based on quoted market prices, which represent a Level 1 measurement within the fair value hierarchy. There have been no transfers between fair value levels during the years ended December 31, 2020 and 2021. The carrying values of other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The fair value of the common and Preferred Stock warrant liabilities was determined using the Black-Scholes The carrying value of each of the Horizon term loan, the SVB term loan, and the equipment financing as of December 31, 2021 approximates their fair value as the interest rate approximates the market rate for loans with similar terms and risk characteristics. The Company estimated the fair value of the convertible debt using a discounted cash flow analysis and currently prevailing market terms as of December 31, 2021. The carrying value and fair value of the convertible debt was $30.2 million and $28.9 million, respectively, as of December 31, 2021. The fair value of the convertible debt was determined using Level 3 inputs. See Note 10 for further detail of all outstanding debt as of December 31, 2021. The following table presents a roll-forward of the aggregate fair values of the Company’s liabilities for which fair value is determined by Level 3 inputs (in thousands): WARRANT Balance — January 1, 2020 $ 103 Change in fair value 22 Balance — December 31, 2020 125 Issuance of common stock warrant 610 Change in fair value 1,370 Balance — December 31, 2021 $ 2,105 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
FAIR VALUE MEASUREMENTS | 6. FAIR VALUE MEASUREMENTS The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of June 30, 2022 and December 31, 2021: DESCRIPTION JUNE 30, 2022 QUOTED SIGNIFICANT SIGNIFICANT ($ in thousands) Asset Money market funds 44,132 44,132 — — Total assets measured at fair value $ 44,132 $ 44,132 $ — $ — Liability Warrant liabilities 470 — — 470 Total liabilities measured at fair value $ 470 $ — $ — $ 470 DESCRIPTION DECEMBER 31, QUOTED SIGNIFICANT SIGNIFICANT ($ in thousands) Asset Money market funds 31,446 31,446 — — Total assets measured at fair value $ 31,446 $ 31,446 $ — $ — Liability Warrant liabilities 2,105 — — 2,105 Total liabilities measured at fair value $ 2,105 $ — $ — $ 2,105 Money market funds were valued by the Company based on quoted market prices, which represent a Level 1 measurement within the fair value hierarchy. There have been no transfers between fair value levels during the three and six months ended June 30, 2022 and 2021, respectively. The carrying values of other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The fair value of the common stock warrant liabilities was determined using the Black-Scholes option-pricing The carrying value of each of the Horizon term loan, the SVB term loan, and the equipment financing as of June 30, 2022, and December 31, 2021 approximates their fair value as the interest rate approximates the market rate for loans with similar terms and risk characteristics. The Company estimated the fair value of the convertible debt using a discounted cash flow analysis and prevailing market terms as of December 31, 2021. The carrying value and fair value of the convertible debt was $30.2 million and $28.9 million, respectively, as of December 31, 2021. The fair value of the convertible debt was determined using Level 3 inputs. See Note 10 for further detail of all outstanding debt as of June 30, 2022. The following table presents a roll-forward of the aggregate fair values of the Company’s liabilities for which fair value is determined by Level 3 inputs (in thousands): WARRANT Balance—December 31, 2021 $ 2,105 Warrants exercised in business combination (1,633 ) Warrants reclassified to equity (387 ) Change in fair value of warrants (956 ) Warrants assume in business combination 1,341 Balance—June 30, 2022 $ 470 |
Collaboration Agreement
Collaboration Agreement | 12 Months Ended |
Dec. 31, 2021 | |
Collaborative Arrangement Disclosure [Line Items] | |
Collaboration Arrangement | 6. COLLABORATION ARRANGEMENT The Company’s collaboration revenue is generated through collaboration arrangements with Ingredion. Starting in December 2015, the Company entered into a Master Collaboration and Exclusive License Agreement and related amendments (collectively, the “Ingredion Agreements”) with Ingredion to develop a semicontinuous cell-free production process for the commercial production of certain molecules using biological synthesis tools and proprietary technology developed by the Company. The parties have mutually agreed to end the collaboration and an official termination notice was received on September 30, 2021. As per the Ingredion Agreements, (a) the Company and Ingredion were to agree to specific collaboration projects from time to time and the Company was to be compensated by Ingredion for each project according to an agreed-upon billing schedule, (b) Ingredion was to make payments to the Company upon achievement of specific technical milestones, and (c) Ingredion was also to make royalty payments, including annual minimum royalty payments, to the Company if and when certain commercial and regulatory milestones are met. The Company recognized funded research and collaboration revenue of approximately $1.0 million and $0 in the consolidated statements of operations during the years ended December 31, 2020 and 2021, respectively, related to specific collaboration projects associated with the Ingredion Agreements. Costs associated with the Ingredion Agreements were recorded as research and development expenses. Under the Ingredion Agreements, the Company was entitled to receive up to $12,000 in milestone payments upon the achievement of six separate milestones, including demonstration of feasibility, achievement of pilot scale production that satisfies specified volume, yield, and cost targets (“Milestone 2”), and achievement of commercial scale production that satisfies specified volume, yield, and cost targets, as well as achievement of three separate targets for net sales by Ingredion of products based on the licensed technology. At the end of each reporting period, the Company re-evaluated catch-up For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). The Company was entitled to receive royalties on net sales by Ingredion of products based on the licensed technology. The royalty rate was in the mid-single |
Grant Revenue
Grant Revenue | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Grant Revenue [Line Items] | ||
Grant Revenue | 7. GRANT REVENUE In July 2020, the Company was approved to receive a grant from the Bill & Melinda Gates Foundation in the amount of approximately $3.3 million. As of December 31, 2021, the Company had received the entire grant award, of which approximately $2.4 million was received during the year ended December 31, 2020, and the remaining approximately $0.9 million was received during the year ended December 31, 2021. The grant funds are to be used for the sole purpose of research for in vivo gene therapy for sickle cell disease and to explore new, low-cost | 7. GRANT REVENUE In July 2020, the Company was approved to receive a grant from the Bill & Melinda Gates Foundation in the amount of approximately $3.3 million. As of December 31, 2021, the Company had received the entire grant award, of which approximately $2.4 million was received during the year ended December 31, 2020, and the remaining approximately $0.9 million was received during the year ended December 31, 2021. The grant funds are to be used for the sole purpose of research for in vivo gene therapy for sickle cell disease and to explore new, low-cost |
Property and Equipment, Net
Property and Equipment, Net | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Property, Plant and Equipment [Line Items] | ||
Property and Equipment, Net | 8. PROPERTY AND EQUIPMENT, NET Property and equipment, net consisted of the following as of June 30, 2022 and December 31, 2021: JUNE 30, DECEMBER 31, ($ in thousands) Computer hardware and software $ 868 $ 732 Laboratory equipment 20,815 19,590 Leasehold improvements 10,883 10,442 Manufacturing equipment 1,214 — Construction in progress 11,636 1,894 Total 45,416 32,658 Less: Accumulated depreciation and amortization (13,331 ) (9,259 ) Property and equipment, net $ 32,085 $ 23,399 As of June 30, 2022 and December 31, 2021, property and equipment, net included capital lease assets of approximately $2.5 million, with accumulated amortization of approximately $1.7 million and $1.5 million, respectively. Depreciation and amortization expense for the three and six months ended June 30, 2022 was approximately $2.0 million and $4.1 million, respectively, and $1.2 million and $2.3 million for the three and six months ended June 30, 2021, respectively. Included in construction in progress as of June 30, 2022 was approximately $6.2 million of leasehold improvements that have been funded through tenant incentive allowances associated with leases signed in September 2021 and March 2022 related to laboratory, office and greenhouse space. | 8. PROPERTY AND EQUIPMENT, NE Property and equipment, net consisted of the following as of December 31, 2020 and 2021 (in thousands): DECEMBER 31, 2020 2021 Computer hardware and software $ 533 $ 732 Laboratory equipment 8,040 19,590 Leasehold improvements 4,545 10,442 Construction in progress 6,847 1,894 Total 19,965 32,658 Less: Accumulated depreciation and amortization (3,686 ) (9,259 ) Property and equipment, net $ 16,279 $ 23,399 As of December 31, 2020 and 2021, property and equipment, net included capital lease assets of approximately $2.5 million, with accumulated |
Accrued Expenses
Accrued Expenses | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Accrued Liabilities, Current [Line Items] | ||
Accrued Expenses | 9. ACCRUED EXPENSES Accrued expenses as of June 30, 2022 and December 31, 2021 consisted of the following: JUNE 30, DECEMBER 31, ($ in thousands) Accrued employee compensation and benefits $ 8,065 $ 8,492 Accrued research and development 20,709 4,059 Accrued professional fees 568 1,888 Accrued other 1,085 185 Total accrued expenses $ 30,427 $ 14,624 | 9. ACCRUED EXPENSES Accrued expenses as of December 31, 2020 and 2021 consisted of the following (in thousands): DECEMBER 31, 2020 2021 Accrued employee compensation and benefits $ 4,024 $ 8,492 Accrued research and development 612 4,059 Accrued professional fees 568 1,888 Accrued other 1,622 185 Total accrued expenses $ 6,826 $ 14,624 |
Debt
Debt | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Debt | 10. DEBT A summary of the outstanding debt as of December 31, 2021 is as follows (in thousands): AS OF DECEMBER 31, 2021 DESCRIPTION ISSUANCE DATE(S) MATURITY STATED RATE PRINCIPAL BALANCE OUTSTANDING UNAMORTIZED DEBT DEBT BALANCE Trinity Equipment Financing March 2021 - August 2021 March 2024 - August 2024 9.48% - 9.73% $ 9,454 $ (252 ) $ 9,202 Term Loan — Silicon Valley Bank September 2021 September 2024 3.50% 10,000 (225 ) 9,775 Term Loan — Horizon December 2021 May 2025 9.00% 15,000 (582 ) 14,418 Capital Lease 992 — 992 Total Debt 35,446 (1,060 ) 34,386 Less: current portion, net of current portion of debt (7,234 ) Total long-term $ 27,152 Convertible Note — PIPE Investors December 2021 December 2022 0.33% 13,500 — 13,500 Convertible Notes April & May 2020 April & May 2022 5.00% 18,213 (22 ) 18,191 31,713 (22 ) 31,691 $ 67,159 $ (1,082 ) $ 66,077 (a) As of December 31, 2020 and 2021, the Company’s debt liability included $16.8 million of convertible notes issued by GLPRI in 2020, as well as the associated accrued interest liability of $0.6 million and $1.4 million, respectively. Convertible Instruments — PIPE Investors In December 2021, certain new and existing investors in GreenLight (the “Prepaying PIPE Investors”) agreed to purchase from GreenLight convertible instruments with an aggregate principal amount of approximately $35.3 million (the “PIPE Instruments”), $13.5 million of which was received on or before December 31, 2021. The remainder of the PIPE Instruments were issued in January 2022 in exchange for cash totaling approximately $21.8 million. As such, the Company recorded $13.5 million of the debt liability as of December 31, 2021. The PIPE Instruments bear interest at the minimum applicable federal rate per annum payable at maturity. The PIPE Instruments have a maturity date on the earlier of twelve months after their issuance dates or an event of default. The PIPE Instruments are pre-payable The PIPE Instruments provided for the automatic conversion of the outstanding principal into shares of the class of capital stock issued in a Qualified Financing (as defined below). Upon the closing of certain change of control transactions or an initial public offering (“IPO”), GreenLight was obligated to repay the Prepaying PIPE Investors an amount equal to the outstanding principal balance and interest accrued on the PIPE Instruments in preference to any payments made to the holders of GreenLight’s common stock. In conjunction with entering into the PIPE Instruments, each PIPE Investor entered into a side letter agreement (the “Side Letter”) with GreenLight, which required the PIPE Investor to tender its PIPE Instrument as a corresponding payment for all or a portion of such PIPE Investor’s purchase of shares upon the closing of a business combination with ENVI. The PIPE Instruments included the following conversion and redemption features: a) Upon an equity financing involving the sale of capital stock of the Company primarily for capital-raising purposes on terms no less favorable to the purchasers than the terms of GreenLight’s Series D Preferred Stock financing (a “Qualified Financing”), all then outstanding principal on each PIPE Instrument would automatically convert into that number of shares of capital stock issued in such Qualified Financing equal to the quotient obtained by dividing (i) the outstanding principal amount of the PIPE Instrument by (ii) the lower of the Conversion Discount Price or the Capped Price (each as defined for purposes of the PIPE Instrument). b) Upon a change of control or an IPO, the holders of the PIPE Instruments would be entitled to receive an amount equal to the outstanding principal and interest on the holders’ PIPE Instruments in preference to the holders of GreenLight’s common stock. c) Upon the occurrence of an event of default, the PIPE Instruments would automatically become due and payable. Upon such acceleration, all outstanding principal (with no penalty) and unpaid accrued interest would become payable. The Company assessed the embedded features within the PIPE Instruments and did not identify any material embedded derivative in connection with the automatic conversion upon a Qualified Financing. The other embedded features did not meet the definition of a derivative or were clearly and closely related to the host contract, and thus did not require separate accounting. In February of 2022, in accordance with the Side Letter, the PIPE Instruments were surrendered and cancelled upon the occurrence of a business combination with Environmental Impact Acquisition Corp. See Note 18 for further discussion of the business combination. Term Loan — Horizon In December 2021, the Company entered into a loan and security agreement with Horizon Technology Finance Corporation and Powerscourt Investments XXV, LP (together “Horizon”), which provided for a term loan facility in an aggregate principal amount of up to $25.0 million, $15.0 million of which was borrowed at the closing and the remainder of which may be borrowed following the achievement of certain milestones, but not after June 30, 2022. Accrued interest is payable monthly. The principal of each term loan must be repaid in equal monthly installments beginning (or August 1, 2023 if any of the remaining $ million is borrowed), with a scheduled final maturity date of . The Company may prepay the term loans in full, but not in part, without premium or penalty, other than a premium equal to (i) % of the principal amount of any prepayment made within 12 months after the applicable funding date, (ii) % of the principal amount of any prepayment made between 12 and 24 months after the applicable funding date and (iii) 1% of the principal amount of any prepayment made more than 24 months after the applicable funding date. On the earlier of the scheduled final maturity date and the prepayment in full of the term loans, the Company must pay a final payment fee equal to % of the original principal amount of the funded term loans. The debt was recorded based on proceeds received net of related debt issuance costs of approximately $0.6 million. The debt issuance costs include the fair value of approximately $0.4 million for the warrants the Company is committed to issue in conjunction with this financing. The Company is obligated to issue 80% of the warrant obligation during the three months ending March 31, 2022, and such warrant obligation is calculated at 3% of the loan commitment. The number of warrants to be issued and strike price will be set at the lower of $5.26 and 90% of the public trading value of shares of ENVI if issued after the close of the Business Combination. Since the Company is committed to issue these warrants, the Company has recorded the estimated fair value of these warrants as of the date of the loan and security agreement of $0.5 million, of which $0.4 million is recorded as debt issuance cost and $0.1 million is recorded in other assets for the portion of the principal amount not yet borrowed by the Company as of December 31, 2021. Total debt issuance costs of approximately $0.6 million is being amortized over the term of the financing agreement. Term Loan — Silicon Valley Bank In September 2021, the Company entered into a loan and security agreement with Silicon Valley Bank (“SVB”), which provided for a term loan facility in an aggregate principal amount of up to $15.0 million, $10.0 million of which was borrowed at the closing and the remainder of which may be borrowed following the achievement of certain milestones, but not after March 31, 2022. Accrued interest is payable monthly. The principal of each term loan must be repaid in equal monthly installments beginning April 1, 2022 (or October 1, 2022, if GreenLight borrows any of the remaining $5.0 million), with a scheduled final maturity date of September 1, 2024. On the earlier of the scheduled final maturity date and the prepayment in full of the term loans, the Company must pay a final payment fee equal to 4.0% of the original principal amount of the term loans. GreenLight may prepay the term loans in increments of $5.0 million and without premium or penalty, other than a premium equal to (i) with respect to any prepayment made on or before September 22, 2022, 3% of the principal so prepaid, (ii) with respect to any prepayment made after September 22, 2022 and on or before September 22, 2023, 2% of the principal so prepaid and (iii) with respect to any prepayment made after September 22, 2023 and on or before September 1, 2024, 1% of the principal so prepaid. GreenLight granted a first-priority, perfected security interest in substantially all of its present and future personal property and assets, excluding intellectual property, to secure its obligations to SVB. The debt was recorded based on proceeds received net of related debt issuance costs of approximately $0.3 million. The debt issuance costs include the fair value of approximately $0.2 million for the 34,427 shares of common warrants the Company previously issued in conjunction with this financing. No additional common warrants were issued in conjunction with this financing. Total debt issuance costs of approximately $0.4 million is being amortized over the term of the financing agreement. Equipment Financing On March 29, 2021, the Company entered into a master equipment financing agreement with Trinity Capital (Trinity) authorizing equipment financing in the aggregate of approximately $11.3 million with advances to be made as follows: (1) up to $5.0 million at execution of the agreement and (2) the remaining balance 36- The debt was recorded based on proceeds received net of related debt issuance costs of approximately $0.4 million, which are being amortized over the term of the financing agreement. The debt issuance costs include the fair value of approximately $0.1 million for the 146,325 common stock warrants the Company issued in conjunction with this financing. Convertible Notes In April and May 2020, GLPRI issued a series of convertible notes payable in exchange for cash totaling approximately $16.8 million (the “2020 Notes”). The Company guaranteed payment and performance of the 2020 Notes. The 2020 Notes bear interest at 5% per annum that is accrued each period and is payable at maturity. The effective interest rate was 5.4% as of December 31, 2021. The total amount of accrued interest on the notes is approximately $0.6 million and $1.4 million as of December 31, 2020 and 2021, respectively. The 2020 Notes mature two years after their respective issuance dates. The 2020 Notes are only pre-payable The 2020 Notes provide the option to convert the outstanding principal, plus accrued and unpaid interest, into shares of the Company’s Series D Preferred Stock (on or after the date of the Series D Preferred Stock financing) or the right to receive royalties on future sales of certain of GLPRI’s products. In conjunction with entering into the 2020 Note agreements, each holder entered into a side letter agreement (the “Side Letter”) with GreenLight and GLPRI, which gives the holder the right to convert the 2020 Notes into shares of Series D Preferred Stock at a discounted conversion price (85% of the price per share of the Series D Preferred Stock) in the event that the Series D financing is deemed an inside round. This discount did not apply as the Series D financing was determined not to be an inside round. At issuance, the Company concluded that the fair value of the discount feature was de minimis. The 2020 Notes include the following conversion and redemption features: • From the date of the initial closing of the then-next equity financing of the Company (the “Series D Financing”) until maturity, conversion at the option of the holder into Series D Preferred Stock (based upon the original issue price of the Series D Preferred Stock) or the right to receive certain royalty payments over a 15-year • Upon the occurrence of certain contingent events after the Company’s Series D Financing and before maturity, automatic conversion into Series D Preferred Stock (based upon the original issue price of the Series D Preferred Stock). • Automatic redemption upon an event of default, as defined in the 2020 Notes. Upon the occurrence of an event of default, the 2020 Notes will either automatically become due and payable or can become due and payable at the holder’s option (based on the nature of the event of default). Upon such acceleration, all outstanding principal (with no penalty) and unpaid accrued interest will become payable. The Company assessed the embedded features within the 2020 Notes and determined that the features do not meet the definition of a derivative or were clearly and closely related to the host contract, and thus did not require separate accounting. In addition, the optional redemption feature to receive royalty payments is subject to a scope exception from derivative accounting. The 2020 Notes were recorded based on proceeds received and were recorded net of related debt issuance costs of approximately $0.1 million, which are being amortized to interest expense using the effective interest rate method over the term of the notes. In August 2021, the 2020 Notes were amended and restated to make the Company the sole obligor under the 2020 Notes and to remove the right to receive royalties on future sales of certain products. Loan Interest Expense and Amortization The Company’s total interest expense was approximately $1.0 million and $2.4 million for the year ended December 31, 2020 and 2021, respectively. DECEMBER 31, 2020 2021 Interest paid or accrued $ 440 $ 2,253 Noncash amortization of debt discount and deferred financing cost 588 166 Total $ 1,028 $ 2,419 Scheduled future principal payments on total outstanding debt, as of December 31, 2021, are as follows (in thousands): DECEMBER 31, 2022 $ 37,176 2023 13,916 2024 11,972 2025 and thereafter 2,657 Total $ 65,721 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Debt | 10. DEBT A summary of the outstanding debt as of June 30, 2022 is as follows (in thousands): AS OF JUNE 30, 2022 DESCRIPTION ISSUANCE MATURITY INTEREST PRINCIPAL UNAMORTIZED DEBT Trinity Equipment Financing March 2021 - August 2021 March 2024 - August 2024 9.48% - 9.73% $ 7,722 $ (198 ) $ 7,524 Term Loan — Silicon Valley Bank September 2021 September 2024 5.00% 9,000 (158 ) 8,842 Term Loan — December 2021 May 2025 10.50% 15,000 (472 ) 14,528 Capital lease 664 — 664 Total Debt 32,386 (828 ) 31,558 Less: Current Portion (11,402 ) Total Long-Term $ 20,156 A summary of the outstanding debt as of December 31, 2021 is as follows (in thousands): AS OF DECEMBER 31, 2021 DESCRIPTION ISSUANCE MATURITY STATED PRINCIPAL UNAMORTIZED DEBT Trinity equipment financing March 2021 - August 2021 March 2024 - August 2024 9.48% - 9.73% $ 9,454 $ (252 ) $ 9,202 Term loan — Silicon Valley Bank September 2021 September 2024 3.50% 10,000 (225 ) 9,775 Term loan — Horizon December 2021 May 2025 9.00% 15,000 (582 ) 14,418 Capital lease 992 — 992 Total Debt 35,446 (1,060 ) 34,386 Less: Current Portion (7,234 ) Total Long-Term 27,152 Convertible notes — PIPE Investors December 2021 December 2022 0.33% 13,500 — 13,500 Convertible notes (a) April & May 2020 April & May 2020 5.00% 18,213 (22 ) 18,191 31,713 (22 ) 31,691 Total debt and convertible notes $ 67,159 $ (1,082 ) $ 66,077 a) As of December 31, 2021, the Company’s debt liability included $16.8 million of convertible notes issued by GLPRI in 2020, as well as the associated accrued interest liability of $1.4 million. Convertible Instruments — PIPE Investors In December 2021, certain new and existing investors in GreenLight (the “Prepaying PIPE Investors”) agreed to purchase from GreenLight convertible instruments with an aggregate principal amount of approximately $35.3 million (the “PIPE Instruments”). The Company received $13.5 million in December 2021 and $21.8 million in January of 2022. In conjunction with entering into the PIPE Instruments, each PIPE Investor entered into a side letter agreement (the “Side Letter”) with GreenLight, which required the PIPE Investor to tender its PIPE Instrument as a corresponding payment for all or a portion of such PIPE Investor’s purchase of shares upon the closing of a business combination. In February of 2022, in accordance with the Business Combination, $35.3 million of the PIPE Instruments were surrendered, cancelled, and converted into shares of common stock. The Company determined that the cancellation and conversion of the PIPE Instruments represented an extinguishment for accounting purposes. Term Loan — Horizon In December 2021, the Company entered into a loan and security agreement with Horizon Technology Finance Corporation and Powerscourt Investments XXV, LP (together, “Horizon”), which provided for a term loan facility in an aggregate principal amount of up to $25.0 million, $15.0 million of which was borrowed at the closing and the remainder of which may be borrowed following the achievement of certain milestones, but not after June 30, 2022. As of June 30, 2022, the Company had not borrowed, and may no longer borrow the remainder of the term loan. Accrued interest is payable monthly. The principal of each term loan must be repaid in equal monthly installments beginning February 1, 2023 (or August 1, 2023 if any of the remaining $10.0 million is borrowed), with a scheduled final maturity date of July 1, 2025. The Company may prepay the term loans in full, but not in part, without premium or penalty, other than a premium equal to (i) 3% of the principal amount of any prepayment made within 12 months after the applicable funding date, (ii) 2% of the principal amount of any prepayment made between 12 and 24 months after the applicable funding date and (iii) 1% of the principal amount of any prepayment made more than 24 months after the applicable funding date. On the earlier of the scheduled final maturity date and the prepayment in full of the term loans, the Company must pay a final payment fee equal to 3.0% of the original principal amount of the funded term loans. The debt was recorded based on proceeds received net of related debt issuance costs of approximately $0.6 million. The debt issuance costs include the fair value of approximately $0.4 million for the warrants the Company is committed to issue in conjunction with this financing. The warrants were issued on January 19, 2022. See Note 11 for further discussion of the warrants. Term Loan — Silicon Valley Bank In September 2021, the Company entered into a loan and security agreement with Silicon Valley Bank (“SVB”), which provided for a term loan facility in an aggregate principal amount of up to $15.0 million, $10.0 million of which was borrowed at the closing and the remainder of which may be borrowed following the achievement of certain milestones, but not after March 31, 2022. The remaining $5.0 million was no longer available as it was not borrowed as of March 31, 2022. Accrued interest is payable monthly. The principal of each term loan must be repaid in equal monthly installments beginning April 1, 2022, with a scheduled final maturity date of September 1, 2024. On the earlier of the scheduled final maturity date and the prepayment in full of the term loans, the Company must pay a final payment fee equal to 4.0% of the original principal amount of the term loans. GreenLight may prepay the term loans in increments of $5.0 million and without premium or penalty, other than a premium equal to (i) with respect to any prepayment made on or before September 22, 2022, 3% of the principal so prepaid, (ii) with respect to any prepayment made after September 22, 2022 and on or before September 22, 2023, 2% of the principal so prepaid and (iii) with respect to any prepayment made after September 22, 2023 and on or before September 1, 2024, 1% of the principal so prepaid. GreenLight granted a first-priority, perfected security interest in substantially all of its present and future personal property and assets, excluding intellectual property, to secure its obligations to SVB. The debt was recorded based on proceeds received net of related debt issuance costs of approximately $0.3 million. The debt issuance costs include the fair value of approximately $0.2 million for the 51,724 shares of common warrants the Company previously issued in conjunction with this financing. No additional common warrants were issued in conjunction with this financing. Total debt issuance costs of approximately $0.4 million is being amortized over the term of the financing agreement. Equipment Financing On March 29, 2021, the Company entered into a master equipment financing agreement with Trinity Capital (Trinity) authorizing equipment financing in the aggregate of approximately $11.3 million with advances to be made as follows: (1) up to $5.0 million at execution of the agreement and (2) the remaining balance 36-month The debt was recorded based on proceeds received net of related debt issuance costs of approximately $0.4 million, which are being amortized over the term of the financing agreement. The debt issuance costs include the fair value of approximately $0.1 million for the 219,839 common stock warrants the Company issued in conjunction with this financing. Convertible Notes In connection with the Merger (See Note 3), $16.8 million of the Company’s outstanding convertible notes, which were issued in 2020, and accrued interest of $1.6 million converted into 10.1 million shares of Series D Preferred Stock. Concurrently with the business combination, the Series D Preferred Stock was exchanged for shares of common stock of New GreenLight in February of 2022. Loan Interest Expense and Amortization Interest expense for the three and six months ended June 30, 2022 and 2021 consisted of the following: THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED 2022 2021 2022 2021 ($ in thousands) Interest paid or accrued $ 935 $ 202 $ 1,739 $ 303 Non-cash 199 212 423 422 Total $ 1,134 $ 414 $ 2,162 $ 725 Scheduled future principal payments on total outstanding debt, as of June 30, 2022 are as follows (in thousands): JUNE 30, 2022 Remainder of 2022 $ 4,662 2023 14,226 2024 10,998 2025 and thereafter 2,500 Total $ 32,386 |
Warrants
Warrants | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||
WARRANTS | 11. WARRANTS Preferred Stock Warrants Classified as Liabilities The Company has outstanding warrants to purchase shares of Series A-1, A-2, A-3 AS OF DECEMBER 31, 2020 WARRANT CLASS SHARES FAIR ISSUANCE DATE EXERCISE EXPIRATION DATE Series A-1 48,921 $ 75 December 31, 2011 $ 0.18 The earlier of January 17, 2022 or a deemed Series A-2 21,131 21 August 26, 2014 $ 1.77 The earlier of August 25, 2024 or the date of a qualifying acquisition Series A-3 17,206 29 December 18, 2015 $ 0.24 The earlier of December 18, 2025 or a deemed liquidation or IPO Total 87,258 $ 125 AS OF DECEMBER 31, 2021 WARRANT CLASS SHARES FAIR ISSUANCE DATE EXERCISE EXPIRATION DATE Series A-1 31,830 $ 228 December 31, 2011 $ 0.18 The earlier of January 17, 2022 or a deemed liquidation or IPO Series A-2 21,131 138 August 26, 2014 $ 1.77 The earlier of August 25, 2024 or the date of a qualifying acquisition Series A-3 17,206 110 December 18, 2015 $ 0.24 The earlier of December 18, 2025 or a deemed liquidation or IPO Total 70,167 $ 476 The Company estimated the fair value of the warrants as of December 31, 2020, and 2021 using the Black-Scholes option-pricing model with the following assumptions: AS OF DECEMBER 31, 2020 VALUATION ASSUMPTIONS SERIES A-1 SERIES A-2 SERIES A-3 Fair value of underlying series of preferred stock $ 2.18 $ 2.31 $ 2.64 Risk free interest rate 0.10 % 0.27 % 0.36 % Expected volatility 88.4 % 78.5 % 82.4 % Estimated time (in years) 1.05 3.65 4.97 AS OF DECEMBER 31, 2021 VALUATION ASSUMPTIONS SERIES A-1 SERIES A-2 SERIES A-3 Fair value of underlying series of preferred stock $ 9.19 $ 9.21 $ 9.25 Risk free interest rate 0.06 % 0.97 % 1.12 % Expected volatility 87.6 % 85.5 % 84.9 % Estimated time (in years) 0.05 2.65 3.97 Preferred Stock Warrant Classified as Equity In connection with the July 2020 issuance of Series D convertible Preferred Stock, a warrant to purchase shares of Series D Preferred Stock was issued. The holder of the warrant is entitled to purchase 581,821 shares of the Company’s Series D Preferred Stock at an exercise price of $2.7221 per share. The warrant was determined to represent compensation for services provided by the holder and was accounted for under ASC 718. The warrants were issued to the holder in relation to its role in assisting the Company with identifying the lead investor for the financing round. The warrant meets the requirements for equity classification under ASC 718 and should be measured at cost, which was determined to be equal to its grant date fair value of approximately $0.4 million. As the services related to its issuance were completed during 2020, the Company recognized the cost of the warrant during the year ended December 31, 2020. As the warrant was determined to be a direct and incremental cost of the Series D financing, the cost of the warrant was recorded as a stock issuance cost. PREFERRED STOCK WARRANT WARRANT CLASS SHARES ISSUANCE DATE EXERCISE EXPIRATION DATE Series D preferred stock 581,821 July 24, 2020 $ 2.7221 The earlier of July 24 Common Stock Warrant classified as Liability In connection with the equipment financing in March 2021, the Company issued a warrant to purchase 146,325 shares of the Company’s common stock at an exercise price of $1.23 per share. The warrant was determined to represent additional consideration provided to the lender at the closing of the financing agreement and thus considered a component of the financing transaction, and therefore was accounted for under ASC 480. The warrant meets the requirements for liability classification under ASC 480 and should be measured at cost at its inception date fair value and subsequently remeasured at the end of each reporting period, with changes recorded as a component of other income in the Company’s consolidated statement of operations. WARRANT CLASS SHARES FAIR ISSUANCE DATE EXERCISE EXPIRATION DATE Common stock 146,325 $ 1,188 March 29, 2021 $ 1.23 The earlier of March 29 The warrant’s fair value upon issuance and as of December 31 2021 was estimated to be approximately $0.1 million and $1.2 million, respectively, and was measured using a Black-Scholes option-pricing model with the following assumptions: VALUATION ASSUMPTIONS AT ISSUANCE MARCH 29, 2021) AS OF DECEMBER 31, 2021 Fair value of common stock $ 1.23 $ 8.85 Risk free interest rate 1.73 % 1.52 % Expected volatility 72.10 % 63.30 % Expected term (in years) 10.00 9.25 In connection with Loan Agreement the Company entered into with Horizon Technology Finance Corporation and Powerscourt Investments XXV, LP in December 2021, the Company committed to issue the lender a warrant to purchase shares of the Company’s common stock which was issued subsequent to year-end. The Company valued the commitment to issue warrants using the Black-Scholes option pricing model adjusted based on probability of issuance as of year-end and determined the fair value to be $0.5 million as of December 31, 2021. The significant inputs used to determine fair value are 1.5% risk free interest rate, 59.6% annualized volatility, 10 year term and $7.90 strike price. Common Stock Warrant classified as Equity In connection with the Loan Agreement the Company entered into with Silicon Valley Bank in June 2016, the Company issued the bank a warrant to purchase 26,624 shares of the Company’s common stock at an exercise price per share of $0.33 (the “Common Warrant”). The Common Warrant will be exercisable for ten years from the date of issuance. The Common Warrant was determined to represent additional consideration for services provided by the lender, rather than a component of the financing transaction, and therefore was accounted for under ASC 718. The Common Warrant meets the requirements for equity classification under ASC 718 and is measured at cost, which was determined to be equal to its grant date fair value of approximately $5 thousand. In connection with the term loan obtained in September 2021 from SVB, the Company authorized a warrant to SVB to purchase up to 34,427 shares of the Company’s common stock at an exercise price per share of $2.61 (the “2021 Common Warrant”). As of December 31, 2021, the warrant is exercisable for up to 22,952 shares of common stock. The 2021 Common Warrant is classified as a component of permanent equity because it is a freestanding financial instrument that is legally detachable and separately exercisable from the debt instrument with which it was issued, is immediately exercisable, does not embody an obligation for the Company to repurchase its shares, and permits the holder to receive a fixed number of shares of common stock upon exercise. The Company valued the 2021 Common Warrant at issuance using the Black-Scholes option pricing model and determined the fair value of the 2021 Common Warrant to be approximately $0.2 million. Common stock warrant classified as a component of permanent equity consisted of the following at December 31, 2021: AS OF DECEMBER 31, 2021 WARRANT CLASS SHARES ISSUANCE DATE EXERCISE EXPIRATION DATE Common stock warrant 26,624 June 14, 2016 $ 0.33 The earlier of June 13 Common stock warrant 34,427 September 22, 2021 $ 2.61 The earlier of September 21 Total 61,051 During the years ended December 31, 2020 and 2021 there were no exercises of existing common stock warrants | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | ||
WARRANTS | 11. WARRANTS Common Stock Warrants classified as Liability Private Placement Warrants The Private Placement Warrants may not be redeemed by the Company so long as the Private Placement Warrants are held by the initial purchasers, or such purchasers’ permitted transferees. The Private Placement Warrants have terms and provisions identical to those of the Public Warrants which are discussed below, including as to exercise price, exercisability, and exercise period, except if the Private Placement Warrants are held by someone other than the initial purchasers’ permitted transferees, then the Private Placement Warrants are redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. On the February 2022 Closing Date and as of June 30, 2022, there were 2,062,500 Private Warrants issued and outstanding. These warrants are recognized as liabilities on the condensed consolidated balance sheets and were measured at their inception date fair value and subsequently remeasured at each reporting period with changes recorded as a component of other income in the Company’s condensed consolidated statements of operations. Warrant Class Shares Inception Initial Exercise Expiration Private Placement Warrants 2,062,500 $ 1,341 February 2, $ 11.50 March 2, The fair value of the Private Placement Warrant upon initial recognition and as of June 30, 2022 was estimated to be approximately $1.3 million and $0.5 million respectively, and was measured using a Black-Scholes option-pricing model with the following assumptions: Valuation Assumptions INITIAL AS OF Fair value of common stock $ 8.82 $ 2.21 Risk free interest rate 1.59 % 3.00 % Volatility 15.9 % 51.5 % Expected term (in years) 5.00 4.50 Common Stock Warrants classified as Equity Horizon Debt Warrants In connection with the Loan Agreement the Company entered into with Horizon in December 2021, the Company issued the warrants to Horizon to purchase 85,552 shares of the Company’s common stock at an exercise price per share of $5.26 for the $15.0 million drawn commitment. Upon the issuance during January 2022, the Company reassessed for the classification of these warrants, and noted that there were no variability on the number of shares or the exercise price of the settlement. The Company determined that the Warrants met the requirements for equity classification and the fair value of $0.4 million was reclassified to equity as of March 31, 2022. Warrant Class Shares Issuance Date Exercise Expiration Date Common stock warrant 85,552 January 19, 2022 $ 5.26 January 19, 2032 The warrant’s fair value upon issuance was estimated to be approximately $0.4 million, and was measured using a Black-Scholes option-pricing model with the following assumptions: Valuation Assumptions AT ISSUANCE (AS OF JANUARY 19, Fair value of common stock $ 5.89 Risk free interest rate 1.50 % Expected volatility 59.60 % Expected term (in years) 10.00 In connection with Loan Agreement the Company entered into with Horizon which provided for a term loan facility in an aggregate principal amount of up to $25.0 million, $15.0 million of which was borrowed at the closing (See Note 10). The Company issued warrants for both the $15.0 million loan drawn at the closing and the remaining $10.0 million available commitment which had different terms and conditions. In conjunction with the $10.0 million available commitment, the Company made available Horizon a warrant to purchase up 57,034 shares, of which 28,517 shares of the Company’s common stock were issued at an exercise price per share of $5.26. These warrants are recognized as liabilities on the condensed consolidated balance sheets and were measured at their inception date fair value and subsequently remeasured at each reporting period with changes recorded as a component of other income in the Company’s condensed consolidated statements of operations. The warrants issued for the $10.0 million available commitment was summarized below as a liability classified Common Stock Warrant. Warrant Class Shares Inception Issuance Exercise Expiration Date Common stock warrant 28,517 $ 249 January 19, $ 5.26 The earlier of March 29, 2031 or the date of a qualifying acquisition The warrant’s fair value upon issuance and as of June 30, 2022 was estimated to be approximately $0.2 million and $35 thousand, respectively, and was measured using a probability weighted Black-Scholes option-pricing model with the following assumptions: Valuation Assumptions AT ISSUANCE 2022) AS OF Fair value of common stock $ 5.89 $ 2.21 Risk free interest rate 1.50 % 2.39 % Expected volatility 59.60 % 59.60 % Expected term (in years) 10.50 10.00 At June 30, 2022, the Warrants were determined to have met the requirements for equity classification and the fair value of $35 thousand was reclassified to equity. Public Warrants Each Public Warrant entitles the holder to the right to purchase one share of common stock at an exercise price of $11.50 per share. No fractional shares will be issued upon exercise of the Public Warrants. The Company may elect to redeem the Public Warrants subject to certain conditions, in whole and not in part, at a price of $0.01 per Public Warrant if (i) 30 days’ prior written notice of redemption is provided to the holders, and (ii) the last reported sale price of the Company’s common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading In March 2022, 105,120 of the Public Warrants were exercised into shares of the Company’s common stock for a total exercise price of approximately $1.2 million in cash. The following table presents a roll-forward of the Company’s warrants from December 31, 2021 to June 30, 2022: COMMON PREFERRED Warrants Outstanding, December 31, 2021 (1) 207,376 635,404 Exercised in the business combination (1) (207,376 ) (635,404 ) Issued (1) 75,924 — Assumed in the business combination 12,412,500 — Exercised subsequent to the business combination (105,120 ) — Warrants Outstanding, June 30, 2022 12,383,304 — (1) Number of warrants have been adjusted to reflect the exchange for New GreenLight warrants at an exchange ratio of approximately 0.6656 as a result of the Business Combination. See Note 3 for further information. |
Stockholders' Equity
Stockholders' Equity | 6 Months Ended |
Jun. 30, 2022 | |
Stockholders' Equity Note [Abstract] | |
STOCKHOLDERS' EQUITY | 12. STOCKHOLDERS’ EQUITY Authorized shares The Company was authorized to issue 500,000,000 shares of $0.0001 par value common stock and 10,000,000 shares of $0.0001 par value preferred stock as of June 30, 2022 and 191,500,000 shares of $0.001 par value common stock as of December 31, 2021. As of June 30, 2022, there were 123,663,315 shares of common stock issued and outstanding and 12,383,304 warrants to purchase the Company’s common stock outstanding. As of June 30, 2022, there were no shares of preferred stock issued or outstanding. Legacy Greenlight Redeemable Convertible Preferred Stock In connection with the Business Combination, Legacy Redeemable Convertible Preferred Stock previously classified as temporary equity was retroactively adjusted, converted into common stock at an exchange ratio of approximately 0.6656, and reclassified to permanent equity as a result of the reverse recapitalization. As of June 30, 2022, there was no Legacy Redeemable Convertible Preferred Stock authorized, issued or outstanding. The following table summarizes details of Legacy Redeemable Convertible Preferred Stock authorized, issued, and outstanding immediately prior to the Business Combination. Redeemable Convertible Preferred Stock Classes JUNE 30, DECEMBER 31, ($ in thousands) Series A-1 $ — $ 4,414 Series A-2 — 11,438 Redeemable Convertible Preferred Stock Classes JUNE 30, DECEMBER 31, ($ in thousands) Series A-3 — 19,917 Series B redeemable convertible preferred stock, $0.001 par value, 21,245,353 shares authorized, issued and outstanding as of December 31, 2021 Liquidation preference of $24,017 and $0 at December 31, 2021 and June 30, 2022, respectively — 18,671 Series C redeemable convertible preferred stock, $0.001 par value, 35,152,184 shares authorized, 35,092,183 shares issued and outstanding as of December 31, 2021 Liquidation preference of $69,595 and $0 at December 31, 2021 and June 30, 2022, respectively — 55,851 Series D redeemable convertible preferred stock, $0.001 par value, 71,019,827 shares authorized, 60,184,332 shares issued and outstanding as of December 31, 2021 Liquidation preference of $122,459 and $0 at December 31, 2021 and June 30, 2022, respectively — 108,499 Total $ — $ 218,790 The following describes the rights and preferences of the Legacy GreenLight Redeemable Convertible Preferred Stock prior to the conversion in the Business Combination: Voting Rights The holders of each share of Preferred Stock (“Preferred Stockholders”) generally had the right to one vote for each share of common stock into which such Preferred Stock could then convert. On matters on which the holders of shares of a particular series of Preferred Stock had the right to vote separately as a single class, such holders had the right to one vote per share of Preferred Stock of that particular series. Conversion Each share of Preferred Stock was convertible into common stock at any time at the option of the holder. Each share was converted into such number of shares of common stock as is determined by dividing the applicable original issuance price by the applicable conversion price in effect at the time of the conversion. The conversion price was subject to adjustment upon the happening of specified events, including the issuance or deemed issuance of certain additional shares of common stock, stock splits and combinations, dividends, distributions, mergers, and reorganizations. The original issuances prices of the shares of Series A-1, A-2, A-3, A-1, A-2, A-3, one-for-one A-1, A-2 A-3 Conversion was mandatory at the earlier of the closing of a firm commitment underwritten public offering of the Company’s common stock at a price of at least $5.4354 per share and with net proceeds to the Company of at least $75.0 million or at the election of the holders of a majority of the outstanding shares of Series D Preferred Stock. Dividends The holders of Series A-1 A-2, A-3, as-converted Redemption The Company’s Preferred Stock could only be redeemed upon a deemed liquidation event as described in the Company’s certificate of incorporation. Upon redemption, holders of shares of Preferred Stock of a particular series were entitled to receive a redemption amount equal to the original issue price of the shares of that series, plus any accrued but unpaid dividends and any declared but unpaid dividends for the shares of that series, subject to the terms summarized in the “Liquidation Preference” section below. Liquidation Preference In the event of any liquidation, dissolution or winding up of the Company, the holders of shares of Preferred Stock of a particular series were entitled to receive an amount per share equal to the greater of (i) the original issuance price of the shares of Preferred Stock of that series, plus any accruing dividends that are unpaid, whether or not declared, plus any other dividends declared but unpaid thereon, or (ii) such amount per share as would have been payable had such shares of Preferred Stock been converted into common stock. Such liquidating distributions were payable first, to the holders of shares of Series D Preferred Stock, second, to the holders of shares of Series C Preferred Stock and Series B Preferred Stock on a pari passu basis, third, to the holders of shares of Series A Preferred Stock on a pari passu basis, and finally, to the holders of shares of common stock. If insufficient assets and funds were available to permit payment of the full amount of the applicable liquidation preference payable to the holders of any series of Preferred Stock (or group of series payable on a pari passu basis), then all available assets and funds would have been distributed to the holders of such series (or group of series) on a pro rata basis, taking into account the order of priority set forth in the previous sentence. After payment in full to the Preferred Stockholders, the holders of common stock are entitled to receive the remaining assets of the Company available for distribution on a pro rata basis based on the number of shares held. |
Redeemable Convertible Preferre
Redeemable Convertible Preferred Stock | 12 Months Ended |
Dec. 31, 2021 | |
Redeemable Noncontrolling Interest [Line Items] | |
Redeemable Convertible Preferred Stock | 12. REDEEMABLE CONVERTIBLE PREFERRED STOCK In connection with the Business Combination, Legacy GreenLight redeemable convertible preferred stock previously classified as temporary equity was retroactively adjusted, converted into common stock at an exchange ratio of approximately 0.6656, and reclassified to permanent equity as a result of the reverse recapitalization. The Company’s equity structure has been restated in all comparable periods up to February 2, 2022 to reflect this treatment. As a result, all share and per share amounts related to Legacy GreenLight’s convertible preferred stock below have been adjusted based on the Merger Exchange Ratio of 0.6656. The Company has historically issued Series A-1 A-1 A-2 A-2 A-3 A-3 A-1 A-2 Series D Preferred Stock — In June 2020, the Company issued and sold 37,673,731 shares of Series D Preferred Stock at a price of $2.7221 per share. In July 2020, the Company issued and sold an additional 2,384,960 shares of Series D Preferred Stock at a price of $2.7221 per share, resulting in aggregate gross cash proceeds of approximately $109.0 million. Issuance costs associated with the Series D Preferred Stock closings were approximately $0.5 million, of which $0.4 million represents non-cash Authorized Shares Prior to the retroactive impact of the recapitalization, at December 31, 2020 and 2021 YEARS ENDED DECEMBER 31, LEGACY REDEEMABLE CONVERTIBLE PREFERRED STOCK CLASSES 2020 2021 Series A-1 $ 4,411 $ 4,414 Series A-2 11,438 11,438 Series A-3 19,917 19,917 Series B redeemable convertible preferred stock, $0.001 par value, 21,245,353 shares authorized, issued and outstanding as of December 31, 2020 and December 31, 2021 Liquidation preference of $22,567 and $24,017 at December 31, 2020 and December 31, 2021, respectively 18,671 18,671 YEARS ENDED DECEMBER 31, LEGACY REDEEMABLE CONVERTIBLE PREFERRED STOCK CLASSES 2020 2021 Series C redeemable convertible preferred stock, $0.001 par value, 35,152,184 shares authorized, 35,092,183 shares issued and outstanding as of December 31, 2020 and December 31, 2021 Liquidation preference of $65,014 and $69,595 at December 31, 2020 and December 31, 2021, respectively 55,851 55,851 Series D redeemable convertible preferred stock, $0.001 par value, 71,019,827 shares authorized, 60,184,332 shares issued and outstanding and as of December 31, 2020 and December 31, 2021 Liquidation preference of $113,736 and $122,459 at December 31, 2020 and December 31, 2021, respectively 108,499 108,499 Total $ 218,787 $ 218,790 Voting Rights The holders of each share of Preferred Stock (“Preferred Stockholders”) generally have the right to one vote for each share of common stock into which such Preferred Stock could then convert. On matters on which the holders of shares of a particular series of Preferred Stock have the right to vote separately as a single class, such holders have the right to one vote per share of Preferred Stock of that particular series. Conversion Each share of Preferred Stock is convertible into common stock at any time at the option of the holder. Each share will be converted into such number of shares of common stock as is determined by dividing the applicable original issuance price by the applicable conversion price in effect at the time of the conversion. The conversion price is subject to adjustment upon the happening of specified events, including the issuance or deemed issuance of certain additional shares of common stock, stock splits and combinations, dividends, distributions, mergers and reorganizations. The original issuances prices of the shares of Series A-1, A-2, A-3, A-1, A-2, A-3, one-for-one A-1, Series A-2 A-3 Conversion is mandatory at the earlier of the closing of a firm commitment underwritten public offering of the Company’s common stock at a price of at least $5.4354 per share and with net proceeds to the Company of at least $75.0 million or at the election of the holders of a majority of the outstanding shares of Series D Preferred Stock. Dividends The holders of Series A-1 A-2, A-3, Dividends are payable only when, as and if declared by the Board of Directors. In the event the Company declares, pays, or sets aside any dividends on shares of any class of capital stock of the Company, other than dividends on shares of common stock payable in shares of common stock, the holders of Preferred Stock will be entitled to receive, before or at the same time as such dividends, a dividend on each outstanding share of Preferred Stock in the amount of the accruing dividends unpaid as of such date as well as a comparable dividend on an as-converted Redemption The Company’s Preferred Stock may only be redeemed upon a deemed liquidation event as described in the Company’s certificate of incorporation. Upon redemption, holders of shares of Preferred Stock of a particular series are entitled to receive a redemption amount equal to the original issue price of the shares of that series, plus any accrued but unpaid dividends and any declared but unpaid dividends for the shares of that series, subject to the terms summarized in the “Liquidation Preference” section below. Liquidation Preference In the event of any liquidation, dissolution or winding up of the Company, the holders of shares of Preferred Stock of a particular series are entitled to receive an amount per share equal to the greater of (i) the original issuance price of the shares of Preferred Stock of that series, plus any accruing dividends that are unpaid, whether or not declared, plus any other dividends declared but unpaid thereon, or (ii) such amount per share as would have been payable had such shares of Preferred Stock been converted into common stock. Such liquidating distributions are payable first, to the holders of shares of Series D Preferred Stock, second, to the holders of shares of Series C Preferred Stock and Series B Preferred Stock on a pari passu basis, third, to the holders of shares of Series A Preferred Stock on a pari passu basis, and finally, to the holders of shares of common stock. If insufficient assets and funds are available to permit payment of the full amount of the applicable liquidation preference payable to the holders of any series of Preferred Stock (or group of series payable on a pari passu basis), then all available assets and funds will be distributed to the holders of such series (or group of series) on a pro rata basis, taking into account the order of priority set forth in the previous sentence. After payment in full to the Preferred Stockholders, the holders of common stock are entitled to receive the remaining assets of the Company available for distribution on a pro rata basis based on the number of shares held. |
Common Stock
Common Stock | 12 Months Ended |
Dec. 31, 2021 | |
Class of Stock [Line Items] | |
Common Stock | 13. COMMON STOCK Prior to the retroactive impact of the recapitalization, the Company was authorized to issue 191,500,000 shares of $0.001 par value common stock as of December 31, 2020 and 2021. Upon closing of the business combination, the Company was authorized to issue 500,000,000 shares of $0.0001 par value common stock. The voting, dividend, and liquidation rights of the holders of the Company’s common stock are subject to and qualified by the rights, powers, and preferences of the holders of the Preferred Stock set forth above. Each share of common stock generally entitles the holder to one vote, together with the holders of Preferred Stock, on all matters submitted to the stockholders for a vote. As of December 31, 2020 and 2021, no cash dividends have been declared or paid. As of December 31, 2021, the Company has reserved the following shares of common stock for potential conversion of outstanding Preferred Stock, potential conversion of convertible debt and PIPE Notes with accrued interest through the applicable year-end, into Series D Preferred Stock, the vesting of restricted stock and exercise of stock options and preferred and common stock warrants: AS OF Convertible debt with accrued interest 6,684,122 Options to purchase common stock 19,803,226 Preferred stock warrants 651,988 Common stock warrants 207,376 Total 27,346,712 |
Stock-Based Compensation
Stock-Based Compensation | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Stock-Based Compensation | 14. STOCK-BASED 2012 Stock Incentive Plan The Company adopted the 2012 Stock Incentive Plan (the “Plan”) in April 2012 for the issuance of stock options and other stock-based awards to employees, consultants, officers, and directors. As of December 31, 2020 and 2021, the maximum number of shares of Common Stock issuable under the Plan is 20,337,715. There were 5,053,403 and 1,701,678 shares of common stock available for future grants under the Plan as of December 31, 2020 and 2021, respectively. The Plan is administered by the Company’s board of directors (the “Board”). The exercise prices, vesting and other restrictions are determined at the discretion of the Board, except that the exercise price per share of incentive stock options may not be less than 100% of the fair market value of the common stock on the date of grant. Stock options awarded under the Plan expire ten years after the grant date unless the Board sets a shorter term. Vesting periods for awards under the plans are determined at the discretion of the Board. Incentive stock options granted to employees and non-statutory The fair value of stock option awards is estimated on the grant date using the Black-Scholes option pricing model with the following assumptions: YEARS ENDED DECEMBER 31, 2020 2021 Fair value of underlying common stock $0.69 - $0.98 $1.23 - $8.85 Weighted average risk-free interest rate 0.27% - 1.55% 0.48% - 1.42% Expected term (in years) 5 - 6 6 Expected volatility 69.5% - 70.4% 56.3% - 68.9% Expected dividend yield 0.00% 0.00% The following table summarizes the activity of the Company’s stock options under the Plan for the year ended December 31, 2021: SHARES WEIGHTED- AVERAGE AGGREGATE (in thousands) Outstanding at December 31, 2020 15,001,672 $ 0.62 8.5 $ 9,170 Granted 3,811,151 3.20 — — Exercised (253,027 ) 0.57 2,096 Cancelled or forfeited (458,248 ) 1.61 — Outstanding at December 31, 2021 18,101,548 $ 1.14 8.0 $ 139,505 Vested and expected to vest at December 31, 2021 18,101,548 $ 1.14 8.0 $ 139,505 Exercisable at December 31, 2021 7,449,211 $ 0.51 6.9 $ 62,157 The weighted-average grant date fair value of stock options granted during the years ended December 31, 2020, and 2021 was $ per share and $ per share, respectively. As of December 31, 2021, total unrecognized compensation expense related to stock options totaled approximately $ million, which is expected to be recognized over a weighted-average period of years. The aggregate intrinsic value of common stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock. The intrinsic value of options exercised in 2020 and 2021, was approximately $0.1 million and $2.1 million, respectively. Restricted Stock The fair value of each restricted common stock award is estimated on the date of grant based on the fair value of the Company’s common stock on that same date. Since 2018, the Company has issued 87,809 shares of restricted common stock to independent members of the Board of Directors, members of the Scientific Advisory Board and certain scientific founders, having a fair value of approximately $84 thousand, and subject to vesting over periods of 2 to 4 years. A summary of the Company’s restricted stock activity during the years ended December 31, 2020, and 2021 is presented below: SHARES WEIGHTED Unvested shares as of December 31, 2020 24,937 $ 0.56 Vested (20,706 ) 0.82 Unvested shares as of December 31, 2021 4,231 $ 1.15 The total fair value of restricted stock that vested during the year ended December 31, 2020 and 2021 was approximately $11 thousand and $25 thousand, respectively. Stock-Based Compensation Expense Stock-based compensation expense recorded as research and development and general and administrative expenses, for employees, directors and non-employees YEARS ENDED 2020 2021 Research and development $ 306 $ 1,018 General and administrative 353 973 Total stock-based compensation expense $ 659 $ 1,991 The Company expects to recognize additional stock-based compensation expense associated with 292,650 shares subject to GreenLight options that vest based on both a liquidity and a service condition. At the date of grant in 2020, achievement of the conditions in the performance-based award was deemed not probable and, accordingly, the grant date fair value of the award was zero based upon the probable outcome of such conditions. The liquidity condition is satisfied upon the occurrence of certain events, including a merger or acquisition or other business combination transaction involving the Company and a publicly traded special purpose acquisition company or other similar entity and, as a result, the liquidity condition for certain of GreenLight’s options will be satisfied upon the completion of the Business Combination. Assuming achievement of the highest level of performance, the performance-based award would have had a grant date fair value of $0.2 million. In December 2021, the Company’s Board of Directors voted to extend the length of time to allow for the performance vesting to occur by March 31, 2022. The fair value of the award, as modified, was $2.1 million as of the modification date. Upon closing of the Business Combination, the Company expects to recognize approximately $1.4 million of incremental stock-based compensation expense associated with these options, and the remainder will be recognized over the remaining service period. As of December 31, 2021, the performance condition has not yet been achieved, and 292,650 shares subject to performance-based options were not vested. | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Stock-Based Compensation | 13. STOCK-BASED COMPENSATION 2022 Stock Incentive Plan On February 1, 2022, stockholders approved the New GreenLight 2022 Equity and Incentive Plan, or the “New GreenLight Equity Plan”, or “Equity Plan”, replacing the GreenLight 2012 Equity Plan (the “2012 Plan”), pursuant to which the Company’s Board of Directors may grant stock options, both incentive stock options and nonstatutory stock options, stock appreciation rights, restricted stock, unrestricted stock, restricted stock units, dividend equivalent rights, or cash awards to employees, directors and consultants. There are 31,750,000 registered shares of common stock reserved for issuance under the Equity Plan. During the six months ended June 30, 2022, 6,713,069 stock options were granted under the Equity Plan. The Plan is administered by the Company’s Board of Directors (the “Board”). The exercise prices, vesting and other restrictions are determined at the discretion of the Board, except that the exercise price per share of incentive stock options may not be less than 100% of the fair market value of the common stock on the date of grant. Stock options awarded under the Plan expire ten years after the grant date unless the Board sets a shorter term. Vesting periods for awards under the plans are determined at the discretion of the Board. Incentive stock options granted to employees and non-statutory The fair value of stock option awards is estimated on the grant date using the Black-Scholes option pricing model with the following weighted-average assumptions: SIX MONTHS ENDED JUNE 30, 2022 2021 Fair value of underlying common stock $ 3.56 $ 0.80 Weighted average risk-free interest rate 3.00 % 1.13 % Expected term (in years) 6.04 6.08 Expected volatility 65.38 % 67.83 % Expected dividend yield 0 % 0 % The following table summarizes the activity of the Company’s stock options under the Plan for the six months ended June 30, 2022: SHARES (1) WEIGHTED- (1) AVERAGE AGGREGATE (in thousands) Outstanding at December 31, 2021 18,101,548 $ 1.14 8.0 $ 139,505 Granted 6,713,069 5.79 — — Exercised (760,534 ) 0.46 — 250 Cancelled or forfeited (525,276 ) 1.36 — — Outstanding at June 30, 2022 23,528,807 2.49 8.2 22,335 Vested and expected to vest at June 30, 2022 23,528,807 2.49 8.2 22,335 Exercisable at June 30, 2022 8,891,469 $ 0.71 6.8 $ 13,792 (1) Number of options and weighted average exercise price has been adjusted to reflect the exchange of Legacy GreenLight’s stock options for New GreenLight stock options at an exchange ratio of approximately 0.6656 as a result of the Business Combination. See Note 3 for further information. The weighted-average grant date fair value of stock options granted during the six months ended June 30, 2022 and 2021 was $3.56 per share and $0.80 per share, respectively. As of June 30, 2022, total unrecognized compensation expense related to stock options totaled approximately $32.2 million, which is expected to be recognized over a weighted-average period of 3.5 years. The aggregate intrinsic value of common stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock. The intrinsic value of options exercised for the six months ended June 30, 2022 and 2021, was approximately $1.1 million and $0.2 million, respectively. Restricted Stock The fair value of each restricted common stock award is estimated on the date of grant based on the fair value of the Company’s common stock on that same date. A summary of the Company’s restricted stock activity during the six months ended June 30, 2022 is presented below: SHARES WEIGHTED Unvested shares as of December 31, 2021 4,231 $ 0.76 Vested (2,898 ) 0.23 Unvested shares as of June 30, 2022 1,333 $ 0.22 The total fair value of restricted stock that vested during the six months ended June 30, 2022 and 2021 was approximately $13,000 and $8,000, respectively. Stock-Based Compensation Expense Stock-based compensation expense recorded as research and development and general and administrative expenses, for employees, directors and non-employees THREE MONTHS ENDED SIX MONTHS ENDED JUNE 30, 2022 2021 2022 2021 ($ in thousands) Research and development $ 958 $ 188 $ 1,462 $ 324 General and administrative 676 219 2,359 431 Total stock-based compensation expense $ 1,634 $ 407 $ 3,821 $ 755 The Company recognized additional stock-based compensation expense associated with 292,469 shares subject to GreenLight options that vest based on both a liquidity and a service condition. At the date of grant in 2020, achievement of the conditions in the performance-based award was deemed not probable and, accordingly, the grant date fair value of the award was zero based upon the probable outcome of such conditions. The liquidity condition is satisfied upon the occurrence of certain events, including a merger or acquisition or other business combination transaction involving the Company and a publicly traded special purpose acquisition company or other similar entity and, as a result, the liquidity condition for certain of GreenLight’s options was satisfied upon the completion of the Business Combination. Assuming achievement of the highest level of performance, the performance-based award would have had a grant date fair value of $0.2 million. In December 2021, the Company’s Board of Directors voted to extend the length of time to allow for the performance vesting to occur by March 31, 2022. The fair value of the award, as modified, was $2.2 million as of the modification date. Upon closing of the Business Combination, the Company recognized approximately $1.4 million of incremental stock-based |
Net Loss Per Share
Net Loss Per Share | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Net Loss Per Share | 16. NET LOSS PER SHARE The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except share and per share data): YEARS ENDED 2020 2021 Numerator: Net loss $ (53,251 ) $ (112,310 ) Denominator: Weighted-average common stock outstanding 77,673,953 96,371,189 Net loss per share, basic and diluted $ (0.69 ) $ (1.17 ) The Company’s potential dilutive securities include unvested restricted stock, common stock options and common and preferred stock warrants that will convert to common stock. The Company excluded the following potential common stock, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: AS OF DECEMBER 31, 2020 2021 Convertible debt with accrued interest 6,378,460 6,684,122 Unvested restricted stock 24,937 4,231 Options to purchase common stock 15,001,672 18,101,548 Preferred stock warrants 107,416 651,988 Common stock warrants 26,624 207,376 Total 21,539,109 25,649,265 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Net Loss Per Share | 14. NET LOSS PER SHARE The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company: THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED (In thousands, except shares and per share data) 2022 2021 2022 2021 Numerator: Net loss available to common stockholders $ (51,926 ) $ (27,174 ) $ (90,133 ) $ (48,457 ) Denominator: Weighted-average common stock outstanding 123,249,757 96,327,956 118,430,851 96,314,179 Net loss per share, basic and diluted $ (0.42 ) $ (0.28 ) $ (0.76 ) $ (0.50 ) The Company’s potential dilutive securities include unvested restricted stock, common stock options and common stock warrants. The Company excluded the following potential common stock, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: AS OF JUNE 30, 2022 2021 Unvested restricted stock 1,333 13,926 Options to purchase common stock 23,528,807 17,572,807 Common stock warrants 12,383,304 172,949 Total 35,913,444 17,759,682 |
Income Taxes
Income Taxes | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Income Taxes | 17. INCOME TAXES As the Company generated net operating losses (“NOLs”) during 2020 and 2021, has generated historical NOLs, and is forecasting to continue to generate NOLs, the Company did not record a provision for or benefit from income taxes for the years ended December 31, 2020, and 2021. A reconciliation of the Company’s effective tax rate to the statutory federal income tax rate is as follows for the years ended December 31, 2020, and 2021: YEARS ENDED 2020 2021 Federal income tax (benefit)/expense at statutory rate 21.0 % 21.0 % State income tax benefit 5.4 % 6.9 % Permanent items -0.2 % -0.5 % Change in Valuation Allowance -29.3 % -30.6 % Federal R&D Tax Credits 3.1 % 3.0 % Other 0.0 % 0.2 % Effective income tax rate 0.0 % 0.0 % Deferred tax assets and liabilities reflect the net tax effects of NOLs and tax credit carryforwards and temporary differences between the carrying amount of assets and liabilities for financial reporting and the amounts used for tax purposes. Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2020, and 2021 were as follows (in thousands): YEARS ENDED 2020 2021 Deferred tax assets: Federal net operating loss carryforwards $ 26,464 $ 48,956 State net operating loss carryforwards 6,542 12,477 Tax credits 4,059 8,736 Stock based compensation 89 233 Capitalized research and development expenses 4,398 3,649 Accruals and other 763 1,482 Total deferred tax assets 42,315 75,533 Valuation allowance (39,965 ) (74,340 ) Total deferred tax assets $ 2,350 $ 1,193 Deferred tax liabilities: Depreciation and amortization $ (2,350 ) $ (1,193 ) Total deferred tax liabilities $ (2,350 ) $ (1,193 ) Total net deferred tax assets (liability) $ — $ — As of December 31, 2021, the Company had federal NOL carryforwards of $232,116 and state NOL carryforwards of approximately $197,424, which are available to reduce future taxable income. The Company also had federal tax credits of $7,485 as of December 31, 2021. The federal NOLs generated before 2018 of approximately $27,104 will expire at various dates through 2037, and NOL carryforwards generated after 2017 of approximately $205,012 have an indefinite carryforward period. The state NOLs and tax credit carryforwards will expire at various dates through 2040. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December 31, 2020, and 2021 because the Company’s management has determined that it is more likely than not that these assets will not be fully realized. Utilization of the NOL carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of NOL and research and development credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company has not completed an evaluation of ownership changes through December 31, 2021, to assess whether utilization of the Company’s NOL or research and development credit carryforwards would be subject to an annual limitation under Section 382. To the extent an ownership change occurs in the future, the NOL and credit carryforwards would be subject to limitation. The Company has generated federal and state research and development credits but has not conducted a study to document the qualified activity. This study may result in an adjustment to the Company’s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company’s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance. As of December 31, 2020, and 2021, the Company had not recorded any uncertain tax provisions. The Company files income tax returns in the U.S. federal and various state jurisdictions. The federal and state income tax returns are generally subject to examinations for the tax years ended December 31, 2018, through December 31, 2021. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period. There are currently no federal or state audits in process. | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Income Taxes | 15. INCOME TAXES The Company did not record income tax expense for the three and six months ended June 30, 2022 and 2021 due to the Company’s historical net operating losses, forecasted continued net operating losses, and the Company’s recognition of a full valuation allowance. The effective tax rate differs from the statutory rate, primarily due to the Company’s history of incurring losses, which have not been benefited, and other permanent differences. Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
COMMITMENTS AND CONTINGENCIES | 18. COMMITMENTS AND CONTINGENCIES Operating Leases On May 15, 2009, the Company entered into an operating lease in Medford, Massachusetts, for office and laboratory space that comprises the headquarters. On August 15, 2020, the Company entered into an expansion and extension of its lease effective from August 15, 2020, through the lease term end date of February 14, 2024, unless otherwise extended. On January 15, 2019, the Company entered into an operating lease for office, laboratory, and greenhouse facilities in Research Triangle Park, North Carolina. The Company has occupied the greenhouse space since January 2019 and the office and laboratory space since January 2020. The lease term is for 84 months from the first day of the first full month following the commencement of the office and laboratory space occupation. The initial lease term expires in December 2026. The Company has the option to extend the lease for an additional five-year term. The lease agreement provided for a base tenant improvement allowance of approximately $0.5 million and an additional tenant improvement allowance of $1.0 million to finance a portion of the capital improvements of the facility. The additional tenant improvement allowance paid for by the landlord is repayable along with the monthly base rent at 9% interest over the lease term. As of December 31, 2021, approximately $0.8 million of the additional tenant improvement allowance was recorded in other liabilities. The Company is required to pay for any additional tenant improvement costs. On January 1, 2020, the Company entered into an operating lease for its manufacturing facility in Rochester, New York, for an initial term of 63 months, expiring on March 31, 2025. The Company has the option to extend the lease for up to two additional terms of five years each. The lease agreement provided for a base tenant improvement allowance of approximately $17 thousand and an additional tenant improvement allowance of approximately $0.3 million to finance a portion of the capital improvements of the facility. The additional tenant improvement allowance paid for by the landlord is repayable along with the monthly base rent at 10% interest over 60 months. The Company is required to pay for any additional tenant improvement costs. On October 28, 2020, the Company entered into a license and services agreement for an on-demand pre-clinical 24-month On November 15, 2020, the Company entered into an operating lease with its landlord for additional lab space in Woburn, Massachusetts. On January 11, 2021, the Company entered into an expansion of its Woburn lab space lease effective from March 1, 2021, that was amended on March 22, 2021, and further amended on April 14, 2021, for additional space effective from April 1, 2021, and June 1, 2021, respectively. The lease term has an end date of February 14, 2024. On February 22, 2021, the Company entered into a sublease agreement for additional lab space in Medford, Massachusetts. The initial term of the lease is 48 months, expiring on February 28, 2025, unless otherwise extended. On June 23, 2021, the Company entered into an operating lease agreement for additional office space in Medford, Massachusetts. The initial term of the lease is 44 months, expiring on February 28, 2025, unless otherwise extended. On September 30, 2021, the Company entered into a lease for new laboratory, office and greenhouse space in Research Triangle Park, North Carolina, with an anticipated commencement date in January of 2022. The lease term expires in July 2033, unless extended. The base rent for this lease is approximately $ On November 1, 2021, the Company entered into an operating lease for additional laboratory and office space in Rochester, New York. The initial term of the lease is 51 months, expiring on March 31, 2026, unless otherwise extended. Base rent for this lease is approximately $0.1 million per year with annual escalations for cost-of-living Rent expense is recognized on a straight-line basis over the lease term. Total rent expense in the consolidated statements of operations for the operating leases was approximately $2.1 million and $5.1 million for the years ended December 31, 2020 and 2021, respectively. A summary of the Company’s future minimum lease payments under noncancelable operating leases, excluding tenant improvement payables, as of December 31, 2021, is as follows (in thousands): FOR THE YEARS ENDED 2022 $ 7,841 2023 7,257 2024 2,549 2025 1,450 2026 1,242 Thereafter 5,359 Total $ 25,698 Capital Lease obligation The Company acquired certain equipment with a value of approximately $0.9 million and $0 under capital lease arrangements during the years ended December 31, 2020 and 2021, respectively. Amortization of assets held under capital leases is included in depreciation expense. The Company leases certain laboratory equipment under capital lease agreements with fixed payments due through December 2023. Capital lease obligations are recorded as long-term debt on the Company’s consolidated balance sheet as of December 31, 2020 and 2021. Future minimum lease payments under the capital lease agreements as of December 31, 2021, together with the present value of the minimum lease payments are as follows (in thousands): FOR THE YEARS ENDED 2022 $ 779 2023 330 Thereafter — Total minimum lease payments $ 1,109 Less: amount representing interest (117 ) Present value of obligations under capital leases $ 992 Current portion of capital lease obligations $ 672 Capital lease obligations, long-term $ 320 Legal proceedings Legal claims may arise from time to time in the normal course of business. There are no such claims as of December 31, 2020 and 2021, that are expected to have a material effect on the Company’s consolidated financial statements. Other funding commitments In November 2021, the Company entered into a manufacturing and development contract service agreement with a contract development and manufacturing organization for the Company’s mRNA COVID-19 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
COMMITMENTS AND CONTINGENCIES | 16. COMMITMENTS AND CONTINGENCIES Operating Leases The Company’s significant operating leases entered as of December 31, 2021, are disclosed in Note 18, Commitments and Contingencies — Operating Leases, of the notes to the audited consolidated financial statements for the year ended December 31, 2021 as filed with the SEC on March 31, 2021 on Form 8-K/A. On September 30, 2021, the Company entered into a lease for new laboratory, office and greenhouse space in Durham, North Carolina, which commenced in January 2022. The lease term expires in July 2033, unless extended. The base rent for this lease is approximately $2.3 million per year, subject to a 3% increase each year. In March 2022, the Company entered into a lease for new laboratory space in Lexington, Massachusetts, which commenced in May 2022. The lease term expires in July 2033. The base rent for this lease is $3.9 million per year, subject to a 3% increase each year. Total rent expense in the condensed consolidated statements of operations for the operating leases was approximately $6.8 million and $1.9 million for the six months ended June 30, 2022 and 2021, respectively. Total rent expense in the condensed consolidated statements of operations for the operating leases was approximately $4.0 million and $1.0 million for the three months ended June 30, 2022 and 2021, respectively. A summary of the Company’s future minimum lease payments under noncancelable operating leases, excluding tenant improvement payables, as of June 30, 2022, is as follows (in thousands): AS OF JUNE 30, 2022 Remainder of 2022 $ 4,554 2023 9,573 2024 8,285 2025 7,296 2026 7,018 Thereafter 43,975 Total $ 80,701 Legal proceedings Legal claims may arise from time to time in the normal course of business. There are no such claims as of three and six months ended June 30, 2022 and 2021, that are expected to have a material effect on the Company’s condensed consolidated financial statements. Other funding commitments In December 2020, the Company entered into an assignment and license agreement with Bayer CropScience LLP (“Bayer”) under which the Company may be obligated to make milestone and royalty payments. These payment obligations are contingent upon future events, such as achieving certain development, regulatory, and commercial milestones or generating product sales. The timing of these events is uncertain; accordingly, the Company cannot predict the period during which these payments may become due. The Company have agreed to pay up to $2.0 million in milestone payments under this assignment and license agreement when certain development milestones are met. The Company assessed the milestones for the six months ended June 30, 2022 and concluded no such milestone payments were deemed probable nor due. In November 2021, the Company entered into a manufacturing and development contract service agreement with a contract development and manufacturing organization for the Company’s mRNA COVID-19 |
Defined Contribution Plan
Defined Contribution Plan | 12 Months Ended |
Dec. 31, 2021 | |
Defined Contribution Plan | 19. DEFINED CONTRIBUTION PLAN The GreenLight Biosciences 401(k) Retirement Plan is a defined contribution plan in the form of a qualified 401(k) plan in which substantially all employees are eligible to participate upon employment. Subject to certain IRS limits, eligible employees may elect to contribute from 1% to 100% of their compensation. Company contributions to the plan are at the sole discretion of the Company. During the year ended December 31, 2021, the Company did not provide any matching contribution to employees. |
Subsequent Events
Subsequent Events | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Subsequent Event [Line Items] | ||
Subsequent Events | 20. SUBSEQUENT EVENTS The Company has completed an evaluation of all subsequent events through March 31, 2022, the date these consolidated financial statements were available to be issued. There were no subsequent events that require adjustments to or disclosure in the financial statements, except for those referenced below. Business Combination On February 2, 2022, the Company’s stockholders approved the Business Combination, by and among the company formerly known as ENVI, GreenLight Biosciences, Inc. and Honey Bee Merger Sub, Inc., pursuant to which Honey Bee Merger Sub, Inc. was merged with and into GreenLight, with GreenLight surviving the merger. As a result of the Merger, and upon consummation of the Merger and the other transactions contemplated by the Business Combination Agreement, GreenLight became a wholly owned subsidiary of ENVI. Upon the closing of the Business Combination, the Company changed it’s name to GreenLight Biosciences Holdings, PBC (“New GreenLight”), with stockholders of GreenLight becoming stockholders of New GreenLight. The following transactions at closing of the Merger included: • Merger Sub merged with and into GreenLight, with GreenLight surviving as a wholly owned subsidiary of New GreenLight; • each issued and outstanding share of capital stock of GreenLight converted into a number of shares of New GreenLight Common Stock equal to the product of (x) the conversion ratio applicable to such share, if any, under GreenLight’s certificate of incorporation, multiplied by (y) 0.6656, which is the quotient obtained by dividing (a) 120,000,000, by (b) the number of Fully-Diluted Shares as defined in the Business Combination Agreement; • each GreenLight Option converted into an option to purchase a number of shares of New GreenLight Common Stock in accordance with the terms and subject to the conditions of the Business Combination Agreement; • each GreenLight Warrant, to the extent outstanding and unexercised, converted into a warrant to acquire shares of New GreenLight Common Stock in accordance with the terms and subject to the conditions of the Business Combination Agreement; and • each share of ENVI Class A Common Stock and ENVI Class B Common Stock that was issued and outstanding immediately prior to the Merger became one share of New GreenLight Common Stock. Collaboration Agreement In March 2022, the Company entered into a License Agreement with Serum Institute of India Private Limited (“SIIPL”), pursuant to which the Company granted SIIPL an exclusive, sub-licensable, Pursuant to the License Agreement, SIIPL will pay the Company an upfront license fee of $5.0 million, as well as payments upon target selection and reservation of exclusivity. In addition, the Company may receive up to a total of an additional $22 million in milestone payments across all three product targets, as well as manufacturing technology transfer payments. SIIPL shall pay royalty payments on the sale of products resulting from the licensed technology for the term of the License Agreement. The License Agreement shall terminate on a product-by-product country-by-country SIIPL is responsible for the development, formulation, filling and finishing, registration and commercialization of the products in the SIIPL Territory, subject to oversight from a joint steering committee composed of representatives of the Company and SIIPL. SIIPL will use commercially reasonable efforts to develop and obtain regulatory approval for the products in the countries in the SIIPL Territory. The License Agreement includes terms customary in the industry for provisions related to sublicensing, intellectual property, and termination, and customary representations and warranties of GreenLight and SIIPL, along with certain customary covenants, including confidentiality, limitation of liability and indemnity provisions. Operating Leases In March 2022, the Company entered into a lease for new laboratory space in Lexington, Massachusetts, with an anticipated commencement date of April 2022. The lease term expires in May 2033. The base rent for this lease is $3.9 million per year, subject to a 3% increase each year. | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Subsequent Event [Line Items] | ||
Subsequent Events | 17. SUBSEQUENT EVENTS Private Placement and Securities Subscription Agreement On August 11, 2022, the Company entered into Securities Subscription Agreements (the “August 2022 Subscription Agreements”) with certain accredited investors (collectively, the “Purchasers”), providing for the sale by the Company of 27,640,301 shares (the “Shares”) of its common stock (the “Common Stock”) at a purchase price of $3.92 per share, in a private placement (the “Private Placement”). The Shares were issued (the “Closing”) simultaneously with the execution and delivery of the August 2022 Subscription Agreements. The Company has $108.4 million committed under the executed the August 2022 Subscription Agreements, of which we have received the entire $108.4 million at the time these interim financial statements are issued. The Company intends to use the net proceeds from the Private Placement to fund ongoing clinical development and commercialization of its existing product pipeline. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Accounting Policies, by Policy (Policies) [Line Items] | ||
Principles of Consolidation | Principles of Consolidation The accompanying consolidated financial statements include the operations of the Company and its wholly owned subsidiaries, GLPRI and GLSC. All intercompany transactions and balances have been eliminated in consolidation. | |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the accrual of research and development costs, acquisition of in-process | |
Operating Segments | Operating Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The CODM is the Company’s Chief Executive Officer. The Company manages its operations as a single | |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Investments qualifying as cash equivalents primarily consist of money market funds. The Company’s cash equivalents in the consolidated balance sheets at December 31, 2020 and 2021, were approximately $95.1 million and $31.4 million, respectively. | |
Restricted Cash | Restricted Cash The Company maintains letters of credit in conjunction with the Company’s lease agreements. As of December 31, 2020 and 2021, the underlying cash balance securing these letters of credit of approximately $0.1 million and $0.3 million, respectively, was classified as a noncurrent asset in the consolidated balance sheets based on the terms of the lease agreement. | |
Concentrations of Credit Risk | Concentrations of Credit Risk The Company has no significant off-balance | |
Fair Value Measurements | Fair Value Measurements ASC 820, Fair Value Measurements and Disclosures (“ASC 820”), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier • Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. • Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for a similar asset or liability, either directly or indirectly. • Level 3 inputs are unobservable inputs that reflect the Company’s own assumptions about the inputs that market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hie | |
Property and Equipment | Property and Equipment Property and equipment are recorded at cost and depreciated over the estimated useful lives of the related assets using the straight-line method. Maintenance and repairs to an asset that do not improve or extend its life are expensed in the period incurred. Expenditures made to improve or extend the life of property and equipment are capitalized. Leasehold improvements are depreciated over the shorter of the useful life of the improvements or the remaining term of the associated lease. The estimated useful lives of property and equipment are as follows: ESTIMATED USEFUL LIFE Laboratory equipment 5 years Computer equipment and software 3 years Leasehold improvements Shorter of useful life or Property and equipment subject to a capital lease are depreciated over the shorter of the useful life or the term of the lease. Construction in progress is stated at cost, which includes direct costs attributable to the setup or construction of the related asset. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the Company’s statement of operations. | |
Acquired In-process Research and Development | Acquired In-process The Company measures and recognizes acquisitions that are not deemed to be business combinations as acquisitions of assets based on the cost to acquire the assets, which includes transaction costs, and the consideration is allocated to the items acquired based on a relative fair value methodology. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process The Company applied asset acquisition treatment in accounting for the acquisition of the intangible assets of Bayer Crop Science, LLP acquired during the year ended December 31, 2020. | |
Income Taxes | Income Taxes The Company is primarily subject to U.S. federal, Massachusetts, North Carolina and New York state income taxes. The Company accounts for income taxes using the asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities represent future tax consequences of temporary differences between the consolidated financial statement carrying amounts and the tax basis of assets and liabilities and for loss carryforwards using enacted tax rates expected to be in effect in the years in which the differences reverse. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. The Company also recognizes a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. We evaluate uncertain tax positions on a regular basis. The evaluations are based on several factors, including changes in facts and circumstances, and changes in tax law. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax. To date, we have not been subject to any interest or penalties. | |
Impairment of Long-lived Assets | Impairment of Long-lived Assets The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Such events and circumstances include, but are not limited to, significant decreases in the market value of an asset, adverse changes in the extent or manner in which the asset is being used, or significant changes in business climate. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. During the years ended December 31, 2020 and 2021, no impairment indicators were identified. | |
Redeemable Convertible Preferred Stock | Redeemable Convertible Preferred Stock The Company classifies redeemable convertible Preferred Stock (“Preferred Stock”) as temporary equity in the accompanying consolidated balance sheets due to certain redemption events that are not within the Company’s control such as a liquidation, winding up, certain mergers, and the occurrence of a deemed liquidation event as defined in the Company’s certificate of incorporation. In the event of a deemed liquidation event, the proceeds from the event are distributed in accordance with liquidation preferences (Note 12). Prior to the retroactive impact of the recapitalization, as of December 31, 2020 and 2021, none of the circumstances under which the Company’s Preferred Stock would become redeemable are probable, and, as a result, the Company does not accrete the carrying values of the Preferred Stock to the redemption values. Subsequent adjustments of the carrying values to the ultimate redemption values will be made only when it becomes probable that such a liquidation event will occur. | |
Warrants | Warrants The Company applies relevant accounting guidance for warrants to purchase the Company’s stock based on the nature of the relationship with the counterparty. For warrants issued to investors or lenders in exchange for cash or other financial assets, the Company follows guidance issued within ASC 480, Distinguishing Liabilities from Equity (“ASC 480”), and ASC 815, Derivatives and Hedging (“ASC 815”), to assist in the determination of whether the warrants should be classified as liabilities or equity. Warrants that are determined to require liability classification are measured at fair value upon issuance and are subsequently remeasured to their then fair value at each subsequent reporting period with changes in fair value recorded in current earnings. Warrants that are determined to require equity classification are measured at fair value upon issuance and are not subsequently remeasured unless they are required to be reclassified. For warrants issued to nonemployees for goods or services, or to customers as non-cash | |
Contract Revenue | Contract Revenue The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), which provides a five-step model for recognizing revenue from contracts with customers as follows: • Identify the contract with a customer • Identify the performance obligations in the contract • Determine the transaction price • Allocate the transaction price to the performance obligations in the contract • Recognize revenue when or as performance obligations are satisfied For the year ended December 31, 2020, all contract revenue was generated from a collaboration agreement with Ingredion Incorporated (“Ingredion”) to develop a semicontinuous cell-free production process for the commercial production of certain molecules using biological synthesis tools and proprietary technology developed by the Company. The Ingredion Agreement is within the scope of ASC 606. There was no contract revenue generated during 2021 from the collaboration agreement with Ingredion. Under ASC 606, an entity recognizes revenue when or as its customer obtains control of distinct promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. Our customer arrangements primarily consist of a license, rights to our intellectual property, and research and developments services. Performance obligations are promises in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, we consider factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own, or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract. The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration, which is included in the transaction price, may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the variability is resolved. Under the collaboration agreement with Ingredion, the variability related to the variable consideration would be resolved when the Company has successfully achieved pilot scale production that satisfies specified volume, yield, and cost targets (“Milestone 2”). For revenue related to sales-based royalties received from licensees, including milestone payments based on the level of sales, where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any consideration related to sales-based royalty revenue resulting from the Ingredion collaboration agreement. The Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations and develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in a contract with a customer. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations, which may include other comparable transactions, pricing considered in negotiating the transaction, and the estimated costs. Any variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts we would expect to receive for the satisfaction of each performance obligation. The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations that consist of licenses and other promises, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company has determined that the license and research and development services under the Ingredion agreement are a single combined performance obligation satisfied over time. The Company must select a single measure of progress that best depicts the Company’s measurement of progress. ASC 606-10-26-33 appropriate method for measuring progress. Since activities performed to research and validate one phase may be useful in researching and validating subsequent phases, the Company believes that an input method, which tracks the Company’s efforts required to perform the contracted activities during the contract term, is more representationally faithful tha n a | |
Grant Revenue | Grant Revenue In July 2020, we entered into a grant agreement with the Bill & Melinda Gates Foundation to advance research in in vivo gene therapy for sickle cell disease and to explore new, low-cost | |
Deferred Revenue | Deferred Revenue Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company’s consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve months, the related deferred revenue will be classified in current liabilities. | |
Research and Development Costs | Research and Development Costs Research and development expenses consist primarily of costs related to discovery and research and development of products, including personnel expenses, stock-based compensation expense, allocated facility-related | |
General and Administrative Expenses | General and Administrative Expenses The Company expenses general and administrative costs to operations as incurred. General and administrative expenses consist primarily of compensation, benefits and other employee-related expenses for personnel in the Company’s administrative, finance, legal, information technology, business development, communications, and human resources functions. Other costs include the legal costs incurred in connection with filing and prosecuting patent and trademark applications, general and administrative related facility costs, insurance costs and professional fees for accounting, tax, consulting, legal and other services. | |
Stock-Based Compensation Expense | Stock-Based Compensation Expense The Company accounts for all stock-based payment awards granted to employees and non-employees non-employee stock-based The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing Share-Based non-employees, non-employees | |
Net Loss per Share | Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net l os In connection with the Merger, GreenLight equity has been retroactively adjusted to the earliest period presented to reflect the legal capital of the legal acquirer, ENVI. As a result, net loss per share was also retrospectively adjusted for periods ended prior to the Merger. See Note 1 for details of the Merger and Note 16 for discussion of the retrospective adjustment of net loss per share. | |
Comprehensive Loss | Comprehensive Loss Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner | |
Deferred Offering Costs | Deferred Offering Costs As of December 31, 2021, the Company capitalized deferred offering costs of approximately $4.1 million. Deferred offering costs include certain legal, accounting, consulting and other third-party fees incurred directly related to the anticipated business combination. At the closing of the business combination, these costs will be recorded in stockholders’ deficit as a reduction of additional paid-in | |
Subsequent Events | Subsequent Events The Company considers events or transactions that have occurred after the balance sheet date of December 31, 2021, but prior to March 31, 2022, the date the consolidated financial statements were issued, to provide additional evidence relative to certain estimates or to identify matters that require additional recognition or disclosure. Subsequent events have been evaluated through the date these financial statements were issued. | |
Recently Issued Accounting Pronouncements | Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, 2020-05, COVID-19 one-year beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. As the Company qualifies as an emerging growth company, the Company will follow the annual reporting guidance as of January 1, 2022 in connection with the issuance of its annual financial statements for the year ended December 31, 2022, and apply the provisions of ASC 842 in interim periods commencing after December 15, 2022. The Company will use the optional transition method to the modified retrospective approach in which Topic 842 will not be applied to comparative periods presented and incremental disclosures are not required for periods before the Company’s adoption of Topic 842. The Company has elected this transition approach as well as the package of practical expedients permitted under the transition guidance within the new standard, which allowed the Company to carry forward the historical lease classification of contracts entered into prior to January 1, 2022. As a result of electing the package of practical expedients described above, existing leases and related initial direct costs have not been reassessed prior to the effective date, and therefore, adoption of the lease standard did not have an impact on the Company’s previously reported consolidated financial statements. The Company also elected the following p rac non-lease ter The Company expects the adoption of Topic 842 will result in the recognition of right-of-use In August 2020, the FASB issued ASU No. 2020-06, 470-20) 815-40): 2020-06”). 2020-06 2020-06, if-converted 2020-06 2020-06 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Accounting Policies, by Policy (Policies) [Line Items] | ||
Emerging Growth Company and Smaller Reporting Company Status | Emerging Growth Company and Smaller Reporting Company Status Following the Business Combination, the Company qualifies as an emerging growth company (‘‘EGC’’) as defined in the Jumpstart our Business Startups (‘‘JOBS’’) Act. The JOBS Act permits companies with EGC status to take advantage of an extended transition period to comply with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies. The Company intends to use this extended transition period to enable the Company to comply with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date the Company (i) is no longer an EGC or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, the Company’s condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting standards as of public company effective dates. In addition, the Company intend to rely on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an EGC, the Company is not required to, among other things: (i) provide an auditor’s attestation report on our system of internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act; (ii) provide all of the compensation disclosures that may be required of non-EGCs The Company will remain an emerging growth company until the earlier of: (i) the last day of the fiscal year (a) following the fifth anniversary of the closing of ENVI’s initial public offering, (b) in which the Company has total annual gross revenue of at least $1.1 billion, or (c) in which the Company is deemed to be a large accelerated filer, which means the market value of its common equity that is held by non-affiliates exceeds $700.0 million as of the last business day of its most recently completed second fiscal quarter; and (ii) the date on which the Company has issued more than $1.0 billion in non-convertible three-year The Company is also a “smaller reporting company” as defined in the Exchange Act. The Company may continue to be a smaller reporting company even after the Company is no longer an emerging growth company. The Company may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as the market value of the Company’s voting and non-voting non-affiliates non-voting non-affiliates | |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the accrual of research and development costs, acquisition of in-process | |
Operating Segments | Operating Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The CODM is the Company’s Chief Executive Officer. The Company manages its operations as a single | |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Investments qualifying as cash equivalents primarily consist of money market funds. The Company’s cash and cash equivalents in the condensed consolidated balance sheets at June 30, 2022 and December 31, 2021, were approximately $44.1 million and $31.4 million, respectively. | |
Restricted Cash | Restricted Cash The Company maintains letters of credit in conjunction with the Company’s lease agreements. As of June 30, 2022 and December 31, 2021, the underlying cash balance securing these letters of credit of approximately $1.3 million and $0.4 million, respectively, was classified as a noncurrent asset in the condensed consolidated balance sheets based on the terms of the lease agreement. | |
Accounts Receivable | Accounts Receivable Our accounts receivable consists of amounts due from one customer. We extend credit to our customer based on our evaluation of the customer’s financial condition. Accounts receivable are stated at amounts due net of applicable prompt pay discounts and other adjustments. We assess the need for an allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due and the customer’s ability to pay its obligation. Based on a review of these factors, as of June 30, 2022, we determined that an allowance for doubtful accounts was not required. | |
Concentrations of Credit Risk | Concentrations of Credit Risk The Company has no significant off-balance | |
Fair Value Measurements | Fair Value Measurements ASC 820, Fair Value Measurements and Disclosures ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier • Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. • Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for a similar asset or liability, either directly or indirectly. • Level 3 inputs are unobservable inputs that reflect the Company’s own assumptions about the inputs that market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. | |
Property and Equipment | Property and Equipment Property and equipment are recorded at cost and depreciated over the estimated useful lives of the related assets using the straight-line method. Maintenance and repairs to an asset that do not improve or extend its life are expensed in the period incurred. Expenditures made to improve or extend the life of property and equipment are capitalized. Leasehold improvements are depreciated over the shorter of the useful life of the improvements or the remaining term of the associated lease. The estimated useful lives of property and equipment are as follows: ESTIMATED USEFUL LIFE Manufacturing equipment 10 Furniture and fixtures 7 years Laboratory equipment 5 years Computer equipment and software 3 years Leasehold improvements Shorter of useful Property and equipment subject to a capital lease are depreciated over the shorter of the useful life or the term of the lease. Construction in progress is stated at cost, which includes direct costs attributable to the setup or construction of the related asset. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the Company’s statement of operations. | |
Acquired In-process Research and Development | Acquired In-process The Company measures and recognizes acquisitions that are not deemed to be business combinations as acquisitions of assets based on the cost to acquire the assets, which includes transaction costs, and the consideration is allocated to the items acquired based on a relative fair value methodology. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process | |
Impairment of Long-lived Assets | Impairment of Long-lived Assets The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Such events and circumstances include, but are not limited to, significant decreases in the market value of an asset, adverse changes in the extent or manner in which the asset is being used, or significant changes in business climate. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. During the six months ended June 30, 2022 and 2021, no impairment indicators were identified and no impairments were recorded. | |
Warrants | Warrants The Company applies relevant accounting guidance for warrants to purchase the Company’s stock based on the nature of the relationship with the counterparty. For warrants issued to investors or lenders in exchange for cash or other financial assets, the Company follows guidance issued within ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging For warrants issued to nonemployees for goods or services, or to customers as non-cash Compensation — Stock Compensation | |
Contract Revenue | Contract Revenue The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers • Identify the contract with a customer • Identify the performance obligations in the contract • Determine the transaction price • Allocate the transaction price to the performance obligations in the contract • Recognize revenue when or as performance obligations are satisfied Under ASC 606, an entity recognizes revenue when or as its customer obtains control of distinct promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. Our customer arrangements primarily consist of a license, rights to our intellectual property, and research and developments services. Performance obligations are promises in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, we consider factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own, or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract. The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration, which is included in the transaction price, may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the variability is resolved. For revenue related to sales-based royalties received from licensees, including milestone payments based on the level of sales, where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). The Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations and develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in a contract with a customer. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations, which may include other comparable transactions, pricing considered in negotiating the transaction, and the estimated costs. Any variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts we would expect to receive for the satisfaction of each performance obligation. The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services, which is either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receive and consumes the benefits provided by the entity’s performance, (ii) the entity’s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the entity’s performance does not create an asset with an alternative use to the Company and the Company has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to the customer. For contracts that include a license of intellectual property (“IP”), the Company applies judgment to determine if the license of IP is distinct from other promises in the contract. License of IP that are determined to be distinct from other promises in the contract are recognized as revenue at a point in time when the license of IP is transferred to the customer and the customer can use and benefit from the license. For licenses of IP that are combined with other promises in a contract, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Determining the revenue recognition of a license of IP requires significant judgment and is discussed further in for the Company’s license and collaboration agreements in Note 4, License Agreement At the inception of a contract that includes development or regulatory milestone payment, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable a significant reversal of revenue would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s control or the licensee’s control, such as milestone payments for regulatory approvals, are not considered probable of being achieve until those approvals are received. Therefore, related revenue associated with the milestone payment is constrained as management is unable to assert that a significant reversal or revenue would not be possible. At the end of each subsequent reporting period, the Company re-evaluates catch-up For contracts that include commercial milestone payments, which are based on the achievement of future sales, and sales-based royalties, if the license is determined to be the predominant item to which the commercial milestones and royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the milestone or royalty has been allocated has been satisfied (or partially satisfied). | |
Grant Revenue | Grant Revenue In July 2020, we entered into a grant agreement with the Bill & Melinda Gates Foundation to advance research in in vivo gene therapy for sickle cell disease and to explore new, low-cost with the Bill & Melinda Gates foundation provides for payments for reimbursed costs, which include general and administrative costs. As we are performing services under the agreement that are consistent with the Company’s ongoing central activities and we have determined that we are the principal in the agreement, we recognize grant revenue as we perform services under this agreement when the funding is committed, which occurs as underlying costs are incurred. Revenues and related expenses are presented gross in the condensed consolidated statements of operations as we have determined that we are the primary obligor under the agreement relative to the research and development services we perform as the lead technical expert. | |
Deferred Revenue | Deferred Revenue Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company’s condensed consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve months, the related deferred revenue will be classified in current liabilities. | |
Deferred Financing Costs | Deferred Financing Costs The incremental cost, including the fair value of warrants, directly associated with obtaining debt financing is capitalized as deferred financing costs upon the issuance of the debt and amortized over the term of the related debt agreement using the effective-interest method with such amortized amounts included as a component of interest expense in the condensed consolidated statement of operations. Unamortized deferred financing costs are presented on the condensed consolidated balance sheets as a direct deduction from the carrying amount of the related debt obligation. | |
Research and Development Costs | Research and Development Costs Research and development expenses consist primarily of costs related to discovery and research and development of products, including personnel expenses, stock-based compensation expense, allocated facility-related | |
General and Administrative Expenses | General and Administrative Expenses The Company expenses general and administrative costs to operations as incurred. General and administrative expenses consist primarily of compensation, benefits, and other employee-related expenses for personnel in the Company’s administrative, finance, legal, information technology, business development, communications, and human resources functions. Other costs include the legal costs incurred in connection with filing and prosecuting patent and trademark applications, general and administrative related facility costs, insurance costs and professional fees for accounting, tax, consulting, legal and other services. | |
Stock-Based Compensation Expense | Stock-Based Compensation Expense The Company accounts for all stock-based payment awards granted to employees and non-employees options and grants of common stock, including common stock subject to vesting. The measurement date for employee and non-employee stock-based The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing Share-Based non-employees, non-employees | |
Net Loss per Share | Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Net loss per share attributable to common stockholders is calculated using the two-class The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, warrants and unvested restricted stock. Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the three and six months ended June 30, 2022 and 2021. As the Merger has been accounted for as a reverse recapitalization, the condensed consolidated financial statements of the merged entity reflect the continuation of the pre-merger | |
Comprehensive Loss | Comprehensive Loss Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner | |
Deferred Offering Costs | Deferred Offering Costs As of December 31, 2021, the Company capitalized deferred offering costs of approximately $4.1 million. Deferred offering costs include certain legal, accounting, consulting and other third-party fees incurred directly related to the anticipated business combination. At the closing of the business combination during the first quarter of 2022, these previously deferred costs were recorded in stockholders’ equity as a reduction of additional paid-in | |
Recently Issued Accounting Pronouncements | Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) 2020-05, COVID-19 one-year non-lease The Company expects the adoption of Topic 842 will result in the recognition of material right-of-use In June 2016, the FASB issued ASU 2016-13, model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. This new standard is effective for the Company in the fiscal year beginning January 1, 2023 and must be adopted using a modified retrospective approach, with certain exceptions. The Company is currently evaluating the impact of this standard on its consolidated financial statements. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Summary of Significant Accounting Policies [Line Items] | ||
Summary of Estimated Useful Lives of Property and Equipment | The estimated useful lives of property and equipment are as follows: ESTIMATED USEFUL LIFE Laboratory equipment 5 years Computer equipment and software 3 years Leasehold improvements Shorter of useful life or | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Summary of Significant Accounting Policies [Line Items] | ||
Summary of Estimated Useful Lives of Property and Equipment | The estimated useful lives of property and equipment are as follows: ESTIMATED USEFUL LIFE Manufacturing equipment 10 Furniture and fixtures 7 years Laboratory equipment 5 years Computer equipment and software 3 years Leasehold improvements Shorter of useful |
Business Combination (Tables)
Business Combination (Tables) - GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | 12 Months Ended |
Dec. 31, 2021 | |
Summary of Reconciles Elements of Business Combination | The following table reconciles the elements of the Business Combination to the Condensed Consolidated Statements of Cash Flows and the Condensed Consolidated Statements of Stockholders’ Deficit: BUSINESS Cash — ENVI trust and cash (net of redemptions) $ 12,123 Cash — February 2022 PIPE Investors, including proceeds from conversion of Convertible notes — February 2022 PIPE Investors 124,250 Gross proceeds 136,373 Less: total transaction costs (26,660 ) Less: cash proceeds from Convertible notes — PIPE Investors (35,250 ) Add: transaction costs paid in 2021 4,080 Cash proceeds from Business Combination received in 2022 78,543 Less: transaction costs paid in 2021 (4,080 ) Less: warrant liabilities assumed (1,341 ) Less: net liabilities assumed in the Business Combination (133 ) Reverse merger, net of transactions costs $ 72,989 |
Schedule of Number of Shares of Common Stock Outstanding and Immediately Consummation of Business Combination | The number of shares of common stock outstanding immediately following the consummation of the Business Combination was as follows: Number of Common stock, outstanding prior to the Business Combination 20,700,000 Less: Redemption of ENVI shares (19,489,626 ) ENVI Public Shares 1,210,374 ENVI Sponsor Shares 5,175,000 Shares issued in February 2022 PIPE Financing 12,425,000 Business combination and February 2022 PIPE Financing shares 18,810,374 Legacy GreenLight shares (1) 104,011,760 Total shares of common stock immediately after Business Combination 122,822,134 (1) - The number of Legacy GreenLight shares was determined from the shares of Legacy GreenLight outstanding immediately prior to the closing of the Business Combination converted at the Exchange Ratio. All fractional shares were rounded down. |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items] | ||
Schedule of assets and liabilities at fair value on a recurring basis | The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of June 30, 2022 and December 31, 2021: DESCRIPTION JUNE 30, 2022 QUOTED SIGNIFICANT SIGNIFICANT ($ in thousands) Asset Money market funds 44,132 44,132 — — Total assets measured at fair value $ 44,132 $ 44,132 $ — $ — Liability Warrant liabilities 470 — — 470 Total liabilities measured at fair value $ 470 $ — $ — $ 470 DESCRIPTION DECEMBER 31, QUOTED SIGNIFICANT SIGNIFICANT ($ in thousands) Asset Money market funds 31,446 31,446 — — Total assets measured at fair value $ 31,446 $ 31,446 $ — $ — Liability Warrant liabilities 2,105 — — 2,105 Total liabilities measured at fair value $ 2,105 $ — $ — $ 2,105 | The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands): DESCRIPTION DECEMBER 31, QUOTED IN ACTIVE MARKETS IDENTICAL ASSETS (LEVEL 1) SIGNIFICANT INPUTS SIGNIFICANT (LEVEL 3) Asset Money market funds $ 55,747 $ 55,747 $ — $ — Total assets measured at fair value $ 55,747 $ 55,747 $ — $ — Liability Warrant liability $ 125 $ — $ — $ 125 Convertible debt $ 17,273 $ — $ — $ 17,273 Total liabilities measured at fair value $ 17,398 $ — $ — $ 17,398 DESCRIPTION DECEMBER 31, QUOTED PRICES SIGNIFICANT SIGNIFICANT Asset Money market funds $ 31,446 $ 31,446 $ — $ — Total assets measured at fair value $ 31,446 $ 31,446 $ — $ — Liability Warrant liabilities $ 2,105 $ — $ — $ 2,105 Convertible debt $ 31,691 $ — $ — $ 31,691 Total liabilities measured at fair value $ 33,796 $ — $ — $ 33,796 |
Schedule of changes in the fair value of Level 3 warrant liabilities | WARRANT Balance—December 31, 2021 $ 2,105 Warrants exercised in business combination (1,633 ) Warrants reclassified to equity (387 ) Change in fair value of warrants (956 ) Warrants assume in business combination 1,341 Balance—June 30, 2022 $ 470 | WARRANT Balance — January 1, 2020 $ 103 Change in fair value 22 Balance — December 31, 2020 125 Issuance of common stock warrant 610 Change in fair value 1,370 Balance — December 31, 2021 $ 2,105 |
Property and Equipment, Net (Ta
Property and Equipment, Net (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Property, Plant and Equipment [Line Items] | ||
Summary of Property and Equipment | Property and equipment, net consisted of the following as of June 30, 2022 and December 31, 2021: JUNE 30, DECEMBER 31, ($ in thousands) Computer hardware and software $ 868 $ 732 Laboratory equipment 20,815 19,590 Leasehold improvements 10,883 10,442 Manufacturing equipment 1,214 — Construction in progress 11,636 1,894 Total 45,416 32,658 Less: Accumulated depreciation and amortization (13,331 ) (9,259 ) Property and equipment, net $ 32,085 $ 23,399 | Property and equipment, net consisted of the following as of December 31, 2020 and 2021 (in thousands): DECEMBER 31, 2020 2021 Computer hardware and software $ 533 $ 732 Laboratory equipment 8,040 19,590 Leasehold improvements 4,545 10,442 Construction in progress 6,847 1,894 Total 19,965 32,658 Less: Accumulated depreciation and amortization (3,686 ) (9,259 ) Property and equipment, net $ 16,279 $ 23,399 |
Accrued Expenses (Tables)
Accrued Expenses (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Accrued Liabilities, Current [Line Items] | ||
Summary of Accrued Expenses | Accrued expenses as of June 30, 2022 and December 31, 2021 consisted of the following: JUNE 30, DECEMBER 31, ($ in thousands) Accrued employee compensation and benefits $ 8,065 $ 8,492 Accrued research and development 20,709 4,059 Accrued professional fees 568 1,888 Accrued other 1,085 185 Total accrued expenses $ 30,427 $ 14,624 | Accrued expenses as of December 31, 2020 and 2021 consisted of the following (in thousands): DECEMBER 31, 2020 2021 Accrued employee compensation and benefits $ 4,024 $ 8,492 Accrued research and development 612 4,059 Accrued professional fees 568 1,888 Accrued other 1,622 185 Total accrued expenses $ 6,826 $ 14,624 |
Debt (Tables)
Debt (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Debt Instrument [Line Items] | ||
Summary of the Outstanding Debt | A summary of the outstanding debt as of December 31, 2021 is as follows (in thousands): AS OF DECEMBER 31, 2021 DESCRIPTION ISSUANCE DATE(S) MATURITY STATED RATE PRINCIPAL BALANCE OUTSTANDING UNAMORTIZED DEBT DEBT BALANCE Trinity Equipment Financing March 2021 - August 2021 March 2024 - August 2024 9.48% - 9.73% $ 9,454 $ (252 ) $ 9,202 Term Loan — Silicon Valley Bank September 2021 September 2024 3.50% 10,000 (225 ) 9,775 Term Loan — Horizon December 2021 May 2025 9.00% 15,000 (582 ) 14,418 Capital Lease 992 — 992 Total Debt 35,446 (1,060 ) 34,386 Less: current portion, net of current portion of debt (7,234 ) Total long-term $ 27,152 Convertible Note — PIPE Investors December 2021 December 2022 0.33% 13,500 — 13,500 Convertible Notes April & May 2020 April & May 2022 5.00% 18,213 (22 ) 18,191 31,713 (22 ) 31,691 $ 67,159 $ (1,082 ) $ 66,077 (a) As of December 31, 2020 and 2021, the Company’s debt liability included $16.8 million of convertible notes issued by GLPRI in 2020, as well as the associated accrued interest liability of $0.6 million and $1.4 million, respectively. | |
Summary of Interest Expense | The following summarizes the components of total interest expense (in thousands): DECEMBER 31, 2020 2021 Interest paid or accrued $ 440 $ 2,253 Noncash amortization of debt discount and deferred financing cost 588 166 Total $ 1,028 $ 2,419 | |
Summary of Future Principal Payment of Long Term Debt | Scheduled future principal payments on total outstanding debt, as of December 31, 2021, are as follows (in thousands): DECEMBER 31, 2022 $ 37,176 2023 13,916 2024 11,972 2025 and thereafter 2,657 Total $ 65,721 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Debt Instrument [Line Items] | ||
Summary of the Outstanding Debt | A summary of the outstanding debt as of June 30, 2022 is as follows (in thousands): AS OF JUNE 30, 2022 DESCRIPTION ISSUANCE MATURITY INTEREST PRINCIPAL UNAMORTIZED DEBT Trinity Equipment Financing March 2021 - August 2021 March 2024 - August 2024 9.48% - 9.73% $ 7,722 $ (198 ) $ 7,524 Term Loan — Silicon Valley Bank September 2021 September 2024 5.00% 9,000 (158 ) 8,842 Term Loan — December 2021 May 2025 10.50% 15,000 (472 ) 14,528 Capital lease 664 — 664 Total Debt 32,386 (828 ) 31,558 Less: Current Portion (11,402 ) Total Long-Term $ 20,156 | |
Summary of Debt Instrument | A summary of the outstanding debt as of December 31, 2021 is as follows (in thousands): AS OF DECEMBER 31, 2021 DESCRIPTION ISSUANCE MATURITY STATED PRINCIPAL UNAMORTIZED DEBT Trinity equipment financing March 2021 - August 2021 March 2024 - August 2024 9.48% - 9.73% $ 9,454 $ (252 ) $ 9,202 Term loan — Silicon Valley Bank September 2021 September 2024 3.50% 10,000 (225 ) 9,775 Term loan — Horizon December 2021 May 2025 9.00% 15,000 (582 ) 14,418 Capital lease 992 — 992 Total Debt 35,446 (1,060 ) 34,386 Less: Current Portion (7,234 ) Total Long-Term 27,152 Convertible notes — PIPE Investors December 2021 December 2022 0.33% 13,500 — 13,500 Convertible notes (a) April & May 2020 April & May 2020 5.00% 18,213 (22 ) 18,191 31,713 (22 ) 31,691 Total debt and convertible notes $ 67,159 $ (1,082 ) $ 66,077 a) As of December 31, 2021, the Company’s debt liability included $16.8 million of convertible notes issued by GLPRI in 2020, as well as the associated accrued interest liability of $1.4 million. | |
Summary of Interest Expense | Interest expense for the three and six months ended June 30, 2022 and 2021 consisted of the following: THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED 2022 2021 2022 2021 ($ in thousands) Interest paid or accrued $ 935 $ 202 $ 1,739 $ 303 Non-cash 199 212 423 422 Total $ 1,134 $ 414 $ 2,162 $ 725 | |
Summary of Future Principal Payment of Long Term Debt | Scheduled future principal payments on total outstanding debt, as of June 30, 2022 are as follows (in thousands): JUNE 30, 2022 Remainder of 2022 $ 4,662 2023 14,226 2024 10,998 2025 and thereafter 2,500 Total $ 32,386 |
Warrants (Tables)
Warrants (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Class of Warrant or Right [Line Items] | ||
Summary of Preferred stock warrants classified as liabilities | ||
Summary of estimated the fair value of the warrants | The Company estimated the fair value of the warrants as of December 31, 2020, and 2021 using the Black-Scholes option-pricing model with the following assumptions: AS OF DECEMBER 31, 2020 VALUATION ASSUMPTIONS SERIES A-1 SERIES A-2 SERIES A-3 Fair value of underlying series of preferred stock $ 2.18 $ 2.31 $ 2.64 Risk free interest rate 0.10 % 0.27 % 0.36 % Expected volatility 88.4 % 78.5 % 82.4 % Estimated time (in years) 1.05 3.65 4.97 AS OF DECEMBER 31, 2021 VALUATION ASSUMPTIONS SERIES A-1 SERIES A-2 SERIES A-3 Fair value of underlying series of preferred stock $ 9.19 $ 9.21 $ 9.25 Risk free interest rate 0.06 % 0.97 % 1.12 % Expected volatility 87.6 % 85.5 % 84.9 % Estimated time (in years) 0.05 2.65 3.97 | |
Summary of Common stock warrant classified | ||
Common Stock Warrant Classified As Liability [Member] | ||
Class of Warrant or Right [Line Items] | ||
Summary of estimated the fair value of the warrants | ||
Summary of Common stock warrant classified | ||
Common Stock Warrants Classified As Equity [Member] | ||
Class of Warrant or Right [Line Items] | ||
Summary of Common stock warrant classified | Common stock warrant classified as a component of permanent equity consisted of the following at December 31, 2021: AS OF DECEMBER 31, 2021 WARRANT CLASS SHARES ISSUANCE DATE EXERCISE EXPIRATION DATE Common stock warrant 26,624 June 14, 2016 $ 0.33 The earlier of June 13 Common stock warrant 34,427 September 22, 2021 $ 2.61 The earlier of September 21 Total 61,051 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Class of Warrant or Right [Line Items] | ||
Summary of Roll-forward of the Warrants | The following table presents a roll-forward of the Company’s warrants from December 31, 2021 to June 30, 2022: COMMON PREFERRED Warrants Outstanding, December 31, 2021 (1) 207,376 635,404 Exercised in the business combination (1) (207,376 ) (635,404 ) Issued (1) 75,924 — Assumed in the business combination 12,412,500 — Exercised subsequent to the business combination (105,120 ) — Warrants Outstanding, June 30, 2022 12,383,304 — (1) Number of warrants have been adjusted to reflect the exchange for New GreenLight warrants at an exchange ratio of approximately 0.6656 as a result of the Business Combination. See Note 3 for further information. | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Common Stock Warrant Classified As Liability [Member] | ||
Class of Warrant or Right [Line Items] | ||
Summary of estimated the fair value of the warrants | The warrant’s fair value upon issuance and as of June 30, 2022 was estimated to be approximately $0.2 million and $35 thousand, respectively, and was measured using a probability weighted Black-Scholes option-pricing model with the following assumptions: Valuation Assumptions AT ISSUANCE 2022) AS OF Fair value of common stock $ 5.89 $ 2.21 Risk free interest rate 1.50 % 2.39 % Expected volatility 59.60 % 59.60 % Expected term (in years) 10.50 10.00 | |
Summary of Common stock warrant classified | The warrants issued for the $10.0 million available commitment was summarized below as a liability classified Common Stock Warrant. Warrant Class Shares Inception Issuance Exercise Expiration Date Common stock warrant 28,517 $ 249 January 19, $ 5.26 The earlier of March 29, 2031 or the date of a qualifying acquisition Warrant Class Shares Inception Initial Exercise Expiration Private Placement Warrants 2,062,500 $ 1,341 February 2, $ 11.50 March 2, | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Common Stock Warrants Classified As Equity [Member] | ||
Class of Warrant or Right [Line Items] | ||
Summary of estimated the fair value of the warrants | The warrant’s fair value upon issuance was estimated to be approximately $0.4 million, and was measured using a Black-Scholes option-pricing model with the following assumptions: Valuation Assumptions AT ISSUANCE (AS OF JANUARY 19, Fair value of common stock $ 5.89 Risk free interest rate 1.50 % Expected volatility 59.60 % Expected term (in years) 10.00 The fair value of the Private Placement Warrant upon initial recognition and as of June 30, 2022 was estimated to be approximately $1.3 million and $0.5 million respectively, and was measured using a Black-Scholes option-pricing model with the following assumptions: Valuation Assumptions INITIAL AS OF Fair value of common stock $ 8.82 $ 2.21 Risk free interest rate 1.59 % 3.00 % Volatility 15.9 % 51.5 % Expected term (in years) 5.00 4.50 | |
Summary of Common stock warrant classified | The Company determined that the Warrants met the requirements for equity classification and the fair value of $0.4 million was reclassified to equity as of March 31, 2022. Warrant Class Shares Issuance Date Exercise Expiration Date Common stock warrant 85,552 January 19, 2022 $ 5.26 January 19, 2032 |
Stockholder's Equity (Tables)
Stockholder's Equity (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Redeemable Noncontrolling Interest [Line Items] | ||
Summary of Legacy Redeemable Convertible Preferred Stock Authorized, Issued, and Outstanding | The following table summarizes details of Legacy Redeemable Convertible Preferred Stock authorized, issued, and outstanding immediately prior to the Business Combination. Redeemable Convertible Preferred Stock Classes JUNE 30, DECEMBER 31, ($ in thousands) Series A-1 $ — $ 4,414 Series A-2 — 11,438 Redeemable Convertible Preferred Stock Classes JUNE 30, DECEMBER 31, ($ in thousands) Series A-3 — 19,917 Series B redeemable convertible preferred stock, $0.001 par value, 21,245,353 shares authorized, issued and outstanding as of December 31, 2021 Liquidation preference of $24,017 and $0 at December 31, 2021 and June 30, 2022, respectively — 18,671 Series C redeemable convertible preferred stock, $0.001 par value, 35,152,184 shares authorized, 35,092,183 shares issued and outstanding as of December 31, 2021 Liquidation preference of $69,595 and $0 at December 31, 2021 and June 30, 2022, respectively — 55,851 Series D redeemable convertible preferred stock, $0.001 par value, 71,019,827 shares authorized, 60,184,332 shares issued and outstanding as of December 31, 2021 Liquidation preference of $122,459 and $0 at December 31, 2021 and June 30, 2022, respectively — 108,499 Total $ — $ 218,790 | The following table summarizes details of Legacy Preferred Stock authorized, issued and outstanding as of December 31, 2020 and 2021 (in thousands, except share and per share data): YEARS ENDED DECEMBER 31, LEGACY REDEEMABLE CONVERTIBLE PREFERRED STOCK CLASSES 2020 2021 Series A-1 $ 4,411 $ 4,414 Series A-2 11,438 11,438 Series A-3 19,917 19,917 Series B redeemable convertible preferred stock, $0.001 par value, 21,245,353 shares authorized, issued and outstanding as of December 31, 2020 and December 31, 2021 Liquidation preference of $22,567 and $24,017 at December 31, 2020 and December 31, 2021, respectively 18,671 18,671 YEARS ENDED DECEMBER 31, LEGACY REDEEMABLE CONVERTIBLE PREFERRED STOCK CLASSES 2020 2021 Series C redeemable convertible preferred stock, $0.001 par value, 35,152,184 shares authorized, 35,092,183 shares issued and outstanding as of December 31, 2020 and December 31, 2021 Liquidation preference of $65,014 and $69,595 at December 31, 2020 and December 31, 2021, respectively 55,851 55,851 Series D redeemable convertible preferred stock, $0.001 par value, 71,019,827 shares authorized, 60,184,332 shares issued and outstanding and as of December 31, 2020 and December 31, 2021 Liquidation preference of $113,736 and $122,459 at December 31, 2020 and December 31, 2021, respectively 108,499 108,499 Total $ 218,787 $ 218,790 |
Redeemable Convertible Prefer_2
Redeemable Convertible Preferred Stock (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Redeemable Noncontrolling Interest [Line Items] | ||
Summary of Temporary Equity | The following table summarizes details of Legacy Redeemable Convertible Preferred Stock authorized, issued, and outstanding immediately prior to the Business Combination. Redeemable Convertible Preferred Stock Classes JUNE 30, DECEMBER 31, ($ in thousands) Series A-1 $ — $ 4,414 Series A-2 — 11,438 Redeemable Convertible Preferred Stock Classes JUNE 30, DECEMBER 31, ($ in thousands) Series A-3 — 19,917 Series B redeemable convertible preferred stock, $0.001 par value, 21,245,353 shares authorized, issued and outstanding as of December 31, 2021 Liquidation preference of $24,017 and $0 at December 31, 2021 and June 30, 2022, respectively — 18,671 Series C redeemable convertible preferred stock, $0.001 par value, 35,152,184 shares authorized, 35,092,183 shares issued and outstanding as of December 31, 2021 Liquidation preference of $69,595 and $0 at December 31, 2021 and June 30, 2022, respectively — 55,851 Series D redeemable convertible preferred stock, $0.001 par value, 71,019,827 shares authorized, 60,184,332 shares issued and outstanding as of December 31, 2021 Liquidation preference of $122,459 and $0 at December 31, 2021 and June 30, 2022, respectively — 108,499 Total $ — $ 218,790 | The following table summarizes details of Legacy Preferred Stock authorized, issued and outstanding as of December 31, 2020 and 2021 (in thousands, except share and per share data): YEARS ENDED DECEMBER 31, LEGACY REDEEMABLE CONVERTIBLE PREFERRED STOCK CLASSES 2020 2021 Series A-1 $ 4,411 $ 4,414 Series A-2 11,438 11,438 Series A-3 19,917 19,917 Series B redeemable convertible preferred stock, $0.001 par value, 21,245,353 shares authorized, issued and outstanding as of December 31, 2020 and December 31, 2021 Liquidation preference of $22,567 and $24,017 at December 31, 2020 and December 31, 2021, respectively 18,671 18,671 YEARS ENDED DECEMBER 31, LEGACY REDEEMABLE CONVERTIBLE PREFERRED STOCK CLASSES 2020 2021 Series C redeemable convertible preferred stock, $0.001 par value, 35,152,184 shares authorized, 35,092,183 shares issued and outstanding as of December 31, 2020 and December 31, 2021 Liquidation preference of $65,014 and $69,595 at December 31, 2020 and December 31, 2021, respectively 55,851 55,851 Series D redeemable convertible preferred stock, $0.001 par value, 71,019,827 shares authorized, 60,184,332 shares issued and outstanding and as of December 31, 2020 and December 31, 2021 Liquidation preference of $113,736 and $122,459 at December 31, 2020 and December 31, 2021, respectively 108,499 108,499 Total $ 218,787 $ 218,790 |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Summary of assumptions in the binomial option-pricing model used to determine the fair value of stock options | The fair value of stock option awards is estimated on the grant date using the Black-Scholes option pricing model with the following assumptions: YEARS ENDED DECEMBER 31, 2020 2021 Fair value of underlying common stock $0.69 - $0.98 $1.23 - $8.85 Weighted average risk-free interest rate 0.27% - 1.55% 0.48% - 1.42% Expected term (in years) 5 - 6 6 Expected volatility 69.5% - 70.4% 56.3% - 68.9% Expected dividend yield 0.00% 0.00% | |
Schedule of Stock Option Activity | The following table summarizes the activity of the Company’s stock options under the Plan for the year ended December 31, 2021: SHARES WEIGHTED- AVERAGE AGGREGATE (in thousands) Outstanding at December 31, 2020 15,001,672 $ 0.62 8.5 $ 9,170 Granted 3,811,151 3.20 — — Exercised (253,027 ) 0.57 2,096 Cancelled or forfeited (458,248 ) 1.61 — Outstanding at December 31, 2021 18,101,548 $ 1.14 8.0 $ 139,505 Vested and expected to vest at December 31, 2021 18,101,548 $ 1.14 8.0 $ 139,505 Exercisable at December 31, 2021 7,449,211 $ 0.51 6.9 $ 62,157 | |
Summary of the Company's restricted stock activity | A summary of the Company’s restricted stock activity during the years ended December 31, 2020, and 2021 is presented below: SHARES WEIGHTED Unvested shares as of December 31, 2020 24,937 $ 0.56 Vested (20,706 ) 0.82 Unvested shares as of December 31, 2021 4,231 $ 1.15 | |
Summary of stock-based compensation expense | Stock-based compensation expense recorded as research and development and general and administrative expenses, for employees, directors and non-employees YEARS ENDED 2020 2021 Research and development $ 306 $ 1,018 General and administrative 353 973 Total stock-based compensation expense $ 659 $ 1,991 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Summary of assumptions in the binomial option-pricing model used to determine the fair value of stock options | The fair value of stock option awards is estimated on the grant date using the Black-Scholes option pricing model with the following weighted-average assumptions: SIX MONTHS ENDED JUNE 30, 2022 2021 Fair value of underlying common stock $ 3.56 $ 0.80 Weighted average risk-free interest rate 3.00 % 1.13 % Expected term (in years) 6.04 6.08 Expected volatility 65.38 % 67.83 % Expected dividend yield 0 % 0 % | |
Schedule of Stock Option Activity | The following table summarizes the activity of the Company’s stock options under the Plan for the six months ended June 30, 2022: SHARES (1) WEIGHTED- (1) AVERAGE AGGREGATE (in thousands) Outstanding at December 31, 2021 18,101,548 $ 1.14 8.0 $ 139,505 Granted 6,713,069 5.79 — — Exercised (760,534 ) 0.46 — 250 Cancelled or forfeited (525,276 ) 1.36 — — Outstanding at June 30, 2022 23,528,807 2.49 8.2 22,335 Vested and expected to vest at June 30, 2022 23,528,807 2.49 8.2 22,335 Exercisable at June 30, 2022 8,891,469 $ 0.71 6.8 $ 13,792 (1) Number of options and weighted average exercise price has been adjusted to reflect the exchange of Legacy GreenLight’s stock options for New GreenLight stock options at an exchange ratio of approximately 0.6656 as a result of the Business Combination. See Note 3 for further information. | |
Summary of the Company's restricted stock activity | A summary of the Company’s restricted stock activity during the six months ended June 30, 2022 is presented below: SHARES WEIGHTED Unvested shares as of December 31, 2021 4,231 $ 0.76 Vested (2,898 ) 0.23 Unvested shares as of June 30, 2022 1,333 $ 0.22 | |
Summary of stock-based compensation expense | Stock-based compensation expense recorded as research and development and general and administrative expenses, for employees, directors and non-employees THREE MONTHS ENDED SIX MONTHS ENDED JUNE 30, 2022 2021 2022 2021 ($ in thousands) Research and development $ 958 $ 188 $ 1,462 $ 324 General and administrative 676 219 2,359 431 Total stock-based compensation expense $ 1,634 $ 407 $ 3,821 $ 755 |
Common Stock (Tables)
Common Stock (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Class of Stock [Line Items] | |
Summary Of Common Stock Capital Shares Reserved For Future Issuance | As of December 31, 2021, the Company has reserved the following shares of common stock for potential conversion of outstanding Preferred Stock, potential conversion of convertible debt and PIPE Notes with accrued interest through the applicable year-end, into Series D Preferred Stock, the vesting of restricted stock and exercise of stock options and preferred and common stock warrants: AS OF Convertible debt with accrued interest 6,684,122 Options to purchase common stock 19,803,226 Preferred stock warrants 651,988 Common stock warrants 207,376 Total 27,346,712 |
Net Loss Per Share (Tables)
Net Loss Per Share (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Summary of the computation of basic and diluted net loss per share attributable to common stockholders | The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except share and per share data): YEARS ENDED 2020 2021 Numerator: Net loss $ (53,251 ) $ (112,310 ) Denominator: Weighted-average common stock outstanding 77,673,953 96,371,189 Net loss per share, basic and diluted $ (0.69 ) $ (1.17 ) | |
Summary of the excluded potential common stock | The Company excluded the following potential common stock, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: AS OF DECEMBER 31, 2020 2021 Convertible debt with accrued interest 6,378,460 6,684,122 Unvested restricted stock 24,937 4,231 Options to purchase common stock 15,001,672 18,101,548 Preferred stock warrants 107,416 651,988 Common stock warrants 26,624 207,376 Total 21,539,109 25,649,265 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Summary of the computation of basic and diluted net loss per share attributable to common stockholders | The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company: THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED (In thousands, except shares and per share data) 2022 2021 2022 2021 Numerator: Net loss available to common stockholders $ (51,926 ) $ (27,174 ) $ (90,133 ) $ (48,457 ) Denominator: Weighted-average common stock outstanding 123,249,757 96,327,956 118,430,851 96,314,179 Net loss per share, basic and diluted $ (0.42 ) $ (0.28 ) $ (0.76 ) $ (0.50 ) | |
Summary of the excluded potential common stock | The Company excluded the following potential common stock, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: AS OF JUNE 30, 2022 2021 Unvested restricted stock 1,333 13,926 Options to purchase common stock 23,528,807 17,572,807 Common stock warrants 12,383,304 172,949 Total 35,913,444 17,759,682 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax [Line Items] | |
Summary of net deferred tax assets | A reconciliation of the Company’s effective tax rate to the statutory federal income tax rate is as follows for the years ended December 31, 2020, and 2021: YEARS ENDED 2020 2021 Federal income tax (benefit)/expense at statutory rate 21.0 % 21.0 % State income tax benefit 5.4 % 6.9 % Permanent items -0.2 % -0.5 % Change in Valuation Allowance -29.3 % -30.6 % Federal R&D Tax Credits 3.1 % 3.0 % Other 0.0 % 0.2 % Effective income tax rate 0.0 % 0.0 % |
Schedule of income tax provision | Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2020, and 2021 were as follows (in thousands): YEARS ENDED 2020 2021 Deferred tax assets: Federal net operating loss carryforwards $ 26,464 $ 48,956 State net operating loss carryforwards 6,542 12,477 Tax credits 4,059 8,736 Stock based compensation 89 233 Capitalized research and development expenses 4,398 3,649 Accruals and other 763 1,482 Total deferred tax assets 42,315 75,533 Valuation allowance (39,965 ) (74,340 ) Total deferred tax assets $ 2,350 $ 1,193 Deferred tax liabilities: Depreciation and amortization $ (2,350 ) $ (1,193 ) Total deferred tax liabilities $ (2,350 ) $ (1,193 ) Total net deferred tax assets (liability) $ — $ — As of December 31, 2021, the Company had federal NOL carryforwards of $232,116 and state NOL carryforwards of approximately $197,424, which are available to reduce future taxable income. The Company also had federal tax credits of $7,485 as of December 31, 2021. The federal NOLs generated before 2018 of approximately $27,104 will expire at various dates through 2037, and NOL carryforwards generated after 2017 of approximately $205,012 have an indefinite carryforward period. The state NOLs and tax credit carryforwards will expire at various dates through 2040. |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Commitments And Contingencies [Line Items] | ||
Summary of future minimum lease payments under noncancelable operating leases | A summary of the Company’s future minimum lease payments under noncancelable operating leases, excluding tenant improvement payables, as of December 31, 2021, is as follows (in thousands): FOR THE YEARS ENDED 2022 $ 7,841 2023 7,257 2024 2,549 2025 1,450 2026 1,242 Thereafter 5,359 Total $ 25,698 | |
Summary of future minimum payments under these capital lease arrangements | Future minimum lease payments under the capital lease agreements as of December 31, 2021, together with the present value of the minimum lease payments are as follows (in thousands): FOR THE YEARS ENDED 2022 $ 779 2023 330 Thereafter — Total minimum lease payments $ 1,109 Less: amount representing interest (117 ) Present value of obligations under capital leases $ 992 Current portion of capital lease obligations $ 672 Capital lease obligations, long-term $ 320 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Commitments And Contingencies [Line Items] | ||
Summary of future minimum lease payments under noncancelable operating leases | A summary of the Company’s future minimum lease payments under noncancelable operating leases, excluding tenant improvement payables, as of June 30, 2022, is as follows (in thousands): AS OF JUNE 30, 2022 Remainder of 2022 $ 4,554 2023 9,573 2024 8,285 2025 7,296 2026 7,018 Thereafter 43,975 Total $ 80,701 |
Nature of Business and Basis _2
Nature of Business and Basis of Presentation (Details) $ / shares in Units, $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||
Aug. 12, 2022 USD ($) | Aug. 11, 2022 $ / shares shares | Feb. 02, 2022 USD ($) $ / shares shares | Aug. 09, 2021 USD ($) | Jan. 31, 2022 USD ($) | Jun. 30, 2022 USD ($) $ / shares shares | Jun. 30, 2021 USD ($) $ / shares | Jun. 30, 2022 USD ($) $ / shares shares | Jun. 30, 2021 USD ($) $ / shares | Dec. 31, 2021 USD ($) $ / shares | Dec. 31, 2020 USD ($) $ / shares | Mar. 31, 2022 $ / shares | Mar. 31, 2021 $ / shares | |
Nature Of Business And Basis Of Presentation [Line Items] | |||||||||||||
Assets Held-in-trust | $ 207,000 | ||||||||||||
Paymnets for repurchase of common stock | 194,900 | ||||||||||||
Net Income Loss | $ (51,926) | $ (27,174) | $ (90,133) | $ (48,457) | $ (112,310) | $ (53,251) | |||||||
Retained Earnings (Accumulated Deficit) | (343,716) | (343,716) | (253,569) | (141,259) | |||||||||
Cash and cash equivalents | $ 44,132 | $ 52,340 | 44,132 | 52,340 | 31,446 | 95,068 | |||||||
Net Cash Provided by (Used in) Operating Activities | $ (72,165) | $ (42,300) | $ (91,832) | $ (46,599) | |||||||||
Funds available after redemptions to finance transaction expenses and future operations | 12,100 | ||||||||||||
Number of warrants or rights outstanding | shares | 12,383,304 | 12,383,304 | |||||||||||
Common stock, par value (in Dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||||||||||||
Nature Of Business And Basis Of Presentation [Line Items] | |||||||||||||
Net Income Loss | $ (90,100) | $ (48,500) | |||||||||||
Retained Earnings (Accumulated Deficit) | $ (343,700) | (343,700) | |||||||||||
Cash and cash equivalents | $ 44,100 | 44,100 | $ 31,400 | ||||||||||
Net Cash Provided by (Used in) Operating Activities | $ (72,200) | $ (42,300) | |||||||||||
Business combination exchange ratio | 0.6656 | ||||||||||||
Common stock, par value (in Dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.001 | $ 0.001 | ||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | PIPE [Member] | |||||||||||||
Nature Of Business And Basis Of Presentation [Line Items] | |||||||||||||
Proceeds from divestiture of businesses | $ 136,400 | ||||||||||||
Cash acquired net of redemption | $ 109,700 | ||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Subsequent Event [Member] | August 2022 Subscription Agreements [Member] | |||||||||||||
Nature Of Business And Basis Of Presentation [Line Items] | |||||||||||||
Proceeds from issuance of common stock | $ 108,400 | ||||||||||||
Private Placement Warrants [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||||||||||||
Nature Of Business And Basis Of Presentation [Line Items] | |||||||||||||
Number of warrants or rights outstanding | shares | 2,062,500 | ||||||||||||
Warrants price per share (in Dollars per share) | $ / shares | $ 11.5 | ||||||||||||
Public Warrants [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||||||||||||
Nature Of Business And Basis Of Presentation [Line Items] | |||||||||||||
Number of warrants or rights outstanding | shares | 10,350,000 | ||||||||||||
Warrants price per share (in Dollars per share) | $ / shares | $ 11.5 | ||||||||||||
Public and Private Placement Warrants [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||||||||||||
Nature Of Business And Basis Of Presentation [Line Items] | |||||||||||||
Warrants expiration period | 5 years | ||||||||||||
Environmental Impact Acquisition Corp [Member] | |||||||||||||
Nature Of Business And Basis Of Presentation [Line Items] | |||||||||||||
Advance received under PIPE financing | $ 13,500 | ||||||||||||
Direct and incremental transaction costs | 25,000 | ||||||||||||
GreenLight Biosciences is expected to receive aggregate net proceeds of approximately $282.3 million | $ 111,400 | ||||||||||||
Environmental Impact Acquisition Corp [Member] | Subsequent Event [Member] | |||||||||||||
Nature Of Business And Basis Of Presentation [Line Items] | |||||||||||||
Purchase price | $ 136,400 | ||||||||||||
Business acquisition, equity interest issued or issuable, number of shares | shares | 12,400,000 | ||||||||||||
Advance received under PIPE financing | $ 21,800 | ||||||||||||
Legacy Green Light [Member] | |||||||||||||
Nature Of Business And Basis Of Presentation [Line Items] | |||||||||||||
Shares issued, price per share | $ / shares | $ 0.0001 | ||||||||||||
Business combination exchange ratio | 0.6656 | 0.6656 | |||||||||||
Legacy Green Light [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||||||||||||
Nature Of Business And Basis Of Presentation [Line Items] | |||||||||||||
Business combination exchange ratio | 0.6656 | ||||||||||||
Business combination transaction costs | $ 26,700 | $ 26,700 | |||||||||||
Intangible assets | $ 0 | ||||||||||||
Legacy Green Light [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | PIPE [Member] | |||||||||||||
Nature Of Business And Basis Of Presentation [Line Items] | |||||||||||||
Purchase price | $ 21,800 | $ 13,500 | |||||||||||
Legacy Green Light [Member] | Common Class A [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||||||||||||
Nature Of Business And Basis Of Presentation [Line Items] | |||||||||||||
Business acquisition, equity interest issued or issuable, number of shares | shares | 12,425,000 | ||||||||||||
Common stock, par value (in Dollars per share) | $ / shares | $ 0.0001 | ||||||||||||
Legacy Green Light [Member] | Common Class A [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | PIPE [Member] | |||||||||||||
Nature Of Business And Basis Of Presentation [Line Items] | |||||||||||||
Purchase price | $ 124,300 | ||||||||||||
Private Placement [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Subsequent Event [Member] | |||||||||||||
Nature Of Business And Basis Of Presentation [Line Items] | |||||||||||||
Number of units issued (in Shares) | shares | 27,640,301 | ||||||||||||
Price per unit (in Dollars per share) | $ / shares | $ 3.92 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies (Details) | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 USD ($) Segment | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) Segment | Dec. 31, 2020 USD ($) | |
Summary of Significant Accounting Policies [Line Items] | ||||
Number of Operating Segments | Segment | 1 | |||
Cash | $ 44,132,000 | $ 52,340,000 | $ 31,446,000 | $ 95,068,000 |
Restricted cash | $ 1,321,000 | 167,000 | 362,000 | 80,000 |
Impairment of long lived asset | 0 | 0 | ||
Deferred offering costs | 4,100,000 | |||
Noncurrent Assets [Member] | ||||
Summary of Significant Accounting Policies [Line Items] | ||||
Restricted cash | 300,000 | $ 100,000 | ||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||||
Summary of Significant Accounting Policies [Line Items] | ||||
Number of Operating Segments | Segment | 1 | |||
Cash | $ 44,100,000 | 31,400,000 | ||
Impairment of long lived asset | 0 | $ 0 | ||
Deferred offering costs | 4,100,000 | |||
Emerging growth company gross revenue threshold | 1,100,000,000 | |||
Large accelerated filer threshold of entity common equity held by non affiliates market value | 700,000,000 | |||
Emerging growth company issuance of nonconvertible debt securities | 1,000,000,000 | |||
Smaller reporting company threshold entity voting and nonvoting common stock held by non affiliates | 250,000,000 | |||
Smaller reporting company gross revenue threshold | 100,000,000 | |||
Smaller reporting company threshold entity voting and nonvoting common stock held by non affiliates market value | 700,000,000 | |||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Noncurrent Assets [Member] | ||||
Summary of Significant Accounting Policies [Line Items] | ||||
Restricted cash | $ 1,300,000 | $ 400,000 |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Detail) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Laboratory equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, Plant and Equipment, Useful Life | 5 years | |
Computer hardware and software [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, Plant and Equipment, Useful Life | 3 years | |
Leasehold improvements [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, Plant and Equipment, Estimated Useful Lives | Shorter of useful life orlease term | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Manufacturing equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, Plant and Equipment, Useful Life | 10 years | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Furniture and fixtures [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, Plant and Equipment, Useful Life | 7 years | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Laboratory equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, Plant and Equipment, Useful Life | 5 years | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Computer hardware and software [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, Plant and Equipment, Useful Life | 3 years | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Leasehold improvements [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, Plant and Equipment, Estimated Useful Lives | Shorter of useful life or lease term |
Business Combination - Addition
Business Combination - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands | Jun. 30, 2022 | Mar. 31, 2022 | Feb. 02, 2022 | Jan. 19, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 |
Common stock, shares authorized | 500,000,000 | 500,000,000 | 500,000,000 | |||||
Preferred stock, shares authorized | 10,000,000 | 10,000,000 | ||||||
Common stock, par value (in Dollars per share) | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||
Warrant liabilities | $ 470 | $ 2,105 | $ 125 | |||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||||||||
Authorized shares capital | 510,000,000 | |||||||
Common stock, shares authorized | 500,000,000 | 500,000,000 | 191,500,000 | 191,500,000 | ||||
Preferred stock, shares authorized | 10,000,000 | 10,000,000 | ||||||
Common stock, par value (in Dollars per share) | $ 0.0001 | $ 0.0001 | $ 0.001 | $ 0.001 | ||||
Shares | 10,350,000 | 57,034 | ||||||
Warrant liabilities | $ 1,300 | |||||||
Fair value of warrant liability | $ 500 |
Business Combination - Summary
Business Combination - Summary of Reconciles Elements of Business Combination (Details) - USD ($) $ in Thousands | 6 Months Ended | |
Feb. 02, 2022 | Jun. 30, 2022 | |
Business Acquisition [Line Items] | ||
Less: warrant liabilities assumed | $ (1,341) | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Business Acquisition [Line Items] | ||
Gross Proceeds | $ 136,373 | |
Less: total transaction costs | (26,660) | |
Add: transaction costs paid in 2021 | 4,080 | |
Cash proceeds from Business Combination received in 2022 | 78,543 | |
Less: transaction costs paid in 2021 | (4,080) | |
Less: warrant liabilities assumed | (1,341) | |
Less: net liabilities assumed in the Business Combination | (133) | |
Reverse merger, net of transactions costs | 72,989 | |
Envi Trust [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Business Acquisition [Line Items] | ||
Cash (net of redemption) | 12,123 | |
Pipe Investors [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Business Acquisition [Line Items] | ||
Cash (net of redemption) | 124,250 | |
Less: cash proceeds from Convertible notes - PIPE Investors | $ (35,250) |
Business Combination - Schedule
Business Combination - Schedule of Number of Shares of Common Stock Outstanding Immediately Consummation of Business Combination (Details) - shares | Jun. 30, 2022 | Feb. 02, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Business Acquisition [Line Items] | ||||
Common stock, shares outstanding | 123,663,315 | 96,575,107 | 96,284,283 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||||
Business Acquisition [Line Items] | ||||
Common stock, outstanding prior to the Business Combination | 20,700,000 | |||
Less: Redemption of ENVI shares | (19,489,626) | |||
Shares issued in PIPE financing | 12,425,000 | |||
Business combination and PIPE financing shares | 18,810,374 | |||
Common stock, shares outstanding | 122,822,134 | |||
E N V I Public Shares [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||||
Business Acquisition [Line Items] | ||||
Shares issued | 1,210,374 | |||
E N V I Sponsor Shares [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||||
Business Acquisition [Line Items] | ||||
Shares issued | 5,175,000 | |||
Legacy Green Light Equity Holders [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||||
Business Acquisition [Line Items] | ||||
Common stock, shares outstanding | 104,011,760 |
Bayer Asset Acquisition - Addit
Bayer Asset Acquisition - Additional Information (Detail) - Baayer Asset Acquisition [Member] - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Payments to Acquire Productive Assets | $ 2,000,000 | |
Payment Of Asset Acquisition Contingent Consideration | 0 | $ 0 |
Asset Acquisition, Contingent Consideration, Liability | 0 | $ 0 |
Milestone Payments [Member] | ||
Asset Acquisition, Consideration Transferred, Contingent Consideration | $ 2,000,000 |
License Agreement - Additional
License Agreement - Additional Information (Detail) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
Jan. 31, 2021 | Aug. 31, 2020 | Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Research and Development Expense | $ 2 | $ 0.8 | ||||||
First Non Exclusive License [Member] | ||||||||
License Fee | $ 1.5 | |||||||
Second Non Exclusive License [Member] | ||||||||
License Fee | 1.8 | |||||||
Third Non Exclusive License [Member] | ||||||||
License Fee | 2.8 | |||||||
Acuitas Therapeutics Inc [Member] | ||||||||
Technology Access Fee | 0.8 | |||||||
Management Fee Expense | 0.1 | |||||||
Option exercise fee | $ 1.5 | |||||||
Acuitas Therapeutics Inc [Member] | Target One And Two [Member] | ||||||||
Annual license maintenance fee | 1 | |||||||
Acuitas Therapeutics Inc [Member] | Target Three [Member] | ||||||||
Annual license maintenance fee | 0.8 | |||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||||||||
Development Costs, Period Cost | 0.5 | |||||||
Research and Development Expense | $ 0.2 | $ 0.3 | $ 0.5 | $ 2 | ||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | First Non Exclusive License [Member] | ||||||||
License Fee | 1.5 | |||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Second Non Exclusive License [Member] | ||||||||
License Fee | 1.8 | |||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Third Non Exclusive License [Member] | ||||||||
License Fee | 2.8 | |||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Acuitas Therapeutics Inc [Member] | ||||||||
Technology Access Fee | 0.8 | |||||||
Management Fee Expense | $ 0.1 | |||||||
Option exercise fee | 1.5 | |||||||
Research and Development Expense | $ 0 | $ 0 | ||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Acuitas Therapeutics Inc [Member] | Target One And Two [Member] | ||||||||
Annual license maintenance fee | 1 | |||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Acuitas Therapeutics Inc [Member] | Target Three [Member] | ||||||||
Annual license maintenance fee | $ 0.8 |
License And Collaboration Agr_2
License And Collaboration Agreement - Additional Information (Detail) - Serum Institute of India Private Limited [Member] - Collaborative Arrangement [Member] | 1 Months Ended | 6 Months Ended |
Mar. 31, 2022 Product | Jun. 30, 2022 USD ($) | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
License agreement date | 2022-03 | |
Initial license agreement for number of products | Product | 3 | |
Option to increase license agreement for number of products | Product | 2 | |
Option to purchase developed research plan and clinical trial data for percentage of actual cost | 50% | |
Upfront license fee to be received | $ 5,000,000 | |
Collaborative arrangement aggregate milestone receivable | 17,000,000 | |
Maximum manufacturing technology transfer payments to be received | 10,000,000 | |
Receivable | 10,000,000 | |
Manufacturing technology transfer payment to be fully constrained | 5,000,000 | |
Billed remaining amount recorded as deferred revenue | $ 1,700,000 |
Fair Value Measurements (Detail
Fair Value Measurements (Details) - Schedule of assets and liabilities at fair value on a recurring basis - Fair Value, Recurring [Member] - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Assets: | |||
Total assets measured at fair value | $ 31,446 | $ 55,747 | |
Liabilities: | |||
Warrant Liability | 2,105 | 125 | |
Total liabilities measured at fair value | 33,796 | 17,398 | |
Convertible Debt [Member] | |||
Liabilities: | |||
Warrant Liability | 31,691 | 17,273 | |
Money Market Funds [Member] | |||
Assets: | |||
Money market funds | 31,446 | 55,747 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||
Assets: | |||
Total assets measured at fair value | $ 44,132 | 31,446 | |
Liabilities: | |||
Warrant Liability | 470 | 2,105 | |
Total liabilities measured at fair value | 470 | 2,105 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Money Market Funds [Member] | |||
Assets: | |||
Money market funds | 44,132 | 31,446 | |
Level 1 [Member] | |||
Assets: | |||
Total assets measured at fair value | 31,446 | 55,747 | |
Liabilities: | |||
Warrant Liability | 0 | 0 | |
Total liabilities measured at fair value | 0 | 0 | |
Level 1 [Member] | Convertible Debt [Member] | |||
Liabilities: | |||
Warrant Liability | 0 | 0 | |
Level 1 [Member] | Money Market Funds [Member] | |||
Assets: | |||
Money market funds | 31,446 | 55,747 | |
Level 1 [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||
Assets: | |||
Total assets measured at fair value | 44,132 | 31,446 | |
Liabilities: | |||
Warrant Liability | 0 | 0 | |
Total liabilities measured at fair value | 0 | 0 | |
Level 1 [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Money Market Funds [Member] | |||
Assets: | |||
Money market funds | 44,132 | 31,446 | |
Level 3 [Member] | |||
Assets: | |||
Total assets measured at fair value | 0 | 0 | |
Liabilities: | |||
Warrant Liability | 2,105 | 125 | |
Total liabilities measured at fair value | 33,796 | 17,398 | |
Level 3 [Member] | Convertible Debt [Member] | |||
Liabilities: | |||
Warrant Liability | 31,691 | 17,273 | |
Level 3 [Member] | Money Market Funds [Member] | |||
Assets: | |||
Money market funds | 0 | 0 | |
Level 3 [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||
Assets: | |||
Total assets measured at fair value | 0 | 0 | |
Liabilities: | |||
Warrant Liability | 470 | 2,105 | |
Total liabilities measured at fair value | 470 | 2,105 | |
Level 3 [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Money Market Funds [Member] | |||
Assets: | |||
Money market funds | 0 | 0 | |
Level 2 [Member] | |||
Assets: | |||
Total assets measured at fair value | 0 | 0 | |
Liabilities: | |||
Warrant Liability | 0 | 0 | |
Total liabilities measured at fair value | 0 | 0 | |
Level 2 [Member] | Convertible Debt [Member] | |||
Liabilities: | |||
Warrant Liability | 0 | 0 | |
Level 2 [Member] | Money Market Funds [Member] | |||
Assets: | |||
Money market funds | 0 | $ 0 | |
Level 2 [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||
Assets: | |||
Total assets measured at fair value | 0 | 0 | |
Liabilities: | |||
Warrant Liability | 0 | 0 | |
Total liabilities measured at fair value | 0 | 0 | |
Level 2 [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Money Market Funds [Member] | |||
Assets: | |||
Money market funds | $ 0 | $ 0 |
Fair Value Measurements (Deta_2
Fair Value Measurements (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Mar. 31, 2022 | Mar. 31, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Fair Value Measurements (Details) [Line Items] | ||||||
Long-term Debt, Gross | $ 35,446 | |||||
Debt Instrument, Fair Value Disclosure | 28,900 | |||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||||||
Fair Value Measurements (Details) [Line Items] | ||||||
Long-term Debt, Gross | $ 32,386 | 35,446 | ||||
Carrying value of convertible debt | 30,200 | |||||
Fair value of convertible debt | 28,900 | |||||
Fair Value, Inputs, Level 1, 2 and 3 [Member] | ||||||
Fair Value Measurements (Details) [Line Items] | ||||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net | 0 | $ 0 | ||||
Fair Value, Inputs, Level 1, 2 and 3 [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||||||
Fair Value Measurements (Details) [Line Items] | ||||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net | $ 0 | $ 0 | $ 0 | $ 0 | ||
Fair Value, Inputs, Level 3 [Member] | ||||||
Fair Value Measurements (Details) [Line Items] | ||||||
Long-term Debt, Gross | $ 30,200 |
Fair Value Measurements (Deta_3
Fair Value Measurements (Details) - Schedule of changes in the fair value of Level 3 warrant liabilities - USD ($) $ in Thousands | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||
Fair Value Measurements (Details) - Schedule of changes in the fair value of Level 3 warrant liabilities [Line Items] | |||
Fair value beginning | $ 2,105 | ||
Warrants exercised in business combination | (1,633) | ||
Warrants reclassified to equity | (387) | ||
Change in fair value of warrants | (956) | ||
Warrants assumed in business combination | 1,341 | ||
Fair value ending | 470 | $ 2,105 | |
Warrant Liabilities [Member] | |||
Fair Value Measurements (Details) - Schedule of changes in the fair value of Level 3 warrant liabilities [Line Items] | |||
Fair value beginning | $ 2,105 | 125 | $ 103 |
Change in fair value | 1,370 | 22 | |
Fair value ending | 2,105 | $ 125 | |
Warrant Liabilities [Member] | Common Stock Warrant [Member] | |||
Fair Value Measurements (Details) - Schedule of changes in the fair value of Level 3 warrant liabilities [Line Items] | |||
Issuance of warrant | $ 610 |
Collaboration Arrangement - Add
Collaboration Arrangement - Additional Information (Detail) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Collaborative Arrangement Disclosure [Line Items] | ||
Collaboration revenue | $ 962,000 | |
Collaborative Arrangement [Member] | Thirty Months After Achievement of Milestone Two [Member] | ||
Collaborative Arrangement Disclosure [Line Items] | ||
Collaborative arrangement minimum royalty payment receivable | $ 100,000 | |
Collaborative Arrangement [Member] | After The Fifth Anniversary of Achievement of Milestone Two [Member] | ||
Collaborative Arrangement Disclosure [Line Items] | ||
Collaborative arrangement minimum royalty payment receivable | 500,000 | |
Collaborative Arrangement [Member] | After The Eighth Anniversary Of Achievement Of Milestone Two [Member] | ||
Collaborative Arrangement Disclosure [Line Items] | ||
Collaborative arrangement minimum royalty payment receivable | 1,000,000 | |
Collaborative Arrangement [Member] | Ingredion [Member] | ||
Collaborative Arrangement Disclosure [Line Items] | ||
Collaboration revenue | 0 | $ 1,000,000 |
Collaborative arrangement aggregate milestone receivable | 12,000 | |
Collaborative arrangement milestone payments receivable included in transaction price | $ 0 |
Grant Revenue - Additional Info
Grant Revenue - Additional Information (Detail) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Jul. 31, 2020 | |
Grant Revenue [Line Items] | |||||||
Grant revenue | $ 20 | $ 493 | $ 277 | $ 818 | $ 1,595 | $ 785 | |
Deferred revenue | 8,939 | 8,939 | 963 | 1,663 | |||
Bill and Melinda Gates Foundation [Member] | |||||||
Grant Revenue [Line Items] | |||||||
Deferred revenue | 1,000 | 1,700 | |||||
Bill and Melinda Gates Foundation [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||||||
Grant Revenue [Line Items] | |||||||
Grant receivable | $ 3,300 | ||||||
Aggregate grant received | 2,400 | 900 | |||||
Research and developments costs associated with grant | 16 | 400 | 300 | 700 | 1,400 | 700 | |
Grant revenue | 20 | $ 500 | 300 | $ 800 | 1,600 | $ 800 | |
Deferred revenue | $ 700 | $ 700 | $ 1,300 |
Property and Equipment, Net - A
Property and Equipment, Net - Additional Information (Detail) - GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Property, Plant and Equipment [Line Items] | ||||||
Capital lease assets | $ 2.5 | $ 2.5 | $ 2.5 | $ 2.5 | ||
Capital lease accumulated amortization | 1.7 | 1.7 | 1.5 | 0.9 | ||
Depreciation and amortization expense | 2 | $ 1.2 | 4.1 | $ 2.3 | $ 5.7 | $ 1.7 |
Construction in progress [Member] | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Leasehold improvements | $ 6.2 | $ 6.2 |
Property and Equipment, Net - S
Property and Equipment, Net - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Property, Plant and Equipment [Line Items] | |||
Property and equipment, net | $ 32,085 | $ 23,399 | $ 16,279 |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | 45,416 | 32,658 | 19,965 |
Less: Accumulated depreciation and amortization | (13,331) | (9,259) | (3,686) |
Property and equipment, net | 32,085 | 23,399 | 16,279 |
Computer hardware and software [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | 868 | 732 | 533 |
Laboratory equipment [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | 20,815 | 19,590 | 8,040 |
Leasehold improvements [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | 10,883 | 10,442 | 4,545 |
Manufacturing Equipment [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | 1,214 | 0 | |
Construction in progress [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | $ 11,636 | $ 1,894 | $ 6,847 |
Accrued Expenses - Summary of A
Accrued Expenses - Summary of Accrued Expenses (Detail) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Accrued Liabilities, Current [Line Items] | |||
Accrued employee compensation and benefits | $ 8,492 | $ 4,024 | |
Accrued research and development | 4,059 | 612 | |
Accrued professional fees | 1,888 | 568 | |
Accrued other | 185 | 1,622 | |
Total accrued expenses | $ 30,427 | 14,624 | $ 6,826 |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||
Accrued Liabilities, Current [Line Items] | |||
Accrued employee compensation and benefits | 8,065 | 8,492 | |
Accrued research and development | 20,709 | 4,059 | |
Accrued professional fees | 568 | 1,888 | |
Accrued other | 1,085 | 185 | |
Total accrued expenses | $ 30,427 | $ 14,624 |
Debt - Additional Information (
Debt - Additional Information (Detail) - USD ($) | 1 Months Ended | 2 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||||||||
Feb. 28, 2022 | Feb. 02, 2022 | Jan. 01, 2022 | Dec. 31, 2021 | Dec. 31, 2021 | May 31, 2020 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Sep. 01, 2024 | Sep. 22, 2023 | Aug. 01, 2023 | Sep. 22, 2022 | Mar. 31, 2022 | Dec. 01, 2021 | Sep. 01, 2021 | Mar. 29, 2021 | |
Debt Instrument [Line Items] | ||||||||||||||||||
Proceeds From Convertible Debt | $ 21,750,000 | $ 13,500,000 | $ 16,775,000 | |||||||||||||||
Debt Payable | $ 67,159,000 | $ 67,159,000 | 67,159,000 | |||||||||||||||
Long Term Debt | 34,386,000 | 34,386,000 | $ 34,386,000 | |||||||||||||||
Debt Instrument Final Payment Fee Charged As Percentage Of Principal Amount | 3% | |||||||||||||||||
Debt Instrument Carrying Amount | 35,446,000 | 35,446,000 | $ 35,446,000 | |||||||||||||||
Interest Expense | 2,419,000 | 1,028,000 | ||||||||||||||||
Payment of issuance costs | 134,000 | |||||||||||||||||
Convertible notes | 16,800,000 | 16,800,000 | 16,800,000 | 16,800,000 | ||||||||||||||
Repayments of Debt | 2,732,000 | $ 265,000 | ||||||||||||||||
Equipment Financing [Member] | Maximum [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Deferred offering costs debt issuance costs | 16.3 | 16.3 | 16.3 | |||||||||||||||
Equipment Financing [Member] | Minimum [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Deferred offering costs debt issuance costs | 13.2 | 13.2 | 13.2 | |||||||||||||||
Warrant [Member] | Master Equipment Financing Agreement [Member] | Equipment Financing [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Fair Value Of warrants In Debt Issuance Cost | $ 100,000 | $ 100,000 | 100,000 | |||||||||||||||
Prepayment Year One [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Long Term Debt Prepayment Amount As A Percentage Of Principal | 3% | |||||||||||||||||
Prepayment Year Two [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Long Term Debt Prepayment Amount As A Percentage Of Principal | 2% | |||||||||||||||||
Trinity Capital [Member] | Master Equipment Financing Agreement [Member] | Equipment Financing [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Proceeds from Issuance of Debt | $ 400,000 | |||||||||||||||||
Warrants Issued | 146,325 | 146,325 | 146,325 | |||||||||||||||
Long Term Debt | $ 11,300,000 | |||||||||||||||||
Debt Instrument Current Borrowings Capacity | $ 5,000,000 | |||||||||||||||||
Debt Instrument Unused Borrowing Capacity | 6,300,000 | |||||||||||||||||
Interest Rate | 3.25% | |||||||||||||||||
Debt Instrument Advances Drawn | $ 11,300,000 | $ 11,300,000 | $ 11,300,000 | |||||||||||||||
Long Term Debt Repayment Period in Months | 36 | |||||||||||||||||
Debt Instrument Carrying Amount | 13,300,000 | 13,300,000 | $ 13,300,000 | |||||||||||||||
Horizon Term Loan [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Long Term Debt | 14,418,000 | 14,418,000 | $ 14,418,000 | |||||||||||||||
Debt Instrument Unused Borrowing Capacity | $ 10,000,000 | |||||||||||||||||
Debt Instrument Maturity Date | Feb. 01, 2023 | |||||||||||||||||
Debt Instrument Maturity Date | Jul. 01, 2025 | |||||||||||||||||
Proceeds from Issuance of Debt | $ 600,000 | |||||||||||||||||
Fair Value Of warrants In Debt Issuance Cost | 400,000 | 400,000 | 400,000 | |||||||||||||||
Debt Issuance Cost | 600,000 | 600,000 | 600,000 | |||||||||||||||
Debt Instrument Carrying Amount | $ 15,000,000 | $ 15,000,000 | $ 15,000,000 | |||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 9% | 9% | 9% | |||||||||||||||
Strike price | 5.26 | 5.26 | 5.26 | |||||||||||||||
Percentage of public trading value of shares to number of warrants to be issued | 90% | 90% | 90% | |||||||||||||||
Fair value of warrants issuable | $ 500,000 | $ 500,000 | $ 500,000 | |||||||||||||||
Derivative instrument option to borrow debt principal amount | 100,000 | 100,000 | 100,000 | |||||||||||||||
Horizon Term Loan [Member] | Warrant [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Fair Value Of warrants In Debt Issuance Cost | $ 400,000 | $ 400,000 | $ 400,000 | |||||||||||||||
Horizon Term Loan [Member] | Horizon Technology Finance Corporation [Member] | Powerscourt Investments XXV, LP (Horizon) [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Long Term Debt | $ 25,000,000 | |||||||||||||||||
Debt instrument Current Borrowings Capacity | 15,000,000 | |||||||||||||||||
Horizon Term Loan [Member] | Subsequent Event [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Percentage of warrants obligated to issue during period | 80% | |||||||||||||||||
Percentage of loan commitment | 3% | 3% | 3% | |||||||||||||||
Silicon Valley Bank Term Loan [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Long Term Debt | $ 9,775,000 | $ 9,775,000 | $ 9,775,000 | |||||||||||||||
Debt Instrument Unused Borrowing Capacity | 5,000,000 | |||||||||||||||||
Debt Instrument Maturity Date | Sep. 01, 2024 | |||||||||||||||||
Debt Instrument Final Payment Fee Charged As Percentage Of Principal Amount | 4% | |||||||||||||||||
Proceeds from Issuance of Debt | $ 300,000 | |||||||||||||||||
Warrants Issued | 34,427 | 34,427 | 34,427 | |||||||||||||||
Debt Issuance Cost | $ 400,000 | $ 400,000 | $ 400,000 | |||||||||||||||
Debt Instrument Carrying Amount | $ 10,000,000 | $ 10,000,000 | $ 10,000,000 | |||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 3.50% | 3.50% | 3.50% | |||||||||||||||
Silicon Valley Bank Term Loan [Member] | Warrant [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Fair Value Of warrants In Debt Issuance Cost | $ 200,000 | $ 200,000 | $ 200,000 | |||||||||||||||
Silicon Valley Bank Term Loan [Member] | Prepayment Year One [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Long Term Debt Prepayment Amount As A Percentage Of Principal | 3% | |||||||||||||||||
Silicon Valley Bank Term Loan [Member] | Prepayment Year Two [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Long Term Debt Prepayment Amount As A Percentage Of Principal | 2% | |||||||||||||||||
Silicon Valley Bank Term Loan [Member] | Prepayment Year Three [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Long Term Debt Prepayment Amount As A Percentage Of Principal | 1% | |||||||||||||||||
Silicon Valley Bank Term Loan [Member] | Silicon Valley Bank [Member] | Loan And Security Agreement [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Long Term Debt | 15,000,000 | |||||||||||||||||
Debt instrument Current Borrowings Capacity | 10,000,000 | |||||||||||||||||
Two Thousand And Twenty One PIPE Notes [Member] | Convertible Debt [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Proceeds From Convertible Debt | $ 35,300,000 | |||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 5.40% | 5.40% | 5.40% | |||||||||||||||
Two Thousand And Twenty Notes [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Interest Payable | $ 600,000 | $ 600,000 | $ 600,000 | 1,400,000 | ||||||||||||||
Two Thousand And Twenty Notes [Member] | Convertible Debt [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Proceeds From Convertible Debt | $ 16,800,000 | |||||||||||||||||
Interest Payable | $ 1,400,000 | $ 1,400,000 | $ 1,400,000 | $ 600,000 | ||||||||||||||
Term of Maturity | 2 years | |||||||||||||||||
Debt instrument interest rate | 5% | |||||||||||||||||
Debt instrument convertible discounted conversion price | 85% | 85% | 85% | |||||||||||||||
Debt instrument convertible period for right to receive royalty payments | 15 years | |||||||||||||||||
Payment of issuance costs | $ 100,000 | |||||||||||||||||
Pipe Notes [Member] | Convertible Debt [Member] | Prior Year End [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Debt Instrument, Face Amount | $ 13,500,000 | |||||||||||||||||
PIPE Instruments [Member] | Convertible Debt [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Debt Payable | $ 13,500,000 | $ 13,500,000 | 13,500,000 | |||||||||||||||
PIPE Instruments [Member] | Convertible Debt [Member] | Subsequent Event [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Proceeds From Convertible Debt | $ 21,800,000 | |||||||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Debt Payable | 67,159,000 | 67,159,000 | 67,159,000 | |||||||||||||||
Long Term Debt | $ 31,558,000 | |||||||||||||||||
Debt Instrument Final Payment Fee Charged As Percentage Of Principal Amount | 3% | |||||||||||||||||
Debt Instrument Carrying Amount | 35,446,000 | 35,446,000 | $ 32,386,000 | 35,446,000 | ||||||||||||||
Convertible notes | 16,800,000 | 16,800,000 | 16,800,000 | |||||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Series D Preferred Stock [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Debt conversion, converted instrument, shares issued | 10,100,000 | |||||||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Warrant [Member] | Master Equipment Financing Agreement [Member] | Equipment Financing [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Fair Value Of warrants In Debt Issuance Cost | 100,000 | |||||||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Prepayment Year One [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Long Term Debt Prepayment Amount As A Percentage Of Principal | 3% | |||||||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Prepayment Year Two [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Long Term Debt Prepayment Amount As A Percentage Of Principal | 2% | |||||||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Trinity Capital [Member] | Master Equipment Financing Agreement [Member] | Equipment Financing [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Proceeds from Issuance of Debt | $ 400,000 | |||||||||||||||||
Warrants Issued | 219,839 | |||||||||||||||||
Long Term Debt | 5,000,000 | |||||||||||||||||
Debt Instrument Current Borrowings Capacity | $ 11,300,000 | |||||||||||||||||
Debt Instrument Unused Borrowing Capacity | 6,300,000 | |||||||||||||||||
Interest Rate | 3.25% | |||||||||||||||||
Debt Instrument Advances Drawn | $ 11,300,000 | |||||||||||||||||
Debt Instrument Carrying Amount | 14,700,000 | |||||||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Convertible Debt [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | $ 1,600,000 | |||||||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Horizon Term Loan [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Long Term Debt | 14,418,000 | 14,418,000 | $ 14,528,000 | 14,418,000 | ||||||||||||||
Debt Instrument Unused Borrowing Capacity | $ 10,000,000 | |||||||||||||||||
Debt Instrument Maturity Date | Feb. 01, 2023 | |||||||||||||||||
Debt Instrument Maturity Date | Jul. 01, 2025 | |||||||||||||||||
Proceeds from Issuance of Debt | $ 600,000 | |||||||||||||||||
Debt Instrument Carrying Amount | $ 15,000,000 | $ 15,000,000 | $ 15,000,000 | $ 15,000,000 | ||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 9% | 9% | 10.50% | 9% | ||||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Horizon Term Loan [Member] | Warrant [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Fair Value Of warrants In Debt Issuance Cost | $ 400,000 | |||||||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Horizon Term Loan [Member] | Horizon Technology Finance Corporation [Member] | Powerscourt Investments XXV, LP (Horizon) [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Long Term Debt | 25,000,000 | |||||||||||||||||
Debt instrument Current Borrowings Capacity | 15,000,000 | |||||||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Silicon Valley Bank Term Loan [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Long Term Debt | $ 9,775,000 | $ 9,775,000 | $ 8,842,000 | $ 9,775,000 | ||||||||||||||
Debt Instrument Unused Borrowing Capacity | 5,000,000 | |||||||||||||||||
Debt Instrument Maturity Date | Sep. 01, 2024 | |||||||||||||||||
Debt Instrument Final Payment Fee Charged As Percentage Of Principal Amount | 4% | |||||||||||||||||
Proceeds from Issuance of Debt | $ 300,000 | |||||||||||||||||
Fair Value Of warrants In Debt Issuance Cost | $ 200,000 | |||||||||||||||||
Warrants Issued | 51,724 | |||||||||||||||||
Debt Issuance Cost | $ 400,000 | |||||||||||||||||
Debt Instrument Carrying Amount | $ 10,000,000 | $ 10,000,000 | $ 9,000,000 | $ 10,000,000 | ||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 3.50% | 3.50% | 5% | 3.50% | ||||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Silicon Valley Bank Term Loan [Member] | Prepayment Year One [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Long Term Debt Prepayment Amount As A Percentage Of Principal | 3% | |||||||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Silicon Valley Bank Term Loan [Member] | Prepayment Year Two [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Long Term Debt Prepayment Amount As A Percentage Of Principal | 2% | |||||||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Silicon Valley Bank Term Loan [Member] | Prepayment Year Three [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Long Term Debt Prepayment Amount As A Percentage Of Principal | 1% | |||||||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Silicon Valley Bank Term Loan [Member] | Silicon Valley Bank [Member] | Loan And Security Agreement [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Long Term Debt | 15,000 | |||||||||||||||||
Debt instrument Current Borrowings Capacity | $ 10,000,000 | |||||||||||||||||
Debt Instrument Unused Borrowing Capacity | $ 5,000,000 | |||||||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Two Thousand And Twenty One PIPE Notes [Member] | Convertible Debt [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Proceeds From Convertible Debt | $ 35,300,000 | |||||||||||||||||
Repayments of Debt | $ 35,300,000 | |||||||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Two Thousand And Twenty Notes [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Interest Payable | 1,400,000 | $ 1,400,000 | $ 1,400,000 | |||||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Two Thousand And Twenty Notes [Member] | Convertible Debt [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Convertible notes | $ 16,800,000 | |||||||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Pipe Notes [Member] | Convertible Debt [Member] | Prior Year End [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Debt Instrument, Face Amount | $ 13,500,000 | $ 13,500,000 | $ 13,500,000 | |||||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | PIPE Instruments [Member] | Convertible Debt [Member] | Subsequent Event [Member] | ||||||||||||||||||
Debt Instrument [Line Items] | ||||||||||||||||||
Proceeds From Convertible Debt | $ 21,800,000 |
Debt - Summary Of Interest Expe
Debt - Summary Of Interest Expense (Detail) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Schedule Of Interest Expense Debt [Line Items] | ||||||
Interest paid or accrued | $ 2,253 | $ 440 | ||||
Non-cash amortization of debt discount and deferred financing cost | $ 423 | 166 | 588 | |||
Total | $ 2,419 | $ 1,028 | ||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||||||
Schedule Of Interest Expense Debt [Line Items] | ||||||
Interest paid or accrued | $ 935 | $ 202 | 1,739 | $ 303 | ||
Non-cash amortization of debt discount and deferred financing cost | 199 | 212 | 423 | 422 | ||
Total | $ 1,134 | $ 414 | $ 2,162 | $ 725 |
Debt - Summary Of Future Princi
Debt - Summary Of Future Principal Payment Of Long Term Debt (Detail) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Schedule Of Maturities Of Long Term Debt [Line Items] | ||
Remainder of 2022 | $ 37,176 | |
2023 | 13,916 | |
2024 | 11,972 | |
2025 and thereafter | 2,657 | |
Total | $ 65,721 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Schedule Of Maturities Of Long Term Debt [Line Items] | ||
Remainder of 2022 | $ 4,662 | |
2023 | 14,226 | |
2024 | 10,998 | |
2025 and thereafter | 2,500 | |
Total | $ 32,386 |
Debt - Summary of Outstanding D
Debt - Summary of Outstanding Debt (Detail) - USD ($) $ in Thousands | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Debt Instrument [Line Items] | ||
Principal Balance Outstanding | $ 35,446 | |
Unamortized Debt Discount | (1,060) | |
Debt Balance | 34,386 | |
Capital Lease, Principle Balance | 992 | |
Capital Lease, Debt Balance | 992 | |
Less: currrent portion, net of current portion of debt discount | (7,234) | |
Total long-term | 27,152 | |
Princpal Balance Outstanding (Convertible Note) | 31,713 | |
Unamortized Debt Discount (Convertible Note) | (1,082) | |
Debt Balance (Convertible Note) | 66,077 | |
Total | 67,159 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Debt Instrument [Line Items] | ||
Principal Balance Outstanding | $ 32,386 | 35,446 |
Unamortized Debt Discount | (828) | (1,060) |
Debt Balance | 31,558 | |
Capital Lease, Principle Balance | 664 | 992 |
Capital Lease, Debt Balance | 664 | 992 |
Less: currrent portion, net of current portion of debt discount | (11,402) | (7,234) |
Total long-term | $ 20,156 | 27,152 |
Princpal Balance Outstanding (Convertible Note) | 31,713 | |
Unamortized Debt Discount (Convertible Note) | (22) | |
Debt Balance (Convertible Note) | 31,691 | |
Total | $ 67,159 | |
Silicon Valley Bank Term Loan [Member] | ||
Debt Instrument [Line Items] | ||
Issuance Date(s) | September 2021 | |
Maturity Date(s) | September 2024 | |
Stated Interest Rate | 3.50% | |
Principal Balance Outstanding | $ 10,000 | |
Unamortized Debt Discount | (225) | |
Debt Balance | $ 9,775 | |
Silicon Valley Bank Term Loan [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Debt Instrument [Line Items] | ||
Issuance Date(s) | September 2021 | September 2021 |
Maturity Date(s) | September 2024 | September 2024 |
Stated Interest Rate | 5% | 3.50% |
Principal Balance Outstanding | $ 9,000 | $ 10,000 |
Unamortized Debt Discount | (158) | (225) |
Debt Balance | $ 8,842 | $ 9,775 |
Horizon Term Loan [Member] | ||
Debt Instrument [Line Items] | ||
Issuance Date(s) | December 2021 | |
Maturity Date(s) | May 2025 | |
Stated Interest Rate | 9% | |
Principal Balance Outstanding | $ 15,000 | |
Unamortized Debt Discount | (582) | |
Debt Balance | $ 14,418 | |
Horizon Term Loan [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Debt Instrument [Line Items] | ||
Issuance Date(s) | December 2021 | December 2021 |
Maturity Date(s) | May 2025 | May 2025 |
Stated Interest Rate | 10.50% | 9% |
Principal Balance Outstanding | $ 15,000 | $ 15,000 |
Unamortized Debt Discount | (472) | (582) |
Debt Balance | $ 14,528 | $ 14,418 |
Convertible Note PIPE Investors [Member] | ||
Debt Instrument [Line Items] | ||
Issuance Date(s) | December 2021 | |
Maturity Date(s) | December 2022 | |
Stated Interest Rate | 0.33% | |
Princpal Balance Outstanding (Convertible Note) | $ 13,500 | |
Unamortized Debt Discount (Convertible Note) | 0 | |
Debt Balance (Convertible Note) | $ 13,500 | |
Convertible Note PIPE Investors [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Debt Instrument [Line Items] | ||
Issuance Date(s) | December 2021 | |
Maturity Date(s) | December 2022 | |
Stated Interest Rate | 0.33% | |
Princpal Balance Outstanding (Convertible Note) | $ 13,500 | |
Debt Balance (Convertible Note) | $ 13,500 | |
Convertible Note [Member] | ||
Debt Instrument [Line Items] | ||
Issuance Date(s) | April & May 2020 | |
Maturity Date(s) | April & May 2022 | |
Stated Interest Rate | 5% | |
Princpal Balance Outstanding (Convertible Note) | $ 18,213 | |
Unamortized Debt Discount (Convertible Note) | (22) | |
Debt Balance (Convertible Note) | $ 18,191 | |
Convertible Note [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Debt Instrument [Line Items] | ||
Issuance Date(s) | April & May 2020 | |
Maturity Date(s) | April & May 2020 | |
Stated Interest Rate | 5% | |
Princpal Balance Outstanding (Convertible Note) | $ 18,213 | |
Unamortized Debt Discount (Convertible Note) | (22) | |
Debt Balance (Convertible Note) | 18,191 | |
Total Debt | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Debt Instrument [Line Items] | ||
Debt Balance | $ 34,386 | |
Trinity Equipment Financing [Member] | ||
Debt Instrument [Line Items] | ||
Issuance Date(s) | March 2021 - August 2021 | |
Maturity Date(s) | March 2024 - August 2024 | |
Principal Balance Outstanding | $ 9,454 | |
Unamortized Debt Discount | (252) | |
Debt Balance | $ 9,202 | |
Trinity Equipment Financing [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Debt Instrument [Line Items] | ||
Issuance Date(s) | March 2021 - August 2021 | March 2021 - August 2021 |
Maturity Date(s) | March 2024 - August 2024 | March 2024 - August 2024 |
Principal Balance Outstanding | $ 7,722 | $ 9,454 |
Unamortized Debt Discount | (198) | (252) |
Debt Balance | $ 7,524 | $ 9,202 |
Trinity Equipment Financing [Member] | Maximum [Member] | ||
Debt Instrument [Line Items] | ||
Stated Interest Rate | 9.73% | |
Trinity Equipment Financing [Member] | Maximum [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Debt Instrument [Line Items] | ||
Stated Interest Rate | 9.73% | 9.73% |
Trinity Equipment Financing [Member] | Minimum [Member] | ||
Debt Instrument [Line Items] | ||
Stated Interest Rate | 9.48% | |
Trinity Equipment Financing [Member] | Minimum [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Debt Instrument [Line Items] | ||
Stated Interest Rate | 9.48% | 9.48% |
Debt - Summary of Outstanding_2
Debt - Summary of Outstanding Debt (Parenthetical) (Details) - USD ($) $ in Millions | Dec. 31, 2021 | Dec. 31, 2020 |
Debt Instrument [Line Items] | ||
Convertible notes | $ 16.8 | $ 16.8 |
Two Thousand And Twenty Notes [Member] | ||
Debt Instrument [Line Items] | ||
Interest Payable | 0.6 | $ 1.4 |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Debt Instrument [Line Items] | ||
Convertible notes | 16.8 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Two Thousand And Twenty Notes [Member] | ||
Debt Instrument [Line Items] | ||
Interest Payable | $ 1.4 |
Warrants (Details)
Warrants (Details) $ / shares in Units, $ in Thousands | 1 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||
Jan. 19, 2022 USD ($) $ / shares shares | Mar. 31, 2022 USD ($) shares | Jun. 30, 2016 USD ($) $ / shares shares | Jun. 30, 2022 USD ($) $ / shares shares | Dec. 31, 2021 USD ($) yr $ / shares shares | Dec. 31, 2020 USD ($) shares | Aug. 01, 2023 USD ($) | Feb. 02, 2022 USD ($) shares | Mar. 31, 2021 $ / shares shares | Jul. 31, 2020 USD ($) $ / shares shares | Jun. 30, 2020 $ / shares | |
Class of Warrant or Right Exercised During Period | |||||||||||
Warrants outstanding | shares | 12,383,304 | ||||||||||
Class of warrant or right, Grant date fair value of warrant | $ 1,200 | $ 100 | |||||||||
Exercise of public warrants | $ 1,209 | ||||||||||
Long-term Debt | 34,386 | ||||||||||
Horizon Term Loan [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Debt Instrument, Unused Borrowing Capacity, Amount | $ 10,000 | ||||||||||
Long-term Debt | 14,418 | ||||||||||
Proceeds from Issuance of Debt | $ 600 | ||||||||||
Risk-free interest rate [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Warrants and Rights Outstanding, Measurement Input | 1.5 | ||||||||||
Expected volatility [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Warrants and Rights Outstanding, Measurement Input | 59.6 | ||||||||||
Estimated time [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Warrants and Rights Outstanding, Measurement Input | yr | 10 | ||||||||||
Measurement Input, Share Price [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Warrants and Rights Outstanding, Measurement Input | 7.9 | ||||||||||
Black-Scholes [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Class of warrant or right, Grant date fair value of warrant | $ 500 | ||||||||||
Series D Preferred Stock Warrant [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Class of warrant or right, Grant date fair value of warrant | $ 400 | ||||||||||
Common Stock Warrants [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Class of warrant or right, Exercises of existing warrants during period | shares | 0 | 0 | |||||||||
Common Stock Warrants [Member] | Two Thousand And Twenty One Common Warrant [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Class of warrant or right, Grant date fair value of warrant | $ 5 | ||||||||||
Class of warrant or right, Exercisable, Term | 10 years | ||||||||||
Warrants issued | shares | 22,952 | ||||||||||
Common Stock Warrant Classified As Liability [Member] | Common Stock Warrants [Member] | Two Thousand And Twenty One Common Warrant [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Warrants and rights outstanding | $ 200 | ||||||||||
Common Stock Warrants Classified As Equity [Member] | Two Thousand And Twenty One Common Warrant [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Class of warrant or right, Number of securities called by warrants or rights | shares | 61,051 | ||||||||||
Common Stock Warrants Classified As Equity [Member] | Common Stock Warrants [Member] | Two Thousand And Twenty One Common Warrant [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Class of warrant or right exercise price of warrants or rights | $ / shares | $ 2.61 | ||||||||||
Common Stock [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Class of warrant or right, Number of securities called by warrants or rights | shares | 146,325 | ||||||||||
Common Stock [Member] | Common Stock Warrants [Member] | Two Thousand And Twenty One Common Warrant [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Class of warrant or right, Number of securities called by warrants or rights | shares | 26,624 | 34,427 | |||||||||
Class of warrant or right exercise price of warrants or rights | $ / shares | $ 0.33 | $ 2.61 | |||||||||
Common Stock [Member] | Common Stock Warrant Classified As Liability [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Class of warrant or right exercise price of warrants or rights | $ / shares | $ 1.23 | ||||||||||
Common Stock [Member] | Common Stock Warrant Classified As Liability [Member] | Common Stock Warrants [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Class of warrant or right, Number of securities called by warrants or rights | shares | 146,325 | ||||||||||
Class of warrant or right exercise price of warrants or rights | $ / shares | $ 1.23 | ||||||||||
Common Stock [Member] | Common Stock Warrants Classified As Equity [Member] | Two Thousand And Twenty One Common Warrant [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Class of warrant or right, Number of securities called by warrants or rights | shares | 34,427 | ||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Class of warrant or right, Number of securities called by warrants or rights | shares | 57,034 | 10,350,000 | |||||||||
Long-term Debt | 31,558 | ||||||||||
Number Of Warrants Issued | shares | 28,517 | ||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Horizon Term Loan [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Debt Instrument, Unused Borrowing Capacity, Amount | $ 10,000 | ||||||||||
Long-term Debt | 14,528 | $ 14,418 | |||||||||
Proceeds from Issuance of Debt | $ 600 | ||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Common Stock Warrants [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Warrants outstanding | shares | 12,383,304 | 207,376 | |||||||||
Class of warrant or right, Number of securities called by warrants or rights | shares | 28,517 | ||||||||||
Class of warrant or right exercise price of warrants or rights | $ / shares | $ 5.26 | ||||||||||
Number Of Warrants Issued | shares | 75,924 | ||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Common Stock Warrant Classified As Liability [Member] | Horizon Term Loan [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Debt Instrument, Unused Borrowing Capacity, Amount | $ 10,000 | ||||||||||
Proceeds from Issuance of Debt | 15,000 | ||||||||||
Debt Instrument Current Borrowings Capacity Amount | 10,000 | ||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Common Stock Warrant Classified As Liability [Member] | Horizon Term Loan [Member] | Maximum [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Long-term Debt | $ 25,000 | ||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Common Stock Warrant Classified As Liability [Member] | Common Stock Warrants [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Class of warrant or right exercise price of warrants or rights | $ / shares | $ 5.26 | ||||||||||
Class of warrant or right, Grant date fair value of warrant | $ 200 | $ 35 | |||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Common Stock Warrants Classified As Equity [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Description of redemption of public warrants | The Company may elect to redeem the Public Warrants subject to certain conditions, in whole and not in part, at a price of $0.01 per Public Warrant if (i) 30 days’ prior written notice of redemption is provided to the holders, and (ii) the last reported sale price of the Company’s common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders. | ||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Common Stock Warrants Classified As Equity [Member] | Horizon Term Loan [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Debt Instrument, Unused Borrowing Capacity, Amount | $ 15,000 | ||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Common Stock Warrants Classified As Equity [Member] | Common Stock Warrants [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Class of warrant or right, Number of securities called by warrants or rights | shares | 85,552 | ||||||||||
Class of warrant or right exercise price of warrants or rights | $ / shares | $ 5.26 | $ 11.5 | |||||||||
Class of warrant or right, Grant date fair value of warrant | $ 400 | ||||||||||
Fair value warrants reclassified to equity | $ 400 | $ 35 | |||||||||
Public Warrants [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Public Warrants Exercises | shares | 105,120 | ||||||||||
Exercise of public warrants | $ 1,200 | ||||||||||
Public Warrants [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Common Stock Warrants Classified As Equity [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Warrants outstanding | shares | 10,350,000 | ||||||||||
Shares Issued, Price Per Share | $ / shares | $ 0.01 | ||||||||||
Public Warrants [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Common Stock Warrants Classified As Equity [Member] | Minimum [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Shares Issued, Price Per Share | $ / shares | $ 18 | ||||||||||
Private Placement Warrants [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Common Stock Warrant Classified As Liability [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Warrants outstanding | shares | 2,062,500 | ||||||||||
Class of warrant or right, Grant date fair value of warrant | $ 500 | $ 1,300 | |||||||||
Series D Redeemable Convertible Preferred Stock [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Class of warrant or right, Number of securities called by warrants or rights | shares | 581,821 | ||||||||||
Shares Issued, Price Per Share | $ / shares | $ 1.81 | $ 1.8118 | $ 2.7221 | ||||||||
Series D Redeemable Convertible Preferred Stock [Member] | Series D Preferred Stock Warrant [Member] | |||||||||||
Class of Warrant or Right Exercised During Period | |||||||||||
Class of warrant or right, Number of securities called by warrants or rights | shares | 581,821 | ||||||||||
Class of warrant or right exercise price of warrants or rights | $ / shares | $ 2.7221 |
Warrants - Summary of Preferred
Warrants - Summary of Preferred stock warrants classified as liabilities (Detail) - Preferred Stock Warrants Classified As Liabilities [Member] - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Class of Warrant or Right [Line Items] | ||
Shares | 70,167 | 87,258 |
Fair Value | $ 476 | $ 125 |
Series A1 Redeemable Convertible Preferred Stock [Member] | ||
Class of Warrant or Right [Line Items] | ||
Shares | 31,830 | 48,921 |
Series A2redeemable Convertible Preferred Stock [Member] | ||
Class of Warrant or Right [Line Items] | ||
Shares | 21,131 | 21,131 |
Series A3redeemable Convertible Preferred Stock [Member] | ||
Class of Warrant or Right [Line Items] | ||
Shares | 17,206 | 17,206 |
Series A1 Preferred Stock Warrants [Member] | ||
Class of Warrant or Right [Line Items] | ||
Fair Value | $ 228 | $ 75 |
Issuance Date | Dec. 31, 2011 | Dec. 31, 2011 |
Exercise Price | $ 0.18 | $ 0.18 |
Expiration Date | Jan. 17, 2022 | Jan. 17, 2022 |
Series A2 Preferred Stock Warrants [Member] | ||
Class of Warrant or Right [Line Items] | ||
Fair Value | $ 138 | $ 21 |
Issuance Date | Aug. 26, 2014 | Aug. 26, 2014 |
Exercise Price | $ 1.77 | $ 1.77 |
Expiration Date | Aug. 25, 2024 | Aug. 25, 2024 |
Series A3 Preferred Stock Warrants [Member] | ||
Class of Warrant or Right [Line Items] | ||
Fair Value | $ 110 | $ 29 |
Issuance Date | Dec. 18, 2015 | Dec. 18, 2015 |
Exercise Price | $ 0.24 | $ 0.24 |
Expiration Date | Dec. 18, 2025 | Dec. 18, 2025 |
Warrants - Summary of Common st
Warrants - Summary of Common stock warrant classified (Detail) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||||||
Feb. 02, 2022 | Jan. 19, 2022 | Dec. 31, 2021 | Jun. 30, 2022 | Mar. 31, 2021 | Jul. 31, 2020 | Jun. 30, 2016 | |
Common Stock [Member] | |||||||
Class of Warrant or Right [Line Items] | |||||||
Shares | 146,325 | ||||||
Common Stock Warrants [Member] | Common Stock [Member] | Two Thousand And Twenty One Common Warrant [Member] | |||||||
Class of Warrant or Right [Line Items] | |||||||
Shares | 34,427 | 26,624 | |||||
Price per Share | $ 2.61 | $ 0.33 | |||||
Preferred Stock Warrants Classified As Equity [Member] | Series D Preferred Stock Warrant [Member] | |||||||
Class of Warrant or Right [Line Items] | |||||||
Issuance Date | Jul. 24, 2020 | ||||||
Price per Share | $ 2.7221 | ||||||
Common Stock Warrant Classified As Liability [Member] | Common Stock [Member] | |||||||
Class of Warrant or Right [Line Items] | |||||||
Issuance Date | Mar. 29, 2021 | ||||||
Price per Share | $ 1.23 | ||||||
Common Stock Warrant Classified As Liability [Member] | Common Stock Warrants [Member] | |||||||
Class of Warrant or Right [Line Items] | |||||||
Fair Value | $ 1,188 | ||||||
Expiration Date | Mar. 29, 2031 | ||||||
Common Stock Warrant Classified As Liability [Member] | Common Stock Warrants [Member] | Common Stock [Member] | |||||||
Class of Warrant or Right [Line Items] | |||||||
Shares | 146,325 | ||||||
Price per Share | $ 1.23 | ||||||
Common Stock Warrants Classified As Equity [Member] | Two Thousand And Twenty One Common Warrant [Member] | |||||||
Class of Warrant or Right [Line Items] | |||||||
Shares | 61,051 | ||||||
Common Stock Warrants Classified As Equity [Member] | Common Stock [Member] | Two Thousand And Sixteen Common Warrant [Member] | |||||||
Class of Warrant or Right [Line Items] | |||||||
Shares | 26,624 | ||||||
Common Stock Warrants Classified As Equity [Member] | Common Stock [Member] | Two Thousand And Twenty One Common Warrant [Member] | |||||||
Class of Warrant or Right [Line Items] | |||||||
Shares | 34,427 | ||||||
Common Stock Warrants Classified As Equity [Member] | Series D Preferred Stock Warrant [Member] | |||||||
Class of Warrant or Right [Line Items] | |||||||
Expiration Date | Jul. 24, 2025 | ||||||
Common Stock Warrants Classified As Equity [Member] | Common Stock Warrants [Member] | Two Thousand And Sixteen Common Warrant [Member] | |||||||
Class of Warrant or Right [Line Items] | |||||||
Issuance Date | Jun. 14, 2016 | ||||||
Price per Share | $ 0.33 | ||||||
Expiration Date | Jun. 13, 2026 | ||||||
Common Stock Warrants Classified As Equity [Member] | Common Stock Warrants [Member] | Two Thousand And Twenty One Common Warrant [Member] | |||||||
Class of Warrant or Right [Line Items] | |||||||
Issuance Date | Sep. 22, 2021 | ||||||
Price per Share | $ 2.61 | ||||||
Expiration Date | Sep. 21, 2031 | ||||||
Series D Redeemable Convertible Preferred Stock [Member] | |||||||
Class of Warrant or Right [Line Items] | |||||||
Shares | 581,821 | ||||||
Series D Redeemable Convertible Preferred Stock [Member] | Series D Preferred Stock Warrant [Member] | |||||||
Class of Warrant or Right [Line Items] | |||||||
Shares | 581,821 | ||||||
Price per Share | $ 2.7221 | ||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||||||
Class of Warrant or Right [Line Items] | |||||||
Shares | 10,350,000 | 57,034 | |||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Common Stock Warrants [Member] | |||||||
Class of Warrant or Right [Line Items] | |||||||
Shares | 28,517 | ||||||
Fair Value | $ 249 | ||||||
Price per Share | $ 5.26 | ||||||
Expiration Date | Mar. 29, 2031 | ||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Common Stock Warrant Classified As Liability [Member] | Common Stock Warrants [Member] | |||||||
Class of Warrant or Right [Line Items] | |||||||
Price per Share | $ 5.26 | ||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Common Stock Warrants Classified As Equity [Member] | Common Stock Warrants [Member] | |||||||
Class of Warrant or Right [Line Items] | |||||||
Shares | 85,552 | ||||||
Issuance Date | Jan. 19, 2022 | ||||||
Price per Share | $ 5.26 | $ 11.5 | |||||
Expiration Date | Jan. 19, 2032 | ||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Private Placement Warrants [Member] | Common Stock Warrant Classified As Liability [Member] | |||||||
Class of Warrant or Right [Line Items] | |||||||
Shares | 2,062,500 | ||||||
Fair Value | $ 1,341 | ||||||
Issuance Date | Feb. 02, 2022 | ||||||
Price per Share | $ 11.5 | ||||||
Expiration Date | Mar. 02, 2027 |
Warrants - Summary of estimated
Warrants - Summary of estimated the fair value of the warrants (Detail) | Jun. 30, 2022 $ / shares | Feb. 02, 2022 $ / shares | Jan. 19, 2022 $ / shares | Dec. 31, 2021 yr $ / shares | Mar. 29, 2021 yr | Dec. 31, 2020 $ / shares |
Series A1 Preferred Stock Warrants [Member] | Preferred Stock Warrants Classified As Liabilities [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Fair value of common stock | $ 0.18 | $ 0.18 | ||||
Series A2 Preferred Stock Warrants [Member] | Preferred Stock Warrants Classified As Liabilities [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Fair value of common stock | 1.77 | 1.77 | ||||
Series A3 Preferred Stock Warrants [Member] | Preferred Stock Warrants Classified As Liabilities [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Fair value of common stock | $ 0.24 | $ 0.24 | ||||
Fair value of underlying series of preferred stock [Member] | Series A1 Preferred Stock Warrants [Member] | Preferred Stock Warrants Classified As Liabilities [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Derivative Liability, Measurement Input | 9.19 | 2.18 | ||||
Fair value of underlying series of preferred stock [Member] | Series A2 Preferred Stock Warrants [Member] | Preferred Stock Warrants Classified As Liabilities [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Derivative Liability, Measurement Input | 9.21 | 2.31 | ||||
Fair value of underlying series of preferred stock [Member] | Series A3 Preferred Stock Warrants [Member] | Preferred Stock Warrants Classified As Liabilities [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Derivative Liability, Measurement Input | 9.25 | 2.64 | ||||
Risk-free interest rate [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Warrants, Measurement input | 1.5 | |||||
Risk-free interest rate [Member] | Common Stock Warrant Classified As Liability [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Derivative Liability, Measurement Input | 1.52 | 1.73 | ||||
Risk-free interest rate [Member] | Series A1 Preferred Stock Warrants [Member] | Preferred Stock Warrants Classified As Liabilities [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Derivative Liability, Measurement Input | 0.06 | 0.1 | ||||
Risk-free interest rate [Member] | Series A2 Preferred Stock Warrants [Member] | Preferred Stock Warrants Classified As Liabilities [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Derivative Liability, Measurement Input | 0.97 | 0.27 | ||||
Risk-free interest rate [Member] | Series A3 Preferred Stock Warrants [Member] | Preferred Stock Warrants Classified As Liabilities [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Derivative Liability, Measurement Input | 1.12 | 0.36 | ||||
Expected volatility [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Warrants, Measurement input | 59.6 | |||||
Expected volatility [Member] | Common Stock Warrant Classified As Liability [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Derivative Liability, Measurement Input | 63.3 | 72.1 | ||||
Expected volatility [Member] | Series A1 Preferred Stock Warrants [Member] | Preferred Stock Warrants Classified As Liabilities [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Derivative Liability, Measurement Input | 87.6 | 88.4 | ||||
Expected volatility [Member] | Series A2 Preferred Stock Warrants [Member] | Preferred Stock Warrants Classified As Liabilities [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Derivative Liability, Measurement Input | 85.5 | 78.5 | ||||
Expected volatility [Member] | Series A3 Preferred Stock Warrants [Member] | Preferred Stock Warrants Classified As Liabilities [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Derivative Liability, Measurement Input | 84.9 | 82.4 | ||||
Estimated time [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Warrants, Measurement input | yr | 10 | |||||
Estimated time [Member] | Common Stock Warrant Classified As Liability [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Derivative Liability, Measurement Input | yr | 9.25 | 10 | ||||
Estimated time [Member] | Series A1 Preferred Stock Warrants [Member] | Preferred Stock Warrants Classified As Liabilities [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Derivative Liability, Measurement Input | 0.05 | 1.05 | ||||
Estimated time [Member] | Series A2 Preferred Stock Warrants [Member] | Preferred Stock Warrants Classified As Liabilities [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Derivative Liability, Measurement Input | 2.65 | 3.65 | ||||
Estimated time [Member] | Series A3 Preferred Stock Warrants [Member] | Preferred Stock Warrants Classified As Liabilities [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Derivative Liability, Measurement Input | 3.97 | 4.97 | ||||
Fair value of common stock | Common Stock Warrant Classified As Liability [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Derivative Liability, Measurement Input | 8.85 | 1.23 | ||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Private Placement Warrants [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Fair value of common stock | $ 11.5 | |||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Private Placement Warrants [Member] | Common Stock Warrant Classified As Liability [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Fair value of common stock | $ 2.21 | $ 8.82 | ||||
Warrants, Expected term (in years) | 4 years 6 months | 5 years | ||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Common Stock Warrant [Member] | Common Stock Warrant Classified As Liability [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Fair value of common stock | $ 2.21 | $ 5.89 | ||||
Warrants, Expected term (in years) | 10 years | 10 years 6 months | ||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Common Stock Warrant [Member] | Common Stock Warrants Classified As Equity [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Fair value of common stock | $ 5.89 | |||||
Warrants, Expected term (in years) | 10 years | |||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Risk-free interest rate [Member] | Private Placement Warrants [Member] | Common Stock Warrant Classified As Liability [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Warrants, Measurement input | 3 | 1.59 | ||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Risk-free interest rate [Member] | Common Stock Warrant [Member] | Common Stock Warrant Classified As Liability [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Warrants, Measurement input | 2.39 | 1.5 | ||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Risk-free interest rate [Member] | Common Stock Warrant [Member] | Common Stock Warrants Classified As Equity [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Warrants, Measurement input | 1.5 | |||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Expected volatility [Member] | Private Placement Warrants [Member] | Common Stock Warrant Classified As Liability [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Warrants, Measurement input | 51.5 | 15.9 | ||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Expected volatility [Member] | Common Stock Warrant [Member] | Common Stock Warrant Classified As Liability [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Warrants, Measurement input | 59.6 | 59.6 | ||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Expected volatility [Member] | Common Stock Warrant [Member] | Common Stock Warrants Classified As Equity [Member] | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Warrants, Measurement input | 59.6 |
Warrants - Summary of Roll-forw
Warrants - Summary of Roll-forward of the Warrants (Details) - shares | 6 Months Ended | |
Jan. 19, 2022 | Jun. 30, 2022 | |
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding, Ending balance | 12,383,304 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Class of Warrant or Right [Line Items] | ||
Issued | 28,517 | |
Common Stock Warrants [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding, Beginning balance | 207,376 | |
Exercised in the business combination | (207,376) | |
Issued | 75,924 | |
Assumed in the business combination | 12,412,500 | |
Exercised subsequent to the business combination | (105,120) | |
Warrants Outstanding, Ending balance | 12,383,304 | |
Preferred Stock Warrants [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Class of Warrant or Right [Line Items] | ||
Warrants Outstanding, Beginning balance | 635,404 | |
Exercised in the business combination | (635,404) |
Warrants - Summary of Roll-fo_2
Warrants - Summary of Roll-forward of the Warrants (Parenthetical) (Details) | 6 Months Ended |
Jun. 30, 2022 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |
Class of Warrant or Right [Line Items] | |
Business Combination Exchange Ratio | 0.6656 |
Stockholders' Equity (Details)
Stockholders' Equity (Details) $ / shares in Units, $ in Thousands | 1 Months Ended | 6 Months Ended | 12 Months Ended | ||||||
Feb. 02, 2022 $ / shares shares | Jul. 31, 2020 USD ($) | Jun. 30, 2022 USD ($) $ / shares shares | Dec. 31, 2021 USD ($) $ / shares shares | Dec. 31, 2020 USD ($) $ / shares shares | Mar. 31, 2022 $ / shares | Jun. 30, 2021 $ / shares | Mar. 31, 2021 $ / shares | Jun. 30, 2020 $ / shares | |
Stockholders' Equity (Details) [Line Items] | |||||||||
Common stock, shares authorized | 500,000,000 | 500,000,000 | 500,000,000 | ||||||
Common stock, par value (in Dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||
Preferred stock, shares authorized | 10,000,000 | 10,000,000 | |||||||
Preferred stock, par value (in Dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | |||||||
Preferred stock, shares issued | 0 | 0 | |||||||
Preferred stock, shares outstanding | 0 | 0 | |||||||
Common stock, shares issued | 123,663,315 | 96,575,107 | 96,284,283 | ||||||
Common stock, shares outstanding | 123,663,315 | 96,575,107 | 96,284,283 | ||||||
Warrants outstanding | 12,383,304 | ||||||||
Temporary equity, Voting rights | one | ||||||||
Proceeds from issuance of Series preferred stock | $ | $ 109,042 | ||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||
Common stock, shares authorized | 500,000,000 | 500,000,000 | 191,500,000 | 191,500,000 | |||||
Common stock, par value (in Dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.001 | $ 0.001 | |||||
Preferred stock, shares authorized | 10,000,000 | 10,000,000 | |||||||
Preferred stock, par value (in Dollars per share) | $ / shares | $ 0.0001 | ||||||||
Common stock, shares outstanding | 122,822,134 | ||||||||
Business combination exchange ratio | 0.6656 | ||||||||
Legacy Green Light [Member] | |||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||
Business combination exchange ratio | 0.6656 | 0.6656 | |||||||
Shares issued, price per share | $ / shares | $ 0.0001 | ||||||||
Legacy Green Light [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||
Common stock, shares outstanding | 104,011,760 | ||||||||
Business combination exchange ratio | 0.6656 | ||||||||
Redeemable Convertible Preferred Stock [Member] | |||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||
Redeemable convertible preferred stock authorized | 0 | 145,948,944 | 145,948,944 | ||||||
Redeemable convertible preferred stock issued | 0 | ||||||||
Redeemable convertible preferred stock outstanding | 0 | ||||||||
Temporary equity, Voting rights | one | one | |||||||
Temporary equity conversion basis | one-for-one | one-for-one basis | |||||||
Dividends | $ | $ 0 | $ 0 | |||||||
Redeemable Convertible Preferred Stock [Member] | Mandatory Conversion [Member] | Minimum [Member] | |||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||
Temporary equity conversion price | $ / shares | $ 5.4354 | $ 5.4354 | |||||||
Proceeds from issuance of Series preferred stock | $ | $ 75,000 | $ 75,000 | |||||||
Series A1 Redeemable Convertible Preferred Stock [Member] | |||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||
Redeemable convertible preferred stock authorized | 2,865,698 | 2,865,698 | |||||||
Redeemable convertible preferred stock issued | 2,827,878 | 2,807,571 | |||||||
Redeemable convertible preferred stock outstanding | 2,827,878 | 2,807,571 | |||||||
Shares issued, price per share | $ / shares | $ 1.53 | $ 1.53 | |||||||
Temporary equity conversion price | $ / shares | $ 1.21 | $ 1.21 | 1.21 | ||||||
Number of shares of common stock issuable upon conversion of each share of temporary equity | 1.26446 | ||||||||
Temporary equity, Cumulative dividend accrual rate | 5% | 5% | |||||||
Series A1 Redeemable Convertible Preferred Stock [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||
Number of shares of common stock issuable upon conversion of each share of temporary equity | 1.26446 | ||||||||
Series A2redeemable Convertible Preferred Stock [Member] | |||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||
Redeemable convertible preferred stock authorized | 7,018,203 | 7,018,203 | |||||||
Redeemable convertible preferred stock issued | 6,993,693 | 6,993,693 | |||||||
Redeemable convertible preferred stock outstanding | 6,993,693 | 6,993,693 | |||||||
Shares issued, price per share | $ / shares | $ 1.65 | $ 1.645 | |||||||
Temporary equity conversion price | $ / shares | $ 1.27 | $ 1.27 | 1.27 | ||||||
Number of shares of common stock issuable upon conversion of each share of temporary equity | 1.29528 | ||||||||
Temporary equity, Cumulative dividend accrual rate | 8% | 8% | |||||||
Series A2redeemable Convertible Preferred Stock [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||
Number of shares of common stock issuable upon conversion of each share of temporary equity | 1.29528 | ||||||||
Series A3redeemable Convertible Preferred Stock [Member] | |||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||
Redeemable convertible preferred stock authorized | 8,647,679 | 8,647,679 | |||||||
Redeemable convertible preferred stock issued | 8,629,505 | 8,629,505 | |||||||
Redeemable convertible preferred stock outstanding | 8,629,505 | 8,629,505 | |||||||
Shares issued, price per share | $ / shares | $ 2.32 | $ 2.3185 | |||||||
Temporary equity conversion price | $ / shares | $ 1.63 | $ 1.63 | 1.63 | ||||||
Number of shares of common stock issuable upon conversion of each share of temporary equity | 1.42239 | ||||||||
Temporary equity, Cumulative dividend accrual rate | 8% | 8% | |||||||
Series A3redeemable Convertible Preferred Stock [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||
Number of shares of common stock issuable upon conversion of each share of temporary equity | 1.42239 | ||||||||
Series B Redeemable Convertible Preferred Stock [Member] | |||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||
Redeemable convertible preferred stock authorized | 21,245,353 | 21,245,353 | |||||||
Redeemable convertible preferred stock issued | 21,245,353 | 21,245,353 | |||||||
Redeemable convertible preferred stock outstanding | 21,245,353 | 21,245,353 | |||||||
Shares issued, price per share | $ / shares | $ 0.86 | $ 0.8565 | |||||||
Temporary equity conversion price | $ / shares | $ 0.8565 | $ 0.8565 | 0.86 | ||||||
Temporary equity, Cumulative dividend accrual rate | 8% | 8% | |||||||
Series C Redeemable Convertible Preferred Stock [Member] | |||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||
Redeemable convertible preferred stock authorized | 35,152,184 | 35,152,184 | |||||||
Redeemable convertible preferred stock issued | 35,092,183 | 35,092,183 | |||||||
Redeemable convertible preferred stock outstanding | 35,092,183 | 35,092,183 | |||||||
Shares issued, price per share | $ / shares | $ 1.6 | $ 1.5946 | |||||||
Temporary equity conversion price | $ / shares | $ 1.5946 | $ 1.5946 | 1.6 | ||||||
Temporary equity, Cumulative dividend accrual rate | 8% | 8% | |||||||
Series D Redeemable Convertible Preferred Stock [Member] | |||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||
Redeemable convertible preferred stock authorized | 71,019,827 | 71,019,827 | |||||||
Redeemable convertible preferred stock issued | 60,184,332 | 60,184,332 | |||||||
Redeemable convertible preferred stock outstanding | 60,184,332 | 60,184,332 | |||||||
Shares issued, price per share | $ / shares | $ 1.81 | $ 1.8118 | $ 2.7221 | ||||||
Temporary equity conversion price | $ / shares | $ 1.8118 | $ 1.8118 | $ 1.81 | ||||||
Proceeds from issuance of Series preferred stock | $ | $ 109,000 | ||||||||
Temporary equity, Cumulative dividend accrual rate | 8% | 8% |
Stockholders' Equity - Summary
Stockholders' Equity - Summary of Legacy Redeemable Convertible Preferred Stock Authorized, Issued, and Outstanding (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Temporary Equity [Line Items] | |||
Redeemable convertible preferred stock | $ 218,790 | $ 218,787 | |
Series A1 Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Redeemable convertible preferred stock | 4,414 | 4,411 | |
Series A2redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Redeemable convertible preferred stock | 11,438 | 11,438 | |
Series A3redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Redeemable convertible preferred stock | 19,917 | 19,917 | |
Series B Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Redeemable convertible preferred stock | 18,671 | 18,671 | |
Series C Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Redeemable convertible preferred stock | 55,851 | 55,851 | |
Series D Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Redeemable convertible preferred stock | 108,499 | $ 108,499 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Legacy Greenlight Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Redeemable convertible preferred stock | 0 | 218,790 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Legacy Greenlight Redeemable Convertible Preferred Stock [Member] | Series A1 Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Redeemable convertible preferred stock | 0 | 4,414 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Legacy Greenlight Redeemable Convertible Preferred Stock [Member] | Series A2redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Redeemable convertible preferred stock | 0 | 11,438 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Legacy Greenlight Redeemable Convertible Preferred Stock [Member] | Series A3redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Redeemable convertible preferred stock | 0 | 19,917 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Legacy Greenlight Redeemable Convertible Preferred Stock [Member] | Series B Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Redeemable convertible preferred stock | 0 | 18,671 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Legacy Greenlight Redeemable Convertible Preferred Stock [Member] | Series C Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Redeemable convertible preferred stock | 0 | 55,851 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Legacy Greenlight Redeemable Convertible Preferred Stock [Member] | Series D Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Redeemable convertible preferred stock | $ 0 | $ 108,499 |
Stockholders' Equity - Summar_2
Stockholders' Equity - Summary of Legacy Redeemable Convertible Preferred Stock Authorized, Issued, and Outstanding (Parenthetical) (Details) - USD ($) $ / shares in Units, $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Temporary Equity [Line Items] | |||
Temporary equity par or stated value per share | $ 0.001 | $ 0.001 | |
Series A1 Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Temporary equity par or stated value per share | $ 0.001 | $ 0.001 | |
Temporary equity shares authorized | 2,865,698 | 2,865,698 | |
Temporary equity shares issued | 2,827,878 | 2,807,571 | |
Temporary equity shares outstanding | 2,827,878 | 2,807,571 | |
Temporary equity Liquidation preference | $ 6,334 | $ 6,079 | |
Series A2redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Temporary equity par or stated value per share | $ 0.001 | $ 0.001 | |
Temporary equity shares authorized | 7,018,203 | 7,018,203 | |
Temporary equity shares issued | 6,993,693 | 6,993,693 | |
Temporary equity shares outstanding | 6,993,693 | 6,993,693 | |
Temporary equity Liquidation preference | $ 19,138 | $ 18,224 | |
Series A3redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Temporary equity par or stated value per share | $ 0.001 | $ 0.001 | |
Temporary equity shares authorized | 8,647,679 | 8,647,679 | |
Temporary equity shares issued | 8,629,505 | 8,629,505 | |
Temporary equity shares outstanding | 8,629,505 | 8,629,505 | |
Temporary equity Liquidation preference | $ 30,544 | $ 28,952 | |
Series B Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Temporary equity par or stated value per share | $ 0.001 | $ 0.001 | |
Temporary equity shares authorized | 21,245,353 | 21,245,353 | |
Temporary equity shares issued | 21,245,353 | 21,245,353 | |
Temporary equity shares outstanding | 21,245,353 | 21,245,353 | |
Temporary equity Liquidation preference | $ 24,017 | $ 22,567 | |
Series C Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Temporary equity par or stated value per share | $ 0.001 | $ 0.001 | |
Temporary equity shares authorized | 35,152,184 | 35,152,184 | |
Temporary equity shares issued | 35,092,183 | 35,092,183 | |
Temporary equity shares outstanding | 35,092,183 | 35,092,183 | |
Temporary equity Liquidation preference | $ 69,595 | $ 65,014 | |
Series D Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Temporary equity par or stated value per share | $ 0.001 | $ 0.001 | |
Temporary equity shares authorized | 71,019,827 | 71,019,827 | |
Temporary equity shares issued | 60,184,332 | 60,184,332 | |
Temporary equity shares outstanding | 60,184,332 | 60,184,332 | |
Temporary equity Liquidation preference | $ 122,459 | $ 113,736 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Legacy Greenlight Redeemable Convertible Preferred Stock [Member] | Series A1 Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Temporary equity par or stated value per share | $ 0.001 | ||
Temporary equity shares authorized | 2,865,698 | ||
Temporary equity shares issued | 2,827,878 | ||
Temporary equity shares outstanding | 2,827,878 | ||
Temporary equity Liquidation preference | $ 0 | $ 6,334 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Legacy Greenlight Redeemable Convertible Preferred Stock [Member] | Series A2redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Temporary equity par or stated value per share | $ 0.001 | ||
Temporary equity shares authorized | 7,018,203 | ||
Temporary equity shares issued | 6,993,693 | ||
Temporary equity shares outstanding | 6,993,693 | ||
Temporary equity Liquidation preference | 0 | $ 19,138 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Legacy Greenlight Redeemable Convertible Preferred Stock [Member] | Series A3redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Temporary equity par or stated value per share | $ 0.001 | ||
Temporary equity shares authorized | 8,647,679 | ||
Temporary equity shares issued | 8,629,505 | ||
Temporary equity shares outstanding | 8,629,505 | ||
Temporary equity Liquidation preference | 0 | $ 30,544 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Legacy Greenlight Redeemable Convertible Preferred Stock [Member] | Series B Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Temporary equity par or stated value per share | $ 0.001 | ||
Temporary equity shares authorized | 21,245,353 | ||
Temporary equity shares issued | 21,245,353 | ||
Temporary equity shares outstanding | 21,245,353 | ||
Temporary equity Liquidation preference | 0 | $ 24,017 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Legacy Greenlight Redeemable Convertible Preferred Stock [Member] | Series C Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Temporary equity par or stated value per share | $ 0.001 | ||
Temporary equity shares authorized | 35,152,184 | ||
Temporary equity shares issued | 35,092,183 | ||
Temporary equity shares outstanding | 35,092,183 | ||
Temporary equity Liquidation preference | 0 | $ 69,595 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Legacy Greenlight Redeemable Convertible Preferred Stock [Member] | Series D Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Temporary equity par or stated value per share | $ 0.001 | ||
Temporary equity shares authorized | 71,019,827 | ||
Temporary equity shares issued | 60,184,332 | ||
Temporary equity shares outstanding | 60,184,332 | ||
Temporary equity Liquidation preference | $ 0 | $ 122,459 |
Redeemable Convertible Prefer_3
Redeemable Convertible Preferred Stock- Additional Information (Details) $ / shares in Units, $ in Thousands | 1 Months Ended | 6 Months Ended | 12 Months Ended | ||||||
Feb. 02, 2022 | Jul. 31, 2020 USD ($) $ / shares shares | Jun. 30, 2020 $ / shares shares | Jun. 30, 2022 USD ($) $ / shares shares | Dec. 31, 2021 USD ($) $ / shares shares | Dec. 31, 2020 USD ($) $ / shares shares | Mar. 31, 2022 $ / shares | Jun. 30, 2021 $ / shares | Mar. 31, 2021 $ / shares | |
Redeemable Noncontrolling Interest [Line Items] | |||||||||
Proceeds from issuance of Series preferred stock | $ | $ 109,042 | ||||||||
Temporary equity par or stated value per share | $ 0.001 | $ 0.001 | |||||||
Temporary equity, Voting rights | one | ||||||||
Legacy Green Light [Member] | |||||||||
Redeemable Noncontrolling Interest [Line Items] | |||||||||
Shares issued, price per share | $ 0.0001 | ||||||||
Business combination exchange ratio | 0.6656 | 0.6656 | |||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||||||||
Redeemable Noncontrolling Interest [Line Items] | |||||||||
Business combination exchange ratio | 0.6656 | ||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Legacy Green Light [Member] | |||||||||
Redeemable Noncontrolling Interest [Line Items] | |||||||||
Business combination exchange ratio | 0.6656 | ||||||||
Series C Redeemable Convertible Preferred Stock [Member] | |||||||||
Redeemable Noncontrolling Interest [Line Items] | |||||||||
Shares issued, price per share | $ 1.6 | $ 1.5946 | |||||||
Temporary equity shares authorized | shares | 35,152,184 | 35,152,184 | |||||||
Temporary equity par or stated value per share | $ 0.001 | $ 0.001 | |||||||
Temporary equity conversion price | $ 1.5946 | $ 1.5946 | $ 1.6 | ||||||
Temporary equity, Cumulative dividend accrual rate | 8% | 8% | |||||||
Series D Redeemable Convertible Preferred Stock [Member] | |||||||||
Redeemable Noncontrolling Interest [Line Items] | |||||||||
Temporary Equity Stock Issued During Period Shares New Issues | shares | 37,673,731 | ||||||||
Proceeds from issuance of Series preferred stock | $ | $ 109,000 | ||||||||
Payments of Stock Issuance Cost | $ | 500 | ||||||||
Shares issued, price per share | $ 2.7221 | $ 1.81 | $ 1.8118 | ||||||
Non cash stock issuance costs | $ | $ 400 | ||||||||
Temporary equity shares authorized | shares | 71,019,827 | 71,019,827 | |||||||
Temporary equity par or stated value per share | $ 0.001 | $ 0.001 | |||||||
Temporary equity conversion price | $ 1.8118 | $ 1.8118 | 1.81 | ||||||
Temporary equity, Cumulative dividend accrual rate | 8% | 8% | |||||||
Series D Redeemable Convertible Preferred Stock [Member] | Additional Closings [Member] | |||||||||
Redeemable Noncontrolling Interest [Line Items] | |||||||||
Temporary Equity Stock Issued During Period Shares New Issues | shares | 2,384,960 | ||||||||
Shares issued, price per share | $ 2.7221 | ||||||||
Redeemable Convertible Preferred Stock [Member] | |||||||||
Redeemable Noncontrolling Interest [Line Items] | |||||||||
Temporary equity shares authorized | shares | 0 | 145,948,944 | 145,948,944 | ||||||
Temporary equity par or stated value per share | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | 0.001 | $ 0.001 | |||
Temporary equity, Voting rights | one | one | |||||||
Temporary equity conversion basis | one-for-one | one-for-one basis | |||||||
Redeemable Convertible Preferred Stock [Member] | Mandatory Conversion [Member] | Minimum [Member] | |||||||||
Redeemable Noncontrolling Interest [Line Items] | |||||||||
Proceeds from issuance of Series preferred stock | $ | $ 75,000 | $ 75,000 | |||||||
Temporary equity conversion price | $ 5.4354 | $ 5.4354 | |||||||
Series A1 Redeemable Convertible Preferred Stock [Member] | |||||||||
Redeemable Noncontrolling Interest [Line Items] | |||||||||
Shares issued, price per share | $ 1.53 | $ 1.53 | |||||||
Temporary equity shares authorized | shares | 2,865,698 | 2,865,698 | |||||||
Temporary equity par or stated value per share | $ 0.001 | $ 0.001 | |||||||
Temporary equity conversion price | $ 1.21 | $ 1.21 | 1.21 | ||||||
Number of shares of common stock issuable upon conversion of each share of temporary equity | shares | 1.26446 | ||||||||
Temporary equity, Cumulative dividend accrual rate | 5% | 5% | |||||||
Series A1 Redeemable Convertible Preferred Stock [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||||||||
Redeemable Noncontrolling Interest [Line Items] | |||||||||
Number of shares of common stock issuable upon conversion of each share of temporary equity | shares | 1.26446 | ||||||||
Series A 2Redeemable Convertible Preferred Stock [Member] | |||||||||
Redeemable Noncontrolling Interest [Line Items] | |||||||||
Shares issued, price per share | $ 1.65 | $ 1.645 | |||||||
Temporary equity shares authorized | shares | 7,018,203 | 7,018,203 | |||||||
Temporary equity par or stated value per share | $ 0.001 | $ 0.001 | |||||||
Temporary equity conversion price | $ 1.27 | $ 1.27 | 1.27 | ||||||
Number of shares of common stock issuable upon conversion of each share of temporary equity | shares | 1.29528 | ||||||||
Temporary equity, Cumulative dividend accrual rate | 8% | 8% | |||||||
Series A 2Redeemable Convertible Preferred Stock [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||||||||
Redeemable Noncontrolling Interest [Line Items] | |||||||||
Number of shares of common stock issuable upon conversion of each share of temporary equity | shares | 1.29528 | ||||||||
Series A 3Redeemable Convertible Preferred Stock [Member] | |||||||||
Redeemable Noncontrolling Interest [Line Items] | |||||||||
Shares issued, price per share | $ 2.32 | $ 2.3185 | |||||||
Temporary equity shares authorized | shares | 8,647,679 | 8,647,679 | |||||||
Temporary equity par or stated value per share | $ 0.001 | $ 0.001 | |||||||
Temporary equity conversion price | $ 1.63 | $ 1.63 | 1.63 | ||||||
Number of shares of common stock issuable upon conversion of each share of temporary equity | shares | 1.42239 | ||||||||
Temporary equity, Cumulative dividend accrual rate | 8% | 8% | |||||||
Series A 3Redeemable Convertible Preferred Stock [Member] | GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||||||||
Redeemable Noncontrolling Interest [Line Items] | |||||||||
Number of shares of common stock issuable upon conversion of each share of temporary equity | shares | 1.42239 | ||||||||
Series B Redeemable Convertible Preferred Stock [Member] | |||||||||
Redeemable Noncontrolling Interest [Line Items] | |||||||||
Shares issued, price per share | $ 0.86 | $ 0.8565 | |||||||
Temporary equity shares authorized | shares | 21,245,353 | 21,245,353 | |||||||
Temporary equity par or stated value per share | $ 0.001 | $ 0.001 | |||||||
Temporary equity conversion price | $ 0.8565 | $ 0.8565 | $ 0.86 | ||||||
Temporary equity, Cumulative dividend accrual rate | 8% | 8% |
Redeemable Convertible Prefer_4
Redeemable Convertible Preferred Stock - Summary of Temporary Equity (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Temporary Equity [Line Items] | |||
Redeemable convertible preferred stock | $ 218,790 | $ 218,787 | |
Series A1 Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Redeemable convertible preferred stock | 4,414 | 4,411 | |
Series A2 Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Redeemable convertible preferred stock | 11,438 | 11,438 | |
Series A3 Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Redeemable convertible preferred stock | 19,917 | 19,917 | |
Series B Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Redeemable convertible preferred stock | 18,671 | 18,671 | |
Series C Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Redeemable convertible preferred stock | 55,851 | 55,851 | |
Series D Redeemable Convertible Preferred Stock [Member] | |||
Temporary Equity [Line Items] | |||
Redeemable convertible preferred stock | $ 108,499 | $ 108,499 |
Redeemable Convertible Prefer_5
Redeemable Convertible Preferred Stock - Summary of Temporary Equity (Parenthetical) (Details) - USD ($) $ / shares in Units, $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Temporary Equity [Line Items] | ||
Temporary equity par or stated value per share | $ 0.001 | $ 0.001 |
Series A1 Redeemable Convertible Preferred Stock [Member] | ||
Temporary Equity [Line Items] | ||
Temporary equity par or stated value per share | $ 0.001 | $ 0.001 |
Temporary equity shares authorized | 2,865,698 | 2,865,698 |
Temporary equity shares issued | 2,827,878 | 2,807,571 |
Temporary equity shares outstanding | 2,827,878 | 2,807,571 |
Temporary equity Liquidation preference | $ 6,334 | $ 6,079 |
Series A2 Redeemable Convertible Preferred Stock [Member] | ||
Temporary Equity [Line Items] | ||
Temporary equity par or stated value per share | $ 0.001 | $ 0.001 |
Temporary equity shares authorized | 7,018,203 | 7,018,203 |
Temporary equity shares issued | 6,993,693 | 6,993,693 |
Temporary equity shares outstanding | 6,993,693 | 6,993,693 |
Temporary equity Liquidation preference | $ 19,138 | $ 18,224 |
Series A3 Redeemable Convertible Preferred Stock [Member] | ||
Temporary Equity [Line Items] | ||
Temporary equity par or stated value per share | $ 0.001 | $ 0.001 |
Temporary equity shares authorized | 8,647,679 | 8,647,679 |
Temporary equity shares issued | 8,629,505 | 8,629,505 |
Temporary equity shares outstanding | 8,629,505 | 8,629,505 |
Temporary equity Liquidation preference | $ 30,544 | $ 28,952 |
Series B Redeemable Convertible Preferred Stock [Member] | ||
Temporary Equity [Line Items] | ||
Temporary equity par or stated value per share | $ 0.001 | $ 0.001 |
Temporary equity shares authorized | 21,245,353 | 21,245,353 |
Temporary equity shares issued | 21,245,353 | 21,245,353 |
Temporary equity shares outstanding | 21,245,353 | 21,245,353 |
Temporary equity Liquidation preference | $ 24,017 | $ 22,567 |
Series C Redeemable Convertible Preferred Stock [Member] | ||
Temporary Equity [Line Items] | ||
Temporary equity par or stated value per share | $ 0.001 | $ 0.001 |
Temporary equity shares authorized | 35,152,184 | 35,152,184 |
Temporary equity shares issued | 35,092,183 | 35,092,183 |
Temporary equity shares outstanding | 35,092,183 | 35,092,183 |
Temporary equity Liquidation preference | $ 69,595 | $ 65,014 |
Series D Redeemable Convertible Preferred Stock [Member] | ||
Temporary Equity [Line Items] | ||
Temporary equity par or stated value per share | $ 0.001 | $ 0.001 |
Temporary equity shares authorized | 71,019,827 | 71,019,827 |
Temporary equity shares issued | 60,184,332 | 60,184,332 |
Temporary equity shares outstanding | 60,184,332 | 60,184,332 |
Temporary equity Liquidation preference | $ 122,459 | $ 113,736 |
Common Stock - Additional Infor
Common Stock - Additional Information (Details) - USD ($) | 12 Months Ended | ||||||
Dec. 31, 2021 | Dec. 31, 2020 | Jun. 30, 2022 | Mar. 31, 2022 | Feb. 02, 2022 | Jun. 30, 2021 | Mar. 31, 2021 | |
Class of Stock [Line Items] | |||||||
Common stock, shares authorized | 500,000,000 | 500,000,000 | 500,000,000 | ||||
Common stock, par value (in Dollars per share) | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | |
Common stock, voting rights | one vote | one vote | |||||
Dividends Payable | $ 0 | $ 0 | |||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||||||
Class of Stock [Line Items] | |||||||
Common stock, shares authorized | 191,500,000 | 191,500,000 | 500,000,000 | 500,000,000 | |||
Common stock, par value (in Dollars per share) | $ 0.001 | $ 0.001 | $ 0.0001 | $ 0.0001 |
Common Stock - Summary of commo
Common Stock - Summary of common stock reserved for future issuance (Details) | Dec. 31, 2021 shares |
Convertible debt with accrued interest | |
Summary Of Common Stock Capital Shares Reserved For Future Issuance [Line Items] | |
Common Stock, Capital Shares Reserved for Future Issuance | 6,684,122 |
Options to purchase common stock | |
Summary Of Common Stock Capital Shares Reserved For Future Issuance [Line Items] | |
Common Stock, Capital Shares Reserved for Future Issuance | 19,803,226 |
Common Stock Warrants [Member] | |
Summary Of Common Stock Capital Shares Reserved For Future Issuance [Line Items] | |
Common Stock, Capital Shares Reserved for Future Issuance | 207,376 |
Preferred Stock Warrants [Member] | |
Summary Of Common Stock Capital Shares Reserved For Future Issuance [Line Items] | |
Common Stock, Capital Shares Reserved for Future Issuance | 651,988 |
Previously Reported [Member] | |
Summary Of Common Stock Capital Shares Reserved For Future Issuance [Line Items] | |
Common Stock, Capital Shares Reserved for Future Issuance | 27,346,712 |
Stock-Based Compensation - Summ
Stock-Based Compensation - Summary of assumptions in the binomial option-pricing model used to determine the fair value of stock options (Details) - $ / shares | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Expected dividend yield | 0% | 0% | ||
Maximum [Member] | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Expected term (in years) | 6 | 6 | ||
Expected volatility | 68.90% | 70.40% | ||
Minimum [Member] | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Expected term (in years) | 5 | |||
Expected volatility | 56.30% | 69.50% | ||
Share-based Payment Arrangement, Option [Member] | Maximum [Member] | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Fair value of underlying common stock | $ 8.85 | $ 0.98 | ||
Weighted average risk-free interest rate | 1.42% | 1.55% | ||
Share-based Payment Arrangement, Option [Member] | Minimum [Member] | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Fair value of underlying common stock | $ 1.23 | $ 0.69 | ||
Weighted average risk-free interest rate | 0.48% | 0.27% | ||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Share-based Payment Arrangement, Option [Member] | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Fair value of underlying common stock | $ 3.56 | $ 0.8 | ||
Weighted average risk-free interest rate | 3% | 1.13% | ||
Expected term (in years) | 6.04 | 6.08 | ||
Expected volatility | 65.38% | 67.83% | ||
Expected dividend yield | 0% | 0% |
Stock-Based Compensation - Sche
Stock-Based Compensation - Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | |||
Beginning balance, Shares | 18,101,548 | 15,001,672 | |
Shares, Granted | 3,811,151 | ||
Shares, Exercised | (253,027) | ||
Shares, Cancelled or forfeited | (458,248) | ||
Ending balance, Shares | 18,101,548 | 15,001,672 | |
Shares, Vested and expected to vest | 18,101,548 | ||
Shares, Exercisable | 7,449,211 | ||
Beginning balance, Weighted-Average Exercise Price | $ 1.14 | $ 0.62 | |
Weighted-Average Exercise Price, Granted | 3.2 | ||
Weighted-Average Exercise Price, Exercised | 0.57 | ||
Weighted-Average Exercise Price, Cancelled or forfeited | 1.61 | ||
Ending balance, Weighted-Average Exercise Price | 1.14 | $ 0.62 | |
Weighted-Average Exercise Price, Vested and expected to vest | 1.14 | ||
Weighted-Average Exercise Price, Exercisable | $ 0.51 | ||
Beginning balance, Weighted-Average Remaining Contractual Term | 8 years | 8 years 6 months | |
Ending balance, Weighted-Average Remaining Contractual Term | 8 years | 8 years 6 months | |
Weighted-Average Remaining Contractual Term, Vested and expected to vest | 8 years | ||
Weighted-Average Remaining Contractual Term, Exercisable | 6 years 10 months 24 days | ||
Beginning balance, Aggregate Intrinsic Value | $ 139,505 | $ 9,170 | |
Aggregate Intrinsic Value, Exercised | 2,096 | ||
Ending balance, Aggregate Intrinsic Value | 139,505 | $ 9,170 | |
Aggregate Intrinsic Value, Vested and expected to vest | 139,505 | ||
Aggregate Intrinsic Value, Exercisable, Aggregate Intrinsic Value | $ 62,157 | ||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | |||
Beginning balance, Shares | 18,101,548 | ||
Shares, Granted | 6,713,069 | ||
Shares, Exercised | (760,534) | ||
Shares, Cancelled or forfeited | (525,276) | ||
Ending balance, Shares | 23,528,807 | 18,101,548 | |
Shares, Vested and expected to vest | 23,528,807 | ||
Shares, Exercisable | 8,891,469 | ||
Beginning balance, Weighted-Average Exercise Price | $ 1.14 | ||
Weighted-Average Exercise Price, Granted | 5.79 | ||
Weighted-Average Exercise Price, Exercised | 0.46 | ||
Weighted-Average Exercise Price, Cancelled or forfeited | 1.36 | ||
Ending balance, Weighted-Average Exercise Price | 2.49 | $ 1.14 | |
Weighted-Average Exercise Price, Vested and expected to vest | 2.49 | ||
Weighted-Average Exercise Price, Exercisable | $ 0.71 | ||
Beginning balance, Weighted-Average Remaining Contractual Term | 8 years 2 months 12 days | 8 years | |
Ending balance, Weighted-Average Remaining Contractual Term | 8 years 2 months 12 days | 8 years | |
Weighted-Average Remaining Contractual Term, Vested and expected to vest | 8 years 2 months 12 days | ||
Weighted-Average Remaining Contractual Term, Exercisable | 6 years 9 months 18 days | ||
Beginning balance, Aggregate Intrinsic Value | $ 139,505 | ||
Aggregate Intrinsic Value, Exercised | 250 | ||
Ending balance, Aggregate Intrinsic Value | 22,335 | $ 139,505 | |
Aggregate Intrinsic Value, Vested and expected to vest | 22,335 | ||
Aggregate Intrinsic Value, Exercisable, Aggregate Intrinsic Value | $ 13,792 |
Stock-Based Compensation - Su_2
Stock-Based Compensation - Summary of Stock Options Activity (Parenthetical) (Details) | Feb. 02, 2022 |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | |
Business combination exchange ratio | 0.6656 |
Stock-Based Compensation - Su_3
Stock-Based Compensation - Summary of the Company's restricted stock activity (Details) - Restricted Stock [Member] - $ / shares | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Beginning balance, Unvested shares | 4,231 | 24,937 |
Shares, Vested | (20,706) | |
Ending balance, Unvested shares | 4,231 | |
Beginning balance,Weighted- Average Grant-Date Fair Value | $ 1.15 | $ 0.56 |
Weighted- Average Grant-Date Fair Value, Vested | 0.82 | |
Ending balance, Weighted- Average Grant-Date Fair Value | $ 1.15 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Beginning balance, Unvested shares | 4,231 | |
Shares, Vested | (2,898) | |
Ending balance, Unvested shares | 1,333 | 4,231 |
Beginning balance,Weighted- Average Grant-Date Fair Value | $ 0.76 | |
Weighted- Average Grant-Date Fair Value, Vested | 0.23 | |
Ending balance, Weighted- Average Grant-Date Fair Value | $ 0.22 | $ 0.76 |
Stock-Based Compensation - Su_4
Stock-Based Compensation - Summary of stock-based compensation expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||||
Stock-based compensation expense | $ 1,991 | $ 659 | ||||
Research and Development Expense [Member] | ||||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||||
Stock-based compensation expense | 1,018 | 306 | ||||
General and Administrative Expense [Member] | ||||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||||
Stock-based compensation expense | $ 973 | $ 353 | ||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||||
Stock-based compensation expense | $ 1,634 | $ 407 | $ 3,821 | $ 755 | ||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Research and Development Expense [Member] | ||||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||||
Stock-based compensation expense | 958 | 188 | 1,462 | 324 | ||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | General and Administrative Expense [Member] | ||||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||||
Stock-based compensation expense | $ 676 | $ 219 | $ 2,359 | $ 431 |
Stock-Based Compensation - Addi
Stock-Based Compensation - Additional information (Details) - USD ($) $ / shares in Units, $ in Thousands | 6 Months Ended | 12 Months Ended | ||||
Feb. 01, 2022 | Dec. 31, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||||
Intrinsic value of options exercised | $ 2,096 | |||||
Incremental stock based compensation recognizable on event of business combination | $ 1,400 | $ 1,400 | ||||
Expected Additional Stock Based Compenastion to Recognize Associated With Number Of Options Vest Based On Liquidity And Service Condition | 292,650 | |||||
Number Of Options Not Vested On Which Performance Condition Not Met | 292,650 | 292,650 | ||||
Number of options granted | 3,811,151 | |||||
Employee Stock Option | ||||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||||
Common Stock, Capital Shares Reserved for Future Issuance | 19,803,226 | 19,803,226 | ||||
Performance Based Options [Member] | ||||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||||
Share based payment award fair value assumptions grant date fair value on high level of performance | $ 200 | $ 200 | ||||
Share based payment award fair value assumptions grant date modification fair value | 2,100 | $ 2,100 | ||||
Share-based compensation arrangement by share based payment award modified vesting date | Mar. 31, 2022 | |||||
Share based payment award fair value assumptions grant date fair value on non probable outcome | $ 0 | $ 0 | ||||
2012 Stock Incentive Plan [Member] | ||||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||||
Common Stock, Capital Shares Reserved for Future Issuance | 20,337,715 | 20,337,715 | 20,337,715 | |||
Share based compensation arrangement by share based payment award number of shares available for granted | 1,701,678 | 1,701,678 | 5,053,403 | |||
Share based compensation arrangement by Share based payment award purchase price of fair market value Common Stock Percent | 100% | 100% | ||||
Award expiration period | 10 years | 10 years | ||||
Vested in Period, Fair Value | $ 25,000 | $ 11 | ||||
2012 Stock Incentive Plan [Member] | Independent Directors [Member] | ||||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||||
Vested in Period, Fair Value | $ 84 | |||||
2012 Stock Incentive Plan [Member] | Employee Stock Option | ||||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||||
Weighted average grant date fair value of stock options granted | $ 1.92 | $ 0.6 | ||||
Share based payment arrangement nonvested award option cost not yet recognized amount | $ 9,400 | $ 9,400 | ||||
Share based payment arrangement nonvested award cost not yet recognized period for recognition | 2 years 10 months 24 days | |||||
Intrinsic value of options exercised | $ 2,100 | $ 100 | ||||
Restricted stock awards granted | 87,809 | |||||
2012 Stock Incentive Plan [Member] | Maximum [Member] | ||||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||||
Award vesting period | 5 years | |||||
2012 Stock Incentive Plan [Member] | Maximum [Member] | Employee Stock Option | ||||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||||
Award vesting period | 4 years | |||||
2012 Stock Incentive Plan [Member] | Minimum [Member] | Employee Stock Option | ||||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||||
Award vesting period | 2 years | |||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||||
Intrinsic value of options exercised | $ 250 | |||||
Incremental stock based compensation recognizable on event of business combination | 1,400 | |||||
Share based payment award fair value assumptions grant date modification fair value | $ 2,200 | |||||
Share-based compensation arrangement by share based payment award modified vesting date | Mar. 31, 2022 | |||||
Number of options granted | 6,713,069 | |||||
Number of shares subject to vest for additional stock-based compensation recognized | 292,469 | |||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Performance Based Options [Member] | ||||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||||
Share based payment award fair value assumptions grant date fair value on high level of performance | $ 200 | |||||
Share based payment award fair value assumptions grant date fair value on non probable outcome | $ 0 | |||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Restricted Stock [Member] | ||||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||||
Vested in Period, Fair Value | $ 13 | $ 8 | ||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | 2022 Equity And Incentive Plan [Member] | ||||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||||
Common Stock, Capital Shares Reserved for Future Issuance | 31,750,000 | |||||
Share based compensation arrangement by Share based payment award purchase price of fair market value Common Stock Percent | 100% | |||||
Award expiration period | 10 years | |||||
Award vesting period | 5 years | |||||
Number of options granted | 6,713,069 | |||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | 2022 Equity And Incentive Plan [Member] | Employee Stock Option | ||||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||||
Weighted average grant date fair value of stock options granted | $ 3.56 | $ 0.8 | ||||
Share based payment arrangement nonvested award option cost not yet recognized amount | $ 32,200 | |||||
Share based payment arrangement nonvested award cost not yet recognized period for recognition | 3 years 6 months | |||||
Intrinsic value of options exercised | $ 1,100 | $ 200 |
Net Loss Per Share - Summary of
Net Loss Per Share - Summary of the computation of basic and diluted net loss per share attributable to common stockholders (Details) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Numerator: | ||||||
Net loss | $ (51,926,000) | $ (27,174,000) | $ (90,133,000) | $ (48,457,000) | $ (112,310,000) | $ (53,251,000) |
Net loss available to common stockholders | $ (1,170) | $ (690) | ||||
Denominator: | ||||||
Weighted-average common stock outstanding — basic | 123,249,757 | 96,327,956 | 118,430,851 | 96,314,179 | 96,371,189 | 77,673,953 |
Weighted-average common stock outstanding — diluted | 123,249,757 | 96,327,956 | 118,430,851 | 96,314,179 | 96,371,189 | 77,673,953 |
Net loss per share available to common stockholders — basic | $ (0.42) | $ (0.28) | $ (0.76) | $ (0.5) | $ (1.17) | $ (0.69) |
Net loss per share available to common stockholders — diluted | $ (0.42) | $ (0.28) | $ (0.76) | $ (0.5) | $ (1.17) | $ (0.69) |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||||||
Numerator: | ||||||
Net loss | $ (90,100,000) | $ (48,500,000) | ||||
Net loss available to common stockholders | $ (51,926,000) | $ (27,174,000) | $ (90,133,000) | $ (48,457,000) | ||
Denominator: | ||||||
Weighted-average common stock outstanding — basic | 123,249,757 | 96,327,956 | 118,430,851 | 96,314,179 | ||
Weighted-average common stock outstanding — diluted | 123,249,757 | 96,327,956 | 118,430,851 | 96,314,179 | ||
Net loss per share available to common stockholders — basic | $ (0.42) | $ (0.28) | $ (0.76) | $ (0.5) | ||
Net loss per share available to common stockholders — diluted | $ (0.42) | $ (0.28) | $ (0.76) | $ (0.5) |
Net Loss Per Share - Summary _2
Net Loss Per Share - Summary of the excluded potential common stock (Details) - shares | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 25,649,265 | 21,539,109 | ||
Warrants | ||||
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 207,376 | 26,624 | ||
Preferred Stock Warrants [Member] | ||||
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 651,988 | 107,416 | ||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||||
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 35,913,444 | 17,759,682 | ||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Convertible debt with accrued interest | ||||
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 6,684,122 | 6,378,460 | ||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Unvested restricted stock | ||||
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 1,333 | 13,926 | 4,231 | 24,937 |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Options to purchase common stock | ||||
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 23,528,807 | 17,572,807 | 18,101,548 | 15,001,672 |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Warrants | ||||
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 12,383,304 | 172,949 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
Mar. 31, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | |
Income Tax Examination [Line Items] | |||||
Income tax expense benefit | $ 0 | $ 0 | |||
Domestic Tax Authority [Member] | |||||
Income Tax Examination [Line Items] | |||||
Operating Loss Carryforwards | $ 232,116 | ||||
Tax credit carryforward, Amount | 7,485 | ||||
Domestic Tax Authority [Member] | Tax Period Before 2018 | |||||
Income Tax Examination [Line Items] | |||||
Operating Loss Carryforwards | $ 27,104 | ||||
Operating loss carryforwards, Expiration year | 2037 | ||||
Domestic Tax Authority [Member] | Tax Period Before 2017 | |||||
Income Tax Examination [Line Items] | |||||
Operating Loss Carryforwards | $ 205,012 | ||||
State and Local Jurisdiction [Member] | |||||
Income Tax Examination [Line Items] | |||||
Operating Loss Carryforwards | $ 197,424 | ||||
Operating loss carryforwards, Expiration year | 2040 | ||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | |||||
Income Tax Examination [Line Items] | |||||
Income tax expense benefit | $ 0 | $ 0 |
Income Taxes - Summary of Signi
Income Taxes - Summary of Significant Components of Deferred Tax Assets and Liabilities (Details) - GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Deferred tax assets: | ||
Federal net operating loss carryforwards | $ 48,956 | $ 26,464 |
State net operating loss carryforwards | 12,477 | 6,542 |
Tax credits | 8,736 | 4,059 |
Stock based compensation | 233 | 89 |
Capitalized research and development expenses | 3,649 | 4,398 |
Accruals and other | 1,482 | 763 |
Total deferred tax assets | 75,533 | 42,315 |
Valuation allowance | (74,340) | (39,965) |
Total deferred tax assets | 1,193 | 2,350 |
Deferred tax liabilities: | ||
Depreciation and amortization | (1,193) | (2,350) |
Total deferred tax liabilities | (1,193) | (2,350) |
Total net deferred tax assets (liability) | $ 0 | $ 0 |
Income Taxes - Summary of the r
Income Taxes - Summary of the reconciliation of effective tax rate to the statutory federal income tax rate (Detail) - GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Federal income tax (benefit)/expense at statutory rate | 21% | 21% |
State income tax benefit | 6.90% | 5.40% |
Permanent items | (0.50%) | (0.20%) |
Change in Valuation Allowance | (30.60%) | (29.30%) |
Federal R&D Tax Credits | 3% | 3.10% |
Other | 0.20% | 0% |
Effective income tax rate | 0% | 0% |
Commitments and Contingencies_2
Commitments and Contingencies (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||||||
Mar. 31, 2022 | Nov. 01, 2021 | Sep. 30, 2021 | Jun. 23, 2021 | Feb. 23, 2021 | Nov. 15, 2020 | Aug. 15, 2020 | Jan. 31, 2020 | Jan. 01, 2020 | Jun. 30, 2022 | Mar. 31, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Nov. 30, 2021 | Feb. 22, 2021 | |
Commitments (Details) [Line Items] | ||||||||||||||||||
Base lease rent | $ 100 | $ 2,300 | $ 5,100 | $ 2,100 | ||||||||||||||
Percentage increase decrease in base lease rent | 3% | |||||||||||||||||
Lessee, Operating Lease maturity Date of Contract | Mar. 31, 2026 | Feb. 28, 2025 | Feb. 28, 2025 | Feb. 14, 2024 | Feb. 14, 2024 | Mar. 31, 2025 | ||||||||||||
Lessee, Operating Lease, Term of Contract | 51 months | 44 months | 84 months | 60 months | 48 months | |||||||||||||
Lessee, Operating Lease maturity period | December 2026 | |||||||||||||||||
Payments for Tenant Improvements | $ 500 | $ 17 | ||||||||||||||||
Payments for Additional Tenant Improvements | $ 1,000 | $ 300 | ||||||||||||||||
Lessee, Operating Lease, Discount Rate | 9% | |||||||||||||||||
Payments to Acquire Equipment on Lease | 0 | 900 | ||||||||||||||||
Operating lease liability tenant improvement allowance repayable | $ 800 | |||||||||||||||||
Operating leases | $ 1,000 | $ 1,900 | ||||||||||||||||
Other Funding Commitments [Member] | ||||||||||||||||||
Commitments (Details) [Line Items] | ||||||||||||||||||
Other Commitment | $ 11,500 | |||||||||||||||||
Maximum [Member] | Bayer Cropscience Llp [Member] | License Agreements [Member] | ||||||||||||||||||
Commitments (Details) [Line Items] | ||||||||||||||||||
Milestone payments | $ 2,000 | |||||||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||||||||||||||||||
Commitments (Details) [Line Items] | ||||||||||||||||||
Base lease rent | $ 3,900 | $ 2,300 | ||||||||||||||||
Percentage increase decrease in base lease rent | 3% | 3% | 3% | |||||||||||||||
Proceeds from Legal Settlements | $ 0 | $ 0 | $ 0 | $ 0 | ||||||||||||||
Operating leases | $ 4,000 | 6,800 | ||||||||||||||||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Other Funding Commitments [Member] | ||||||||||||||||||
Commitments (Details) [Line Items] | ||||||||||||||||||
Other Commitment | $ 11,500 | |||||||||||||||||
Cost incurred | $ 3,900 |
Commitments and Contingencies -
Commitments and Contingencies - Summary of future minimum lease payments under noncancelable operating leases (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Operating Lease Liabilities Gross Difference Amount [Line Items] | ||
2022 | $ 7,841 | |
2023 | 7,257 | |
2024 | 2,549 | |
2025 | 1,450 | |
2026 | 1,242 | |
Thereafter | 5,359 | |
Total minimum lease payments | $ 25,698 | |
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | ||
Operating Lease Liabilities Gross Difference Amount [Line Items] | ||
2022 | $ 4,554 | |
2023 | 9,573 | |
2024 | 8,285 | |
2025 | 7,296 | |
2026 | 7,018 | |
Thereafter | 43,975 | |
Total minimum lease payments | $ 80,701 |
Commitments and Contingencies_3
Commitments and Contingencies - Summary of future minimum payments under these capital lease arrangements (Details) $ in Thousands | Dec. 31, 2021 USD ($) |
2022 | $ 779 |
2023 | 330 |
Thereafter | 0 |
Total minimum lease payments | 1,109 |
Less: amount representing interest | (117) |
Present value of obligations under capital leases | 992 |
Current portion of capital lease obligations | 672 |
Capital lease obligations, long-term | $ 320 |
Defined Contribution Plan - Add
Defined Contribution Plan - Additional Information (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Minimum [Member] | |
Defined contribution plan maximum annual contributions per employee percent | 1% |
Maximum [Member] | |
Defined contribution plan maximum annual contributions per employee percent | 100% |
Subsequent Events - Additional
Subsequent Events - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions | 1 Months Ended | 12 Months Ended | |
Aug. 11, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | |
Subsequent Event [Member] | Laboratory Space in Lexington [Member] | |||
Subsequent Event [Line Items] | |||
Operating Leases, Rent Expense, Minimum Rentals | $ 3.9 | ||
Operating Lease Annual Rent Increase Percentage | 3% | ||
Collaboration Agreement [Member] | Serum Institute of India Private Limited [Member] | |||
Subsequent Event [Line Items] | |||
License Fees Received | $ 5 | ||
Revenue From Milestone Payments | $ 22 | ||
GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member] | Subsequent Event [Member] | Private Placement [Member] | |||
Subsequent Event [Line Items] | |||
Sale of shares | 27,640,301 | ||
Purchase price per share | $ 3.92 | ||
Committed amount | $ 108.4 |